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1. INTRODUCTION 
 
1. INTRODUCTION 
 
 
1.1. Muscarinic  receptors 
 
1.1.1. Historical background 
 
The autonomic nervous system consists of various neural pathways associated 
with ganglionic synapses residing outside the central nervous system. In one part 
of the autonomic nervous system, the parasympathetic nervous system, 
acetylcholine (ACh) is the principal neurotransmitter. 
Early in the past century, fundamental studies carried out by Hunt and Taveau 
(1906), Dale (1914) and Loewi (1921), provided the basis for the classical 
definition of muscarinic and nicotinic acetylcholine receptors: muscarinic receptors 
are selectively activated by muscarine and blocked by atropine, whereas effects at 
nicotinic receptors are mimicked by nicotine and abolished by d-tubocurarine. 
These receptors are members of two quite different gene superfamilies, and only 
share the property of being stimulated by the same endogenous ligand, ACh. 
 
 
1.1.2. Subclassification and nomenclature 
 
Whereas only a few years later the nicotinic receptors were further subdivided into 
a muscular and a ganglionic type, the muscarinic receptors were regarded as a 
homogeneous population for a long time. Historically, the first indications of a 
possible heterogeneity of muscarinic receptors were the cardioselective actions of 
the neuromuscular relaxant gallamine (Riker and Wescoe, 1951), antagonising 
effects induced by the muscarinic agonist methacholine. Gallamine did not affect 
the decrease of blood pressure caused by methacholine, but reduced its negative 
chronotropic effect. The reverse selectivity of 4-diphenylacetoxy-N-
methylpiperidine methiodide (4-DAMP; Barlow et al., 1976) further supported the 
view of different muscarinic receptor subtypes. The first functionally selective 
muscarinic agonist, 4-(3-chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium 
chloride (McN-A-343) was described by Roszkowski (1961). This quaternary 
ammonium compound was found to stimulate excitatory muscarinic receptors in 
sympathetic ganglia without affecting muscarinic receptors present in the heart or 
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jejunum. Since then, there was a growing interest in the subclassification of the 
muscarinic receptors. 
The first nomenclature system for the subdivision was introduced by Woodruff and 
Walker (1971), who proposed to denote muscarinic receptors stimulated by McN-
A-343 as M1 receptors, and those unaffected by this agonist as M2 receptors. 
Subsequently, this classification was confirmed by investigations of many other 
groups (Goyal and Rattan, 1978; Mutschler and Lambrecht, 1984; Wess et al., 
1987). 
An important milestone in the classification of muscarinic receptors was the 
development of the muscarinic antagonist pirenzepine. Hammer et al. (1980) 
demonstrated in radioligand binding studies that pirenzepine displayed a higher 
affinity for muscarinic receptors expressed in neuronal tissues, e.g. cerebral 
cortex, hippocampus, sympathetic ganglia, compared to those expressed in 
peripheral organs, e.g. heart, smooth muscle, secretory glands, and certain brain 
stem areas. Soon afterwards, Hammer and Giacetti (1982) concluded from their 
observations made in functional and binding studies, that pirenzepine and McN-A-
343 may recognise a common receptor subtype. The confirmation of these 
findings in subsequent studies led to the introduction of the first generally 
accepted nomenclature for muscarinic receptors (Hirschowitz et al., 1984) on the 
first international symposium ”Subtypes of Muscarinic Receptors” in 1983 in 
Boston/USA: muscarinic receptors with high affinity for pirenzepine were 
designated as M1 receptors, and those with low affinity for pirenzepine were 
termed M2 receptors. However, it had already been pointed out, that the M2 
receptors most likely represent a heterogeneous population. 
The following years were characterised by the development of selective 
muscarinic agonists and antagonists. The heterogeneity of M2 receptors became 
substantially evident with the introduction of hexahydro-sila-difenidol (HHSiD) and 
its para-fluoro-analogue (p-F-HHSiD). In functional experiments as well as in 
radioligand binding studies these compounds exhibited an up to 70-fold higher 
affinity for smooth muscle and glandular muscarinic receptors than for muscarinic 
receptors in the heart (Mutschler and Lambrecht, 1984; Lambrecht et al., 1988, 
1989a; Waelbroeck et al., 1991). Further support to the differentiation of 
muscarinic receptor subtypes was contributed by a number of structurally quite 
different compounds exhibiting higher affinities to M2 than to M3 receptors and, 
thus, displaying an inverse selectivity to the above mentioned compounds HHSiD 
and p-F-HHSiD, e.g. the alkaloid himbacine, the pirenzepine analogues AF-DX 
116, AF-DX 384 and AQ-RA 741, and the polymethylene-tetraamines 
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methoctramine and mefurtramine (reviewed by Mutschler et al., 1995; Eglen and 
Watson, 1996). Based on the findings in functional and radioligand binding studies 
with the antagonists described above, Doods et al. (1987) suggested an extended 
nomenclature, which was presented on the ”Fourth Symposium on Subtypes of 
Muscarinic Receptors”: M1, M2 and M3 receptors (Birdsall et al., 1989). 
In the meantime, a fourth pharmacologically defined muscarinic receptor, the M4 
receptor, has been identified using radioligand and biochemical techniques in a 
variety of different tissues and cell lines. The confirmation in functional 
experiments was first shown by combining the data obtained with the relatively 
subtype-selective muscarinic antagonists. Therefore, a major step forward was the 
presentation of the isolated rabbit anococcygeus muscle as a robust test model 
for this receptor subtype by Gross et al. (1995, 1997b). Later, this group was able 
to confirm with this model data from binding studies with the novel M4-selective 
muscarinic antagonist, PD102807 (Augelli-Szafran et al., 1997, 1998; Schwarz et 
al., 1997). This compound displayed in functional experiments the following 
selectivity profile: M4 > M3 (10-fold) > M2 (3-fold) > M1 (Gross et al., 1997a). 
 
The chemical structure of some key muscarinic agonists and antagonists are 
given in Figs. 1.1. and 1.2., respectively. 
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Fig. 1.1. Chemical structure of some muscarinic key agonists. The asterisks 
denote the centres of chirality. 
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Fig. 1.2. Chemical structure of some muscarinic key antagonists. The asterisks 
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A major aim of current research consequently lies in the identification of selective 
ligands for each of the muscarinic receptor subtypes. In terms of agonists, this aim 
has not really been achieved, because of the complexity of this field. Drug-
receptor theory proposes that agonist potencies depend on several tissue factors, 
including receptor density, G protein density and the efficiency of the stimulus 
response coupling (Kenakin et al., 1992). All these factors may vary between 
tissues and cell lines with consequent variation in muscarinic agonist potency. 
This complication may be one reason why relatively little progress has been made 
in the area of muscarinic agonists with adequate subtype selectivity (Lambrecht et 
al., 1993; Angeli, 1995). 
However, several advances have been made in the identification of selective 
antagonists. In the past few years a number of new muscarinic antagonists have 
been described, which will prove useful as both therapeutics with reduced side 
effects and tools to define muscarinic receptor subtypes operationally, because 
they show at least some selectivity for one of these subtypes: 
 M1 receptor: telenzepine (Eltze et al., 1985), guanylpirenzepine (Micheletti et al., 
1990) and spirotramine (Melchiorre et al., 1995), MT7 (Jerusalinsky et al., 2000);  
  M2 receptor: tripitramine (Melchiorre et al., 1993), (S)-enantiomer of 
dimethindene (Pfaff et al., 1995; Pfaff, 1996); 
  M3 receptor: darifenacin (Wallis et al., 1995; Alexander and Peters, 1997), 
zamifenacin (Eglen, 1994; Wallis, 1995) and tiotropium bromide (Ba 679 BR), a 
muscarinic antagonist with kinetic selectivity for M3 receptors (Barnes et al., 1995; 
Barnes, 2000; Norman et al., 2000); 
  M4 receptor: muscarinic toxin 3 (MT3), a peptide toxin isolated from green 
mamba venom (Jolkkonen et al., 1994; Olianas et al., 1999; Jerusalinsky et al., 
2000), PD102807 (Augelli-Szafran et al., 1997, 1998; Gross et al., 1997a; 
Schwarz et al., 1997). 
 
 
1.1.3. Cloning studies and structure 
 
The use of recombinant receptors and polymerase chain reaction (PCR) 
confirmed the heterogeneity of muscarinic receptors. In 1986, the group of Numa 
was successful in cloning the first two muscarinic receptor genes from porcine 
cDNA libraries. These genes encoded the porcine cerebral and cardiac muscarinic 
receptors, termed m1 and m2 receptors, respectively (Kubo et al., 1986a, b). The 
sequence of the m2 receptor was subsequently reported by Peralta et al. (1987b). 
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The receptor genes for the muscarinic m3, m4 and m5 receptors have been 
cloned from rat cerebral cortex (Bonner et al., 1987, 1988). Finally, the last step 
was the cloning and sequencing of all five human muscarinic receptor subtypes 
(Peralta et al., 1987a; Bonner et al., 1988). When the gene products of the m1 - 
m5 receptors were expressed in Xenopus oocytes and stably transformed 
mammalian cell lines, e.g. COS-7 and CHO cells, functional muscarinic receptors 
were produced. Their antagonist binding properties were in good agreement with 
the corresponding pharmacologically defined M1 - M4 receptors (Buckley et al., 
1989; Hulme et al., 1990; Dörje et al., 1991c; Richards, 1991; Bolden et al., 1992). 
However, no functional M5 receptor has been characterised to date, although 
mRNA corresponding to the m5 gene as well as the respective receptor protein 
were detected at very low levels in rat brain (striatum, hippocampus, cerebellum 
and pons) by means of in situ hybridisation and immunoprecipitation (Vilaró et al., 
1990; Yasuda et al., 1993). Recently, Reever et al. (1997) developed a novel 
pharmacological labelling strategy which permits for the first time a comparison of 
relative expression levels and autoradiographic localisation studies of the five 
muscarinic receptor subtypes in the brain. Their results suggest a potential 
physiological role for the M5 receptor in modulating the actions of ACh in this 
tissue. 
 
Based on the existing knowledge of the good homology between native and 
cloned muscarinic receptor subtypes, it is now recommended by the NC-IUPHAR 
that M1, M2, M3, M4 and M5 terms should be used to describe both (Caulfield and 
Birdsall, 1998). 
 
The size of the five human muscarinic receptor proteins ranges from 460 (M1) to 
590 (M3) amino acids (Caulfield and Birdsall, 1998). They exhibit a substantial 
sequence homology, particularly within the seven putative transmembrane regions 
(TM I -TM VII). Variable regions include the third cytoplasmatic loop (i3) 
connecting TM V and TM VI as well as the extracellular located amino-(N-) and 
intracellular located carboxyl-(C-) terminal sequences (Hulme et al., 1990). In 
agreement with findings obtained with the photoreceptor protein 
bacteriorhodopsin, the ligand binding site of muscarinic receptors appears to be 
formed by the seven transmembrane domains, which enclose a well-conserved 
ligand binding pocket. Affinity labelling studies and mutagenesis experiments have 
demonstrated that an aspartic acid residue in the transmembrane region III 
appears to be essential in muscarinic ligand binding. Formation of an ionic bond 
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between the ammonium headgroup and the aspartic acid of TM III thus appears to 
be a general feature of ligand binding to muscarinic receptors. Moreover, Wess et 
al. (1991, 1992) have shown that two threonine and four tyrosine residues in the 
transmembrane regions III, V, VI and VII are probably involved in recognising the 
muscarinic ligands specifically. It has been proposed that the hydroxyl groups 
present in the side chains of these amino acids would form a hydrogen bond with 
the ester group of ACh. Studies on chimeric muscarinic receptors clearly indicate 
that sequences within the i3 loop dictate the G protein-coupling selectivity of the 
muscarinic receptor subtypes (Bonner, 1992; Wess, 1993; Blüml et al., 1994; 
Wess et al. 1995, 1997). 
 
 
1.1.4. Signal transduction pathways 
 
The muscarinic receptors are structurally classified as members of the superfamily 
of membrane-bound G protein-coupled receptors. In response to agonist 
stimulation, these heptahelical receptors activate heterotrimeric guanine-binding 
proteins (G proteins) by catalysing the exchange of GTP for GDP bound to the G 
subunit of the GG heterotrimer. The separated G protein subunits activate 
various second messenger systems directly or indirectly (Clapham, 1996). 
While it was originally thought that effector regulation was exclusively 
accomplished via activated  subunits, there is now also increasing evidence that 
muscarinic receptors may act via G subunits as well. Thus, it appears that 
activation of phospholipase C (PLC), adenylate cyclase (AC), cardiac K
+
 channels 
as well as inhibition of neuronal Ca
2+
 channels can be produced by G subunits. 
The physiological role of this route and its importance has yet to be established 
(Caulfield, 1993; Clapham and Neer, 1997). 
 
On the basis of sequence homology and preferential G protein-coupling, 
muscarinic receptors can be divided into two functional classes: one consisting of 
M1, M3 and M5 receptors and the other of M2 and M4 receptor subtypes. 
 
Activation of the odd-numbered muscarinic receptor subtypes, M1, M3 and M5, 
results in various biochemical effects, including stimulation of PLC, release of 
arachidonic acid, stimulation of protein kinase C, activation of intracellular calcium-
dependent potassium and chloride currents. These responses are mediated by 
pertussis toxin (PTX)-insensitive G proteins of the Gq/11 family. 
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Activation of the even-numbered muscarinic M2 and M4 receptors is mainly 
coupled to inhibition of AC and stimulation of the inwardly rectifying potassium 
current. These responses are thought to be mediated by PTX-sensitive G proteins 
of the Gi/Go class (Hulme et al., 1990; Jones, 1993). The signal transduction 
pathways of the M1 to M5 receptors are illustrated in Fig. 1.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3. Summary of the signal transduction pathways of the five muscarinic 
receptor subtypes (taken from Jones, 1993). The solid lines represent known 
pathways and the dashed lines indicate suggested pathways. 
 
 
1.1.5. Localisation and biological function 
 
The muscarinic receptors are widely expressed throughout the peripheral tissues 
and the central nervous system. The lack of muscarinic agonists and antagonists 
with pronounced subtype-selectivity has represented a major limitation in studying 
the physiological roles of the M1 - M5 receptors. However, the availability of the 
cloned muscarinic receptor genes, immunological methods and recent progress in 
gene knockout methodologies have provided the opportunity to examine the 
physiological functions of the individual muscarinic receptor subtype in an 
unambiguous fashion (Levey, 1993; Gomeza et al., 1999). 
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Cardiovascular system 
  The first demonstration that chemical transmission occurred between 
nerves and end organs was the classical experiment by Loewi (1921) on frog 
heart, showing that a substance, released by vagus nerve stimulation, was 
responsible for the cardiac slowing by the vagus. The substance was 
subsequently identified as ACh, and it is now accepted that both the reduction in 
rate and force of heart beat resulting from parasympathetic nerve action is due to 
an action of ACh on muscarinic M2 receptors located on the heart cells (Caulfield, 
1993). However, there is a fundamental difference in effector mechanisms 
activated by ACh in atria and ventricles. In both, stimulation of M2 receptors, 
coupling to PTX-sensitive Gi/o proteins leads to inhibition of AC and hence 
decreases intracellular cAMP. As a consequence, the force of contraction is 
decreased in an indirect manner via reduction of the L-type Ca
2+
 currents. In atrial 
myocytes ACh also opens inwardly rectifying potassium channels (IK.ACh) through 
direct effects of G protein or  subunits. This results in hyperpolarisation, 
slowing heart rate, abbreviation of the L-type Ca
2+
 currents, and reduction in the 
force of contraction in a direct way. In case of human ventricular myocardium 
activation of M2 receptors has no direct negative inotropic effect, and it is still a 
matter of debate, whether ACh might stimulate IK.ACh (Brodde and Michel, 1999). 
In recent studies mRNA for M1 receptors has been identified in rat and guinea-pig 
ventricular cardiomyocytes (reviewed by Brodde and Michel, 1999). Moreover, 
studies using molecular cloning and patch-clamp techniques as well as mRNA 
expression detection reported data showing the expression of mRNAs for M3 and 
M4 subtypes beside M2 receptor subtype in the chick and canine heart (Shi et al., 
1999). The role of these gene products and/or their presence has not yet been 
associated with any functional response. 
 
Gastrointestinal tract 
  It is a well-recognised fact that parasympathetic nerve activity results in gut 
contraction, and that this effect is mediated by released ACh acting on muscarinic 
receptors. Muscarinic receptors are expressed abundantly in smooth muscle 
throughout the gastrointestinal tract in a manner that approximates a three-to-one 
mixture of the M2 and M3 subtypes (Ehlert et al., 1997, 1999). Muscarinic agonists 
elicited contractions through the M3 receptor via stimulation of PLC causing IP3 
accumulation and calcium mobilisation. The M2 receptor has been shown to 
cause an indirect contraction in the ileum by preventing the relaxant effects of 
forskolin and isoproterenol on histamine-induced contractions, when the M3 
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receptor subtype was selectively blocked by 4-DAMP mustard (Thomas et al., 
1993). Therefore, muscarinic agonists are known to have a dual effect on 
contraction, a direct M3-mediated contraction and an indirect M2-mediated 
inhibition of relaxation (Sawyer and Ehlert, 1998; Ostrom and Ehlert, 1999). 
 
Respiratory tract 
  The respiratory tract receives efferent cholinergic parasympathetic 
innervation via the vagus nerve, stimulation of which produces rapid 
bronchoconstriction that is blocked by atropine (Richardson, 1979). 
Autoradiographic mapping studies in animals and human lung have demonstrated 
that muscarinic receptors are widely distributed, being identified on smooth 
muscle, submucosal glands, epithelium, blood vessels and parasympathetic 
nerves (Barnes, 1993; Pendry, 1993; White, 1995). In the respiratory tract, M2 and 
M3 receptor subtypes predominate, whereas M1 receptors are the minor subtype. 
In rabbit lung, M4 receptors are expressed on alveolar walls and smooth muscle 
(Lazareno et al., 1990; Dörje et al., 1991a; Mak et al., 1993; Vockert, 1996). M1 
receptors are thought to facilitate neurotransmission through parasympathetic 
ganglia and enhance cholinergic reflexes. M2 receptors in the airway act as 
autoreceptors on postganglionic neurons, inhibiting ACh release, and may also act 
in smooth muscle to counteract the bronchodilatator actions of adrenergic 
stimulation. M3 receptors appear to mediate smooth muscle constriction and 
secretion from submucosal glands (Barnes, 1993; Costello et al., 1998; Barnes, 
2000). The localisation of the muscarinic receptors made it evident that cholinergic 
vagal stimulation provides the major bronchoconstrictor stimulus to the respiratory 
system and may contribute to airway narrowing in both chronic obstructive 
pulmonary disease (COPD) and chronic asthma. 
 
Genitourinary tract 
  Activation of the parasympathetic system is the major pathway by which 
bladder contraction, and thus voiding, is achieved in man and primates. Binding 
and subtype-selective immunoprecipitation studies have demonstrated that the 
majority of muscarinic receptors in the urinary bladder is of the M2 subtype, 
whereas on the other hand pharmacological studies using subtype-selective 
antagonists indicate that the M3 receptor mediates smooth muscle contraction 
(Braverman and Ruggieri, 1999; Hegde and Eglen, 1999). 
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Central nervous system (CNS) 
  The brain is among the organs with the highest density of muscarinic 
receptors. M1 - M4 receptor proteins have been detected in nearly all parts of the 
brain. In the CNS, M1 receptors are found in relatively high density in forebrain 
areas such as the hippocampus, cerebral cortex and striatum, and therefore play 
an important role in learning and memory processes. Muscarinic M2 receptors are 
present in moderate abundance in forebrain areas, but are predominant in the 
brainstem, e.g. pons and cerebellum. These receptors are involved in the control 
of vegetative functions. The density of the M3 receptor protein is very low in all 
parts of the brain and its function is still unknown. The M4 receptor subtype is 
localised in high levels in the striatum, in moderate levels in the cerebral cortex, 
hippocampus and midbrain and with the lowest levels in hindbrain. Its localisation 
in the striatum has led to the proposal that this subtype is involved in the control of 
motor behaviour (Grimm et al., 1994b; Widzowski et al., 1997). 
 
 
1.1.6. Therapeutic  potential  of selective muscarinic agonists and 
antagonists 
 
Muscarinic antagonists, such as the belladonna alkaloids atropine and 
scopolamine, have long been used for treatment of a variety of human diseases, 
including disorders of the nervous system, e.g. Parkinson’s disease and motion 
sickness, the digestive tract system, e.g. peptic ulcer and irritable bowel 
syndrome, and the respiratory system, e.g. COPD and asthma (Widzowski et al., 
1997). However, while these compounds have modest clinical benefit, their utility 
is limited by the classical antimuscarinic side effects such as dry mouth, blurred 
vision, dizziness and tachycardia, because they are non-selective across the 
muscarinic receptor subtypes and many of the troublesome side effects result 
from interactions with certain receptor subtypes. Therefore, much research over 
the past years has focused on developing agonists and antagonists selective for 
one muscarinic receptor subtype.  
 
Cardiovascular system 
  The peripherally acting muscarinic M2 receptor antagonist, AF-DX 116 
(Otenzepad) may be useful in the treatment of bradycardia (Schulte et al., 1991). 
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Gastrointestinal tract 
  In the digestive tract, cholinergic innervation reaches from the 
parasympathetic nervous system through the vagus nerve to various structures, 
including salivary glands, esophagus, stomach and gut. Preganglionic, vagal 
efferents innervate cholinergic postganglionic cells, such as the myenteric nerve 
plexus, which in turn innervates smooth muscle and glandular tissue, leading to 
smooth muscle contraction and secretory responses, respectively. 
Clinical studies of M1 antagonists have been ongoing since the 1980s and have 
generally demonstrated that these compounds are moderately effective in the 
acute treatment of duodenal and gastric ulcers. Pirenzepine, an antagonist with 
relatively high affinity for the muscarinic M1 and modest affinity for M2 - M4 
receptors, is approved for the treatment of peptic ulcer disease (reviewed by 
Hirschowitz et al., 1995). Structurally related compounds that had been in clinical 
development include telenzepine and nuvenzepine. 
 
Respiratory system 
  Cholinergic mechanisms play an important role in the pathophysiology of 
diseases characterised by chronic airway obstruction, particularly in COPD and 
asthma (Barnes, 1986). The introduction of antimuscarinics as bronchodilatators 
has been hampered by the narrow safety margin of tertiary compounds, such as 
atropine. The new class of quaternary compounds promises better results. 
Ipratropium bromide is a quaternised derivative of atropine, which is poorly 
absorbed into the systemic circulation when given by inhalation. Although non-
selective between subtypes, the poor absorption following inhalation facilitates 
selective antagonism of airway muscarinic receptors (Eglen and Watson, 1996). 
Tiotropium bromide (BA 679 BR) is a novel long-acting antimuscarinic agent, 
which is structurally related to ipratropium bromide. In in vitro receptor binding 
studies, tiotropium bromide showed kinetic receptor subtype selectivity with rapid 
dissociation from hm2 and slow dissociation rates from hm1 and hm3 (Disse et 
al., 1993). The prolonged duration of action after inhalation of tiotropium bromide 
could be confirmed in clinical studies with patients with COPD (Barnes et al., 
1995; Disse et al., 1993, 1999; Maesen et al., 1995; Van Noord et al., 2000). 
Tiotropium bromide is in Phase III trials as a once-daily dry powder inhalation and 
is more effective than ipratropium bromide given three times daily (Barnes, 1999; 
Littner et al., 2000). The prolonged protection against cholinergic neural 
bronchoconstriction may also be useful in the control of nocturnal asthma (Barnes 
et al., 1995). 
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Genitourinary tract 
  Antimuscarinic agents remain the oldest and most widely prescribed drugs 
for the treatment of urge urinary incontinence. 
Oxybutynin (Ditropan
) has been shown to be clinically effective in the treatment 
of detrusor instability and hyperreflexia. However, blockade of muscarinic 
receptors outside the bladder results in significant side-effects, e.g. dry mouth, 
that severely limit the utility of this compound (Butera and Argentieri, 1998). 
Tolterodine (Detrusitol
, Detrol
) is a new muscarinic receptor antagonist, 
specifically developed for the treatment of bladder instability (Nilvebrant et al., 
1997). Clinically it produces significantly less dry mouth than oxybutynin. 
 
CNS 
  Much of the treatment research and development for Alzheimer’s disease 
(AD) in recent years has been based on the cholinergic hypothesis of memory 
dysfunction and muscarinic regulation of amyloid metabolism. 
The best-developed and most successful approach to cholinergic therapy is the 
acetylcholinesterase (AChE) inhibition. The AChE inhibitors currently available for 
the treatment of AD are tacrine, donezepil, rivastigmine and galantamine. Tacrine 
(Cognex
) was the first agent with Food and Drug Administration-approved 
labelling for use in the treatment of AD, but hepatotoxicity, cholinergic side effects, 
and a short half-life have limited the widespread use of tacrine. Donezepil 
(Aricept
) was the second drug available for the treatment of AD with advances of 
no hepatotoxicity, a long half-live (70 hours, which allows once-daily dosing), and 
a low incidence of peripheral side effects. Rivastigmine (Exelon
) also inhibits the 
butyrylcholinesterase, which could led to additional benefits in late-stage AD, but 
causes more gastrointestinal side effects at initiation of therapy (Jann, 2000). 
Galantamine (Reminyl
), a novel medicine for AD since march 2001, has a dual 
mechanism of action, combining allosteric modulation of nicotinic receptors with 
reversible, competitive inhibition of AChE (Scott and Goa, 2000). To date, 
cholinesterase inhibition has been the most effective approach to the treatment of 
AD. Several compounds have been tested or are in development, e.g. 
physostigmine, eptastigmine, velnacrine, metrifonate (Allain et al., 1997; Farlow 
and Evans, 1998; Francis et al., 1999; Hampel et al., 1999; Krall et al., 1999). 
Another approach to the cholinergic treatment of AD is direct activation of the 
postsynaptically located M1 receptors. WAL 2014 (talsaclidine) might be a 
promising candidate for cholinergic replacement therapy in AD (Ensinger et al., 
1993). Xanomeline has been demonstrated as a potent but moderately selective 
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M1 receptor agonist that might be another compound used in this respect 
(Shannon et al., 1994; Bymaster et al., 1998a; Christopoulos et al., 1999). 
Furthermore, M1 agonists may alter amyloid precursor protein (APP) processing in 
favour of the generation of neurotrophic APPs (soluble form of APP) and 
decreased production of amyloidogenic APP fragments (Roßner et al., 1998). 
The selective M2 receptor antagonist, BIBN 99, may be useful in the treatment of 
AD, since it could reverse the autoinhibitory control of ACh release (Doods et al., 
1993; Doods, 1995). 
The most exciting strategy is the search for a postsynaptic M1 agonist coupled 
with a presynaptic autoinhibitory M2 antagonist. Lu 25-109 was described as a 
combined M1 agonist and M2/M3 antagonist, which effectively increases the 
soluble form of APP and may therefore be useful for both the replacement of ACh 
in AD as well as for the modulation of the time course of the disease via the 
interaction with APP procession pathways (Müller et al., 1998). 
 
The poor results obtained in clinical studies with cholinergic drugs can be 
explained by the fact that the muscarinic agonists used so far possess very little 
selectivity for muscarinic receptor subtypes or, as in the case of esterase 
inhibitors, lack CNS selectivity. Due to the widespread involvement of muscarinic 
receptors in peripheral functions, unwanted side effects will occur, and 
consequently, these classical muscarinic agents possess a narrow therapeutic 
window (Eglen et al., 1999). 
 
An additional CNS indication for muscarinic antagonists has been for idiopathic 
and drug-induced Parkinson’s disease, particularly in the treatment of tremor and 
rigidity. Parkinson’s disease is a hypokinetic movement disorder characterised by 
the loss of dopaminergic cells in the substantia nigra, with disruption of normal 
neural activity in basal ganglia circuits. Among other drugs like dopamine agonists, 
M1/M4 preferring muscarinic antagonists, e.g. trihexiphenidyl, procyclidine and 
biperiden are therapeutically used to restore the impaired balance between 
dopaminergic and cholinergic activity (Wess et al., 1990; Grimm et al., 1994b) The 
rational use of selective M4 antagonists is based on the predominance of the M4 
subtype in the striatum relative to the M1 subtype, although the functional role of 
the M4 subtype remains unclear. Recently, Parke-Davis have discovered a new 
M4 selective lead compound, PD102807 (Schwarz et al., 1997). 
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Furthermore, muscarinic receptors are abundant in pain pathways, including 
substantia gelatinosa of the dorsal horn of the spinal cord, thalamus and cortex, 
suggesting the possibility that muscarinic agonists could be acting at all levels of 
the CNS to modulate nociceptive information. Early studies have demonstrated 
that muscarinic agonists, e.g. arecoline and oxotremorine, as well as 
cholinesterase inhibitors, e.g. physostigmine and neostigmine, can produce 
antinociception in animals (Hartvig et al., 1989). However, the utility of the 
currently available non-selective muscarinic agonists is limited by their prominent 
parasympathomimetic side effects, and which muscarinic receptor subtype 
mediates antinociception is still debated. Recently, a novel compound, 
butylthio[2.2.2], (+)-(S)-3-(4-butylthio-1,2,5-thiadiazol-3-yl)-1-azabicyclo[2.2.2] 
octane, with mixed muscarinic receptor agonist (M1) and antagonist (M2 and M3) 
activity was described (Shannon et al., 1997a, b; Swedberg et al., 1997). 
Butylthio[2.2.2] is currently undergoing clinical development as a novel analgesic 
(Shannon et al., 1997b). 
Since it has been suggested that stimulation of the M1 receptor subtype is not a 
requirement for antinociceptive effects (Sheardown et al., 1997), and, in vivo, the 
antinociceptive effect was blocked by pertussis toxin, the involvement of the 
muscarinic M4 subtype in antinociception is under discussion (Ellis et al., 1999). 
 
New insights in the involvement of the central cholinergic system in the 
pathophysiology of schizophrenia have been suggested by Bymaster et al. 
(1998b, 1999). They presented a new compound, PTAC, exhibiting partial agonist 
properties at the human M2 and M4 and antagonist properties at the human M1, 
M3 and M5 muscarinic receptors, which does not produce tremor or salivation. 
Furthermore, PTAC shows functional dopamine antagonism despite its lack of 
affinity for dopamine receptors and exhibits a preclinical profile suggestive of 
antipsychotic efficacy. 
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1.2.   P2 receptors 
 
1.2.1. Historical background 
 
For many years the focus of interest in purines and pyrimidines was the 
involvement of intracellular nucleotides in cell metabolism and the role of ATP as 
an energy source. 
In 1929, the first concept of purines as extracellular signalling molecules was 
investigated in a pivotal study by Drury and Szent-Györgyi, demonstrating that 
adenosine and adenosine 5’-monophosphate (AMP), extracted from heart muscle, 
exert pronounced biological effects including bradycardia, coronary vasodilatation, 
decrease in systemic blood pressure, and inhibition of intestinal contraction. Since 
that time, the interest in extracellular nucleosides and nucleotides was constantly 
growing, and their pharmacological effects were studied in various tissues. 
Nearly 50 years later, Burnstock proposed the existence of specific surface 
receptors for nucleosides (P1 receptors) and nucleotides (P2 receptors) mediating 
the physiological effects of adenosine and adenosine 5’-triphosphate (ATP; 
Burnstock, 1978). This first subdivision established the fundamental part of purine 
receptor classification and was based on the following four criteria: (i) comparison 
of the relative potencies of ATP, ADP, AMP, and adenosine; (ii) selective 
antagonism of the effect of adenosine, but not ATP, by methylxanthines; (iii) 
modulation of adenylate cyclase by adenosine, but not ATP; and (iv) induction of 
prostaglandin synthesis by ATP and ADP, but not adenosine.  
Whereas adenosine acts on metabotropic A1, A2A, A2B and A3 receptors 
(Fredholm et al., 1994, 1997), it is now widely acknowledged that ATP and its 
analogues function as extracellular signalling molecules in the central, peripheral 
and enteric nervous system via cell surface metabotropic or ionotropic P2 
receptors. The further development in the field of P2 receptors led to a more 
detailed classification according to their molecular structures, evidence of distinct 
effector systems, pharmacological profiles and tissue distribution. 
 
 
1.2.2. Subclassification and nomenclature 
 
As previously noted, based on studies on neurotransmission that was resistant to 
conventional adrenergic and cholinergic antagonists, Burnstock (1971) postulated 
that ATP, released at synaptic junctions, might mediate this ”non-adrenergic, non-
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cholinergic” (NANC) signalling. Nerves releasing ATP as putative neurotransmitter 
were termed ”purinergic nerves”, and the receptors that were activated by ATP or 
by its breakdown product, adenosine, were called ”purinergic receptors”.  
Originally, P2 receptors were subclassified into P2X and P2Y purinoceptors on the 
basis of distinct pharmacological responses of various tissues to a series of 
analogues of ATP (Burnstock and Kennedy, 1985). The P2X purinoceptors were 
shown to be most potently activated by ,-methylene ATP (,-meATP) and ,-
methylene ATP (,-meATP), and were found to be localised in vas deferens, 
urinary bladder and vascular smooth muscle to mediate contraction. In contrast, 
P2Y purinoceptors were mainly stimulated by 2-methylthio ATP (2-MeSATP), 
whereas ,-meATP and ,-meATP were weak or inactive. P2Y purinoceptors 
were shown to be present in guinea-pig taenia coli and on vascular endothelial 
cells causing relaxation. Also, repeated administration of ,-meATP selectively 
desensitised the P2X but not the P2Y purinoceptors. After Burnstock and 
Kennedy’s proposal, additional P2 purinoceptor subtypes have been described 
according to their different pharmacological profiles: P2T purinoceptors, which 
were principally found in platelets and which prefer ADP as an agonist, whereas 
ATP is an antagonist; P2U purinoceptors of the human neutrophils, at which ATP 
as well as UTP act as agonists, but ,-meATP and 2-MeSATP have no effect; 
P2Z purinoceptors, localised on cells of haemopoietic origin (e.g. macrophages, 
mast cells and lymphocytes), which are highly selective for the tetrabasic ATP
4-
 
form and the unique response of which is characterised by the opening of non-
selective membrane pores permeable to hydrophilic solutes as large as 9 kD 
(reviewed by Abbracchio and Burnstock, 1994; Fredholm et al., 1994; Boarder et 
al., 1995; Windscheif, 1996). 
Besides the P2 purinoceptor subtypes, there also appear to be receptors for 
adenine dinucleotide polyphosphates (ApxA), leading to the proposal of an 
additional receptor subtype, the P2D purinoceptor (Abbracchio and Burnstock, 
1994). 
 
In 1994, Abbracchio and Burnstock outlined the basis for the currently accepted 
subclassification of P2 purinoceptors, namely the subdivision into a P2X family of 
ligand-gated ion channel receptors and a P2Y family of G protein-coupled 
receptors (Abbracchio and Burnstock, 1994). 
 
Based on the rapid development in the field of the purinoceptors, the 
nomenclature has permanently been changed. The existence of receptors that are 
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structurally similar to receptors for ATP, but which strongly prefer, or are even 
selective for UTP or UDP, led to the suggestion that the family of receptors should 
be named ‘P2 receptors’ rather than ‘P2 purinoceptors’. A P2 receptor is now 
defined as a receptor for purine or pyrimidine nucleotides, and its P2X/P2Y-
classification is fully accepted and recommended by the IUPHAR Subcommittee 
for the Nomenclature and Classification of Purinoceptors (Fredholm et al., 1997). 
 
Unambiguous delineation of P2 receptor subtypes has followed from the cloning 
and expression of functional proteins from nucleotide sequences encoding these 
receptors. To date, seven mammalian P2X receptors, P2X1-7, and six P2Y 
receptor subtypes, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, have been cloned, 
pharmacologically characterised and accepted as valid members of the P2 
receptor family (Ralevic and Burnstock, 1998; Burnstock and Williams, 2000). 
 
 
1.2.3. Cloning studies and structure 
 
1.2.3.1.  Structural features of P2X receptors 
 
The first two P2X receptor subunits were identified in  rat vas deferens, rP2X1, 
and PC12 cells, rP2X2, by expression cloning. Subsequently, five additional P2X 
receptor clones were found in rat tissues either by screening of diverse libraries 
and/or PCR-techniques. The P2X proteins have 379 - 472 amino acids and are 
thought to have intracellular N- and C-termini, and two transmembrane domains 
separated by a large extracellular loop (Fig. 1.4.) (Brake et al., 1994; Valera et al., 
1994; Newbolt et al., 1998). The amino acid identity among the different subunits 
(30 - 50 %) and the lack of homology with other ligand-gated ion channels indicate 
that they belong to a new family of membrane receptors (Soto et al., 1997). 
Despite the low amino acid identity between the members of the P2X family, some 
motifs are conserved in all subunits. The loop connecting the two transmembrane 
domains contains a number of conserved amino acids, largely glycines and 
lysines, which might be involved in the formation of the ATP binding site. 
Furthermore, there are ten cysteine residues conserved in the extracellular loop, 
suggesting a role in maintaining the tertiary structure of the protein, possibly by 
forming disulfide bridges. Additionally, a highly homologous hydrophobic segment 
(H5) preceding the second transmembrane domain is found in each P2X subunit. 
This region together with the second transmembrane domain is proposed to form 
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the ionic pore (reviewed by Barnard et al., 1997; Soto et al., 1997). In contrast to 
other ligand-gated channels, the putative transmembrane domains show a 
significant variability between the different P2X receptor subunits: one and two 
amino acids are conserved in transmembrane domain M1 and M2, respectively. 
The subunit stoichiometry of the P2X receptors is still under investigation, but the 
involvement of three subunits or multiples of three was described by Nicke and 
colleagues (1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4. Schematic model of the putative topology of P2X receptors (taken from 
Soto et al., 1997). 
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1.2.3.2.  Cloned P2X receptors 
 
P2X1 receptor 
 The  P2X1 was the first recombinant P2X receptor to be identified by 
expression cloning from rat vas deferens (Valera et al., 1994). Recently, species 
orthologues were isolated from mouse and human urinary bladder (Valera et al., 
1995). When the P2X1 receptor was expressed in Xenopus oocytes or in HEK 293 
cells large inward currents to ATP, ,-meATP, and 2-MeSATP were observed 
(Valera et al., 1994, 1995). The rank order of potency of the different P2 agonists 
are: 2-MeSATP  ATP > ,-meATP >> ADP. The currents are characterised by a 
rapid desensitisation (within hundreds of milliseconds). The P2 antagonists, 
suramin and PPADS, readily antagonise the agonist-evoked responses. When 
human P2X1 receptors were stably expressed in 1321N1 human astrocytoma 
cells, 2’- and 3’-O-(4-benzoylbenzoyl) ATP (BzATP), which has been widely 
reported as a P2X7-selective agonist, was shown to be the most potent agonist 
(pEC50 = 8.74; Bianchi et al., 1999).  
 
P2X2 receptor 
  The cDNA was originally isolated by Brake et al. (1994) from a library of 
PC12 rat pheochromocytoma cells and displays only 41 % amino acid homology 
with the rat vas deferens P2X1 receptor. Agonists, such as ATP  2-MeSATP  
ATPS, are usually 20 - 30 times less potent at this receptor than at the P2X1 
receptor subtype. ,-meATP has no agonist activity. During prolonged 
application of agonist this channel shows very little desensitisation (Brake and 
Julius, 1996; Bianchi et al., 1999). Suramin and PPADS are, as it was found for 
the P2X1 receptor, potent antagonists. Recently, Lynch et al. (1999) reported on 
the cloning and characterisation of a novel human P2X receptor gene with 
structural and functional properties identifying it as a homologue of the rat P2X2 
subtype. 
 
P2X3 receptor 
 The  P2X3 receptor was cloned from a dorsal root ganglion cDNA library, 
which encoded a 397-amino-acid-protein, having 41 - 46 % identity with other P2X 
receptors (Chen et al., 1995a; Lewis et al., 1995). In terms of agonist selectivity, 
rate of desensitisation and antagonism, this recombinant receptor has similar 
pharmacological properties to that of the P2X1 subtype. The following order of 
activity was found for the P2X3 receptor obtained from rat and human: 2-MeSATP 
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> ATP > ,-meATP (Garcia-Guzman et al., 1997b). Expression of the P2X3 
receptor in HEK293 cells has shown the following properties: (i) ATP and ,-
meATP evoked rapidly desensitising currents, (ii) currents induced by ATP (30 
µM) were maximally inhibited by 100 µM suramin and 30 µM PPADS, (iii) inhibition 
by PPADS developed rapidly (< 30 s) and could be washed out within 2 min, 
unlike the very slow kinetics of block observed with P2X1 and P2X2 receptors. 
 
P2X4 receptor 
  The isolation of this cDNA from rat hippocampus was first reported by Bo et 
al. (1995). cDNAs encoding the P2X4 subunit were also isolated from rat cervical 
superior ganglia (Buell et al., 1996) and, more recently, from human brain (Garcia-
Guzman et al., 1997a). The P2 agonists showed the following rank order of 
potency: ATP  2-MeSATP > ATPS >> ADP > ,-meATP (weak or inactive) 
(reviewed by Barnard et al., 1997). The rat and human homologues of the P2X4 
receptor appear to differ in their sensitivity to suramin and PPADS, where the 
human P2X4 receptor is weakly sensitive and the rat P2X4 is relatively insensitive 
to these putative inhibitors (Bo et al., 1995; Garcia-Guzman et al., 1997a). A lysine 
residue present in the P2X1 and P2X2 receptors, but absent in the P2X4 receptor, 
is critical for the binding of antagonists but not agonists (Buell et al., 1996). 
 
P2X5 receptor 
  The cDNA was isolated from a library prepared from rat coeliac ganglia 
(Collo et al., 1996). The predicted protein has 417 amino acids. The P2X5 
receptor was characterised by rapid activation by ATP > 2-MeSATP > ADP, 
minimal desensitisation and lack of effect of ,-meATP. The currents were 
inhibited readily by suramin (1 - 30 µM) and PPADS (1 - 30 µM). The inhibition by 
PPADS developed slowly and was only partially reversible. 
 
P2X6 receptor 
 The  P2X6 receptor cDNA was isolated from a superior cervical ganglion 
cDNA library (Collo et al., 1996). The predicted protein has 379 amino acids. 
Currents evoked by ATP in cells expressing P2X6 receptors showed only little 
desensitisation. Rank order of potency of P2 agonists are: ATP  2-MeATP > 
ATPS >> ADP. ,-meATP has no effect. ATP-induced currents were unaffected 
by suramin (1 - 30 µM) or PPADS (1- 30 µM), when the antagonists were present 
in the bath for up to 15 min. Longer applications (30 - 60 min) resulted in partial 
inhibition (Collo et al., 1996). 
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Currently it is under discussion, that homomeric P2X6 channels were not readily 
expressed (summarised by Khakh et al., 2001). 
 
P2X7 receptor 
 The  P2X7 receptor, cloned from rat brain, has a pharmacological profile 
typical of the receptor previously termed P2Z (Surprenant et al., 1996). Brief 
application of agonist in the presence of divalent cations opens the P2X7 channel, 
permeable only to small cations like the other known P2X receptors. Agonist 
application after removal of the extracellular divalent cations produces a much 
larger, sustained inward current and leads to lysis of the cells, because of the 
formation of large membrane pores (Surprenant et al., 1996). A special structural 
feature of the P2X7 receptor is a significantly longer intracellular C-terminal (240 
amino acids), of which at least 117 are crucial for the induction of the non-
selective pore. The P2X7 shows the following agonist pharmacology: 2’- and 3’-O-
(4-benzoylbenzoyl) ATP (BzATP) >> ATP > 2-MeSATP > ATPS >> ADP, 
suggesting that ATP
4-
 is the active form of ATP. ,-meATP was found to be 
inactive. The evoked current desensitised very slowly (> 10 s) and was relatively 
insensitive to suramin and moderately sensitive to PPADS (reviewed by Barnard 
et al., 1997). Recently, Bianchi et al. (1999) demonstrated that the human P2X7, 
when stably expressed in 1321N1 human astrocytoma cells, mediates 
submaximal responses to ATP as compared to BzATP, whereas all other tested 
nucleotide ligands, including 2-MeSATP, ATPS and ADP, were functionally 
inactive as human P2X7 agonists. 
 
Based on agonist efficacy and desensitisation characteristics the P2X receptors 
can be grouped into three classes (reviewed by Burnstock and Williams, 2000): 
 
(1) P2X1 and P2X3: 
  high affinity for ATP (EC50 = 1 µM) and ,-meATP, rapidly activated and 
 desensitised; 
(2) P2X2, P2X4, P2X5 and P2X6: 
  lower affinity for ATP ( EC50 = 10 µM) and ,-meATP-insensitive, slow 
  desensitisation and sustained depolarising currents; 
(3) P2X7: 
  very low affinity to ATP (EC50 = 300 - 400 µM), little or no desensitisation, 
  can also function as a non-selective ion pore. 
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1.2.3.3.  Co-assembly of distinct P2X receptor subunits 
 
The phenotypic differences among the expressed receptors, particularly with 
respect to the actions of ,-meATP, the rate of desensitisation, and the 
effectiveness of antagonists do not always correspond to those observed in native 
tissues, suggesting that the native channels might be heteropolymers or that they 
contain additional subunits not yet cloned. Only the P2X7 receptor is unique in that 
its subunits do not co-immunoprecipitate with any others (North and Surprenant, 
2000). 
Heteropolymerisation of P2X subunits has been first demonstrated for P2X2 and 
P2X3 receptor subunits heterologously expressed in HEK293 cells (Lewis et al., 
1995). These receptors, when expressed as homo-oligomers, have clearly 
different properties: the P2X2 channel being insensitive to ,-meATP and 
desensitising very slowly, and the P2X3 channel being sensitive to ,-meATP 
and desensitising rapidly. Coexpression of P2X2 and P2X3 subunits in mammalian 
cells produced a channel with mixed characteristics (,-meATP-sensitive and 
little desensitisation). 
Torres and colleagues reported on the coexpression of P2X1 and P2X5 receptor 
subunits revealing a novel ATP gated ion channel (Torres et al., 1998), and 
furthermore, they presented results about the co-assembly for several subunits of 
the P2X family. Only the P2X7 subunits preferentially form homo-oligomeric rather 
than hetero-oligomeric assemblies (Torres et al., 1999). 
The P2X heteromeric receptor, containing central P2X4 and P2X6 subunits, was 
also described by Lê et al. (1998). Coexpression in Xenopus oocytes led to the 
generation of this novel pharmacological phenotype of ionotropic P2 receptors, 
P2X4+6, which is activated by low-micromolar ,-meATP concentrations (EC50 = 
12 µM) and is blocked by suramin and reactive blue 2 (RB-2), contrary to the fact, 
that RB-2 at low concentrations can potentiate actions at homomeric P2X4 
receptors. Furthermore, studies by Lê and co-workers supported the existence of 
hetero-oligomeric P2X1+5 channels, demonstrating that, when expressed in 
Xenopus oocytes, these channels were characterised by slow desensitisation as 
well as sensitivity to ,-meATP (EC50 = 1.1 µM) and trinitrophenyl ATP (TNP-
ATP; IC50 = 64 nM; Lê et al., 1999). 
However, not all known recombinant subunits can form heteromeric receptors, as 
suggested by observation from a co-immunoprecipitation study where protein-
protein interactions could be detected neither for P2X1/P2X4, P2X2/P2X4, 
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P2X3/P2X4, P2X3/P2X6, nor for any combination containing P2X7 subunits 
(Torres et al., 1999). 
It is important to elucidate if heteromultimerisation is a common occurrence in the 
native setting, especially, if the hetero-oligomeric nature of such combinations 
may be masked by the ability of a single subunit type to dominate the phenotype 
of the complex. If such dominance is exhibited, it could be misleading, as it might 
affect only the obvious biophysical phenotype but not any underlying 
developmental and/or regulatory mechanisms, and would thus prevent a more 
complete understanding of the physiological significance of ATP transmission via 
that hetero-oligomer. 
 
 
1.2.3.4.  Properties of P2Y receptors 
 
The molecular structure and membrane topology of P2Y receptors is shown in Fig. 
1.5. 
 
P2Y1 receptor 
  A cDNA encoding a protein of 362 residues was originally cloned from late-
embryonic chick brain and confirmed to be a P2Y-type receptor, by oocyte 
expression (Webb et al., 1993). In P2Y1-transfected cells, agonist application led 
to the formation of IP3 (Simon et al., 1995). ATP, ADP, and many of their 
substituted derivatives were found to be agonists at this receptor, with 2-MeSATP 
as the most potent agonist, whereas pyrimidine based molecules and ,-meATP 
were inactive. This was hence assigned as a new subtype of the 
pharmacologically defined P2Y receptors, P2Y1. The P2Y antagonists suramin, 
RB-2 and PPADS are strongly inhibitory at the P2Y1 receptors (Simon et al., 1995; 
Charlton et al., 1996b). The cloned chick receptor, called cP2Y1, was the first 
member of a proposed extended family of metabotropic P2 receptors (Abbracchio 
and Burnstock, 1994). Subsequently, by cross-hybridisation and PCR 
amplification based upon this clone, P2Y1 has been cloned from a variety of 
species, e.g. turkey, bovine, mouse, rat and human. Notably, the relative potency 
of ATP and ADP differs widely between recombinant and endogenous P2Y1 
receptors (summarised by Fredholm et al., 1996; Barnard et al., 1997; Ralevic and 
Burnstock, 1998). 
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P2Y2 receptor 
  In 1993, Lustig and co-workers isolated the mouse P2Y2 receptor cDNA 
using a functional expression cloning strategy (Lustig et al., 1993). UTP and ATP, 
with approximately equal potency, as well as Ap4A were full agonists at this 
receptor subtype, whereas 2-MeSATP was inactive. Agonist effects were 
antagonised by suramin, whereas PPADS was ineffective (Charlton et al., 1996b). 
The P2Y2 receptor has shown an agonist profile consistent with that of the P2U 
receptor in mammalian tissues, and since its discovery, it has been widely held 
that the recombinant P2Y2 receptor corresponds to the P2U receptor (King et al., 
1998). 
 
P2Y4 receptor 
 The  P2Y4 was cloned from human genomic DNA and from placental and 
pancreas RNA (see Barnard et al., 1997). Analysis of the nucleotide efficacy at 
this receptor subtype originally indicated that UTP and UDP acted as full agonists, 
whereas ATP and ADP appeared to be either weak partial agonists or inert. Other 
groups have observed that UTP was a full agonist, UDP was inactive, and ATP 
acted as a full agonist with lower potency than UTP (for review see Barnard et al., 
1997; King et al., 1998). Recent studies, monitoring the release of intracellular 
Ca
2+
 evoked by extracellular nucleotides, indicate that the human P2Y4 has a 
restricted nucleotide selectivity for UTP, GTP and ITP, whereas the rat P2Y4 was 
additionally activated by ATP, Ap4A, CTP and XTP (Kennedy et al., 2000). In view 
of its agonist profile the rat P2Y4 receptor expressed in Xenopus oocytes did not 
match the profile for the human P2Y4 but, instead, was closer to the profile of rat 
P2Y2 (Bogdanov et al., 1998). ATP was shown to act as a competitive antagonist 
at the human P2Y4 receptor. P2Y4 receptors have been reported to be insensitive 
to suramin, whereas the effect of PPADS remains unclear, as it has been found to 
be either inactive or active (Charlton et al., 1996a; Communi et al., 1996a). 
 
P2Y6 receptor 
 The  P2Y6 receptor was originally cloned from rat aorta cells (Chang et al., 
1995), and subsequently, a human sequence has been isolated from placenta and 
spleen (Communi et al., 1996b). In several studies, UDP and UTP were found to 
be the most potent agonists, whereas 2-MeSATP and ATP were less active 
(Barnard et al., 1997). This receptor is blocked by PPADS and suramin (reviewed 
by Von Kügelgen and Wetter, 2000). 
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P2Y11 receptor 
  Sequences encoding the P2Y11 receptor have been isolated from human 
placenta cDNA (Communi et al., 1997). In terms of protein structure, the second 
and third extracellular loops are significantly longer than those of the other P2Y 
receptors. The recombinant human P2Y11 receptor stably expressed in 1321N1 
astrocytoma cells for measuring IP3 and CHO-K1 cells for measuring cAMP has 
been shown to couple to both pathways, a unique feature among the P2Y receptor 
family (Communi et al., 1997). The rank order of potency of the tested nucleotides 
was almost identical for both pathways: ATP > 2-MeSATP >>> ADP. UTP and 
UDP were inactive. The ATP analogue AR-C67085, a potent inhibitor of ADP-
induced platelet aggregation, was the most potent agonist. Suramin behaved as a 
competitive antagonist with a pA2 value of 6.09, and PPADS was inactive 
(Communi et al., 1999). 
 
P2Y12 receptor 
  This ADP-sensitive receptor (formerly designated as P2T or P2YADP), 
which plays an important role in blood platelet aggregation, has long been waiting 
for its molecular biological characterisation. Latest reports from Hollopeter and 
colleagues (2001) provided evidence that this receptor is now cloned from a cDNA 
library from rat as well as from human platelets. On the basis of measuring PTX-
sensitive Gi-linked responses through a sensitive electrophysiological assay they 
could clearly identify the long-sought ADP receptor on platelets as P2Y12 receptor 
subtype. 2-MeSADP was shown to be the most potent agonist tested, displaying 
two orders of magnitude higher potency than ADP (with half-maximal responses at 
0.9 nM and 300 nM, respectively). UDP and adenosine failed to have agonist 
effects in Xenopus oocytes expressing the rat or human P2Y12. The P2Y1-
selective antagonist A3P5P had no inhibitory effect in this assay. Northern blot 
analysis demonstrated that the P2Y12 receptor has a restricted expression pattern 
and is abundantly present in platelets and to a smaller extend in the brain. 
 
The deduced protein sequences of cloned P2Y receptors share approximately 
25 % identity with other members of the G protein-coupled receptor family and 
about 40 % identity with one another, indicating that they form a distinct branch of 
the G protein-coupled receptor superfamily (Brake and Julius, 1996). 
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Fig. 1.5. Molecular structure of P2Y receptors (modified from Burnstock, 1996). 
 
 
1.2.3.5. Further P2Y receptors 
 
P2Y3 receptor 
  The cDNA has been cloned from chick brain (Webb et al., 1996). This 
receptor shows a preference for UDP, and to a lesser extent for UTP and ADP. 
Because no mammalian homologue has yet been identified, it is not included as a 
distinct subtype within the P2Y receptor family by the IUPHAR nomenclature 
committee. It has been suggested that the p2y3 may be the chick homologue of 
the mammalian P2Y6 receptor, but this has not yet been confirmed (for review see 
Ralevic and Burnstock, 1998; Von Kügelgen and Wetter, 2000). 
The cloned G protein-coupled p2y5, p2y9, and p2y10 receptors have now been 
shown unequivocally not belonging to the P2Y receptor family. The receptor 
initially termed p2y7 was found to be a leukotriene B4 receptor. There are also 
some doubts about the inclusion of the turkey tp2y receptor as well as the p2y8 
receptor expressed in the neural plate of Xenopus laevis, as mammalian 
homologues have not been identified (summarised by Ralevic and Burnstock, 
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1998). However, they seem to be similar to the rat P2Y4 receptor (Von Kügelgen 
and Wetter, 2000). 
 
The originally termed P2D (P2YApnA or P4) receptor, which has high affinity for 
diadenosine polyphosphates, has not yet been cloned and thus is now designated 
as the dinucleotide receptor (Pintor and Miras-Portugal, 2000). This receptor might 
be a subtype of the P2Y receptor family because it seems to couple to G proteins 
(Ralevic and Burnstock, 1998). 
 
 
1.2.4. Agonists 
 
According to the widespread occurrence of P2 receptors, they have a broad ligand 
specificity, recognising ATP, ADP, UTP, and UDP as well as the diadenosine 
polyphosphates. However, most of the agonist ligands used for pharmacological 
characterisation of P2 receptor subtypes are structural variations of the parent 
purine or pyrimidine nucleotide pharmacophore at the ring system, the ribose 
moiety, or the polyphosphate side-chain (Fig. 1.6.). Structure-activity relationships 
(SAR) efforts have predominantly focused on improved ligands potency, 
enzymatic stability and/or receptor subtype-selectivity (reviewed by Jacobson and 
Suzuki, 1996; Ralevic and Burnstock, 1998). 
 
The stable analogue of ATP, ,-meATP, which is more resistant than ATP to 
hydrolysis by ecto-nucleotidases present on cell membranes, was first shown to 
produce a selective desensitisation of P2 receptors in guinea-pig bladder and vas 
deferens. Since then, ,-meATP has been the most widely used compound in 
the investigation of P2X receptor-mediated responses in many tissues, because it 
is effective especially at recombinant P2X1, P2X3, heteromeric P2X2+3 and 
P2X1+5 receptors as well as at their endogenous counterparts, and generally 
inactive at P2Y receptors (see review Dalziel and Westfall, 1994; Ralevic and 
Burnstock, 1998; Lambrecht, 2000). 
Another stable and also useful purine analogue is adenosine 5’-O-(2-
thiodiphosphate) (ADPS), as it is an agonist at some P2Y receptors, e.g. P2Y1, 
but weak or inactive at P2X receptors (Ralevic and Burnstock, 1998). 
 
The use of other P2 receptor agonists, e.g. 2-MeSATP, is limited in whole tissue 
studies by their insufficient stability in the presence of ecto-nucleotidases.  
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1.2.5. Antagonists 
 
Functional subtype-identification of P2 receptors in native tissues is based on the 
use of agonists and subtype-preferring antagonists. However, most antagonists 
are highly limited in terms of their kinetics of antagonism, receptor-affinity, 
selectivity and P2 receptor-specificity (Lambrecht et al., 1999).  
In the following, such P2 antagonists are described, which were extensively tested 
at recombinant and/or native P2 receptors, and which were used for P2 receptor 
characterisation in the present study (see chapter 4.2.) (Fig. 1.7.). 
 
Suramin, the symmetrical urea of 8-(3-benzamido-4-methylbenzamido)-
naphthalene-1,3,5-trisulfonic acid (Fig. 1.7.), a polysulfonated aromatic 
antitrypanocidal drug, is an effective antagonist of P2 receptors, and might be a 
useful tool in discriminating between P1 and P2 receptor-mediated responses. 
The antagonist effect of suramin was first shown in the mouse vas deferens (Dunn 
and Blakeley, 1988). Subsequent studies have investigated the P2 antagonism of 
suramin in a variety of tissues, such as mouse vas deferens, rat vas deferens, 
pithed rat, guinea-pig urinary bladder and taenia coli, and rabbit ear artery (for 
review see Dalziel and Westfall, 1994; Ralevic and Burnstock, 1998). 
Unfortunately, the compound also interacts with glutamate, nicotinic, 5-
hydroxytryptamine and GABA receptors, ecto-nucleotidases, various protein 
kinases, and G protein subunits (Bhagwat and Williams, 1997; Ralevic and 
Burnstock, 1998; Lambrecht, 2000), indicating that suramin possesses a spectrum 
of biological activities that might limit its usefulness as a P2 receptor antagonist. 
Simplification of the structure of suramin has resulted in NF023. 
 
The symmetrical 3’-urea of 8-(benzamido)naphthalene-1,3,5-trisulfonic acid 
(NF023; Fig. 1.7.) was found to be selective for native P2X1 receptors (pA2 = 5.5 - 
5.7) antagonising effects at these receptors in rat, hamster and rabbit tissues 
(Bültmann et al., 1996; Lambrecht, 1996; Ziyal et al., 1996, 1997). The effect of 
NF023 studied on voltage-clamped Xenopus oocytes heterologously expressing 
homomultimeric P2X1 - P2X4 as well as heteromultimeric P2X2+3 receptors 
confirmed the subtype-selectivity for the P2X1 receptor (Soto et al., 1999). Like 
the parent compound suramin, NF023 inhibited ecto-nucleotidases activity, but its 
P2X1-selectivity is dominating (Lambrecht, 2000). In order to increase the potency 
of NF023 at the P2X1 receptor and, hence, to alter its functional selectivity in 
favour of the P2X1 subtype, further structural variations have been examined. 
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The suramin-related compound NF279 (8, 8’-(carbonylbis(imino-4,1-
phenylenecarbonylimino-4,1-phenylenecarbonylimino))bis(1,3,5-naphthalene-
trisulfonic acid); Fig. 1.7.) is a novel and highly potent antagonist blocking P2X 
receptor-mediated responses in rat vas deferens (pIC50 = 5.71), and having only 
little effects at P2Y receptors in guinea-pig taenia coli (pA2 = 4.10; Damer et al., 
1998). At cloned P2X receptors expressed in Xenopus oocytes (P2X1 - P2X4, 
P2X7), the compound was wholly selective for P2X1 receptors (Lambrecht, 2000). 
NF279 was found to be weak at recombinant P2Y1 (pIC50 = 4.6) and inactive (up 
to 100 µM) at P2Y2, P2Y4 and P2Y6 receptor subtypes (Boyer and Harden, 
personal communication). Thus, NF279 is the compound with the highest P2X1 
vs. P2Y receptor and ecto-nucleotidase selectivity presently available (Lambrecht 
et al., 1999; Lambrecht, 2000). 
 
A diazo derivative of the coenzyme pyridoxal phosphate, pyridoxalphosphate-6-
azophenyl-2’,4’-disulfonic acid (PPADS; Fig. 1.7.), is another widely used P2 
receptor antagonist, which is not selective for one of the P2 receptor subtypes 
(Lambrecht et al., 1992; Lambrecht, 1996). It exhibits pA2 values of 6 - 6.7 at 
endogenous P2X1-like receptors in a variety of smooth muscle preparations 
(Ralevic and Burnstock, 1998). At recombinant P2X1, P2X2, P2X3, and P2X5 
receptors PPADS had antagonistic effects with IC50 values of 1 - 2.6 µM, whereas 
rat P2X4 and P2X6 receptors were unaffected (Collo et al., 1996). Within the P2Y 
receptor family, PPADS generally antagonises endogenous P2Y1-like and 
recombinant P2Y1 receptors coupled to PLC but not P2Y receptors coupled to 
inhibition of AC. PPADS has been reported to block P2Y1-like receptors in rat 
duodenum (pA2 = 5.1), guinea-pig taenia coli (pA2 = 5.3; Windscheif et al., 1995), 
and rat mesenterial arterial bed (pA2 = 6.0; Ralevic and Burnstock, 1996), but was 
inactive at those in smooth muscle of rabbit mesenteric artery and endothelium of 
rabbit aorta (Ziganshin et al., 1994b). PPADS also blocks P2Y2-like receptors in 
astrocytes from the dorsal horn of the spinal cord, but not those on rat mesenteric 
arterial endothelium or on cultured bovine aortic endothelial cells. Furthermore, it 
antagonises responses to UTP at recombinant P2Y4 receptors, and at high 
concentrations PPADS blocks P2ADP receptor-mediated platelet aggregation and 
inhibits ecto-nucleotidase activity (reviewed by Ralevic and Burnstock, 1998). 
 
In order to increase the selectivity of PPADS in favour of the P2X1 subtype a 
series of 6-naphthylazo analogues was synthesised and pharmacologically 
characterised by Lambrecht and co-workers (1999). The most promising 
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compound, pyridoxal-5’-phosphate-6-(2’-naphthylazo-6’-nitro-4’,8’-disulfonate) 
(PPNDS; Fig. 1.7.), has shown high affinity at P2X1 in rat vas deferens (pKB = 
7.43) and in inhibition of inward currents to 1 µM ATP in Xenopus laevis oocytes 
expressing homomeric cloned rat P2X1 receptors (pIC50 = 7.84). In contrast, its 
antagonistic properties at the P2Y receptor in guinea-pig taenia coli (pA2 = 4.84) 
and at the P2Y1 subtype in guinea-pig ileum (pA2 = 6.13) were clearly lower. 
Thus, PPNDS is a novel P2 antagonist with high affinity at and selectivity for the 
P2X1 receptor subtype. 
 
Recently, Lambrecht and co-workers (2000) introduced an interesting antagonist, 
SB9 (Fig. 1.7.), resulting from extensive SAR studies with heterodimers, which 
potently antagonises P2Y1 receptor-mediated responses. SB9, 6-[(4,6,8-trisulfo-1-
naphthyl)iminocarbonyl-1,3-(4-methylphenylene)iminocarbonyl-1,3-phenylene-
azo]-pyridoxal-5’-phosphate, is a bivalent ligand consisting of pyridoxal-5’-
phosphate and the monomer of suramin linked through a diazo group as spacer. It 
has been found that the compound exerts a remarkable selectivity for P2Y1-like 
receptors in GPI (pA2 = 6.98 ± 0.07) with an about 10-fold lower antagonistic 
potency at P2X1-like receptors in rat vas deferens (pA2 = 6.05 ± 0.13). In the ecto-
nucleotidase assay, SB9 has shown a 447-fold lower inhibitory potency. Thus, 
heteromeric bivalent ligands might be useful P2 antagonists and especially SB9 
could be used as lead compound for further investigations. 
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Fig. 1.6. Chemical structure of some P2 receptor agonists. 
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Fig. 1.7. Chemical structure of some P2 receptor antagonists. 
 
 
1.2.6. Agonist breakdown 
 
As already emphasised, the problems associated with the breakdown of ATP and 
its hydrolysable analogues have profound implications for the pharmacology of P2 
receptors. It is evident that many tissues have cell-surface enzymes that are 
capable of dephosphorylating ATP sequentially to ADP, AMP and adenosine 
(Ziganshin et al., 1994a). The catalytic site of this ectonucleotidases faces the 
extracellular medium, and for its catalytic activity the presence of divalent cations 
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such as Ca
2+
 or Mg
2+
 is necessary. The expression of the individual enzymes can 
vary between tissues, cells, and developmental stages. A key function of these 
enzymes presumably is the inactivation of nucleotides or nucleosides that have 
been released as signalling substances or during pathological events and, 
subsequent, purine salvage (for review see Zimmermann, 1996, 1999). The 
simplistic nomenclature used so far in the literature, e.g. ecto-ATPase, ecto-
ADPase, has to be revised after the molecular and functional characterisation of 
several novel enzyme families with overlapping substrate specificities and tissue 
distribution. The following enzymes are mainly involved in the degradation of 
nucleotides (see Zimmermann, 2000). 
 
Ecto-nucleoside 5’-triphosphate diphosphohydrolase (E-NTPDase) family 
 
Members of this family can hydrolyse nucleoside 5’-triphosphates (NTP) and 
nucleoside 5’-diphosphates (NDP) albeit with varying preference for an individual 
type of nucleotide. According to their presumptive membrane topography they can 
be separated into two groups: (1) NTPDase1 to 4, which are predicted to have a 
transmembrane domain at the N- and C-terminus; (2) NTPDase5 and putative 6; 
but only NTPDase5 has been expressed and characterised (lack of C-terminus, 
whereas N-terminal hydrophobic leader sequence is cleaved, resulting in a soluble 
and secreted form of the enzyme). The enzymes of the E-NTPDase family differ 
regarding their preference for NTP and NDP. 
 
 NTPDase1  (Ecto-ATPDase):  NTP   NMP + 2 Pi; NDP  NMP + Pi 
 NTPDase2  (Ecto-ATPase):  NTP   NDP + Pi; (NDP  NMP + Pi) 
 NTPDase3  (Ecto-ATPDase):  NTP   NDP + Pi; NDP  NMP + Pi 
 NTPDase4  (UDPase):    UDP   UMP + Pi; UTP  UDP + Pi 
 
  NTPDase5:     NDP   NMP + Pi 
 
Ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) family 
 
The members of this family are characterised by a single transmembrane domain, 
an intracellular N- and an extracellular C-terminus. The enzymes (NPP1 to NPP3) 
possess a surprisingly broad substrate specificity - alkaline phosphodiesterase as 
well as nucleotide pyrophosphatase activity. That means that these enzymes are 
capable of hydrolysing: 
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 NTP   NMP + PPi (ATP  AMP + PPi) 
 ADP   AMP + Pi 
 AMP   adenosine + Pi 
 
Alkaline phosphatases 
 
These enzymes are non-specific ecto-phosphomonoesterases that are releasing 
inorganic phosphate from a variety of organic compounds including NTP, NDP 
and NMP. They may also hydrolyse PPi. 
 
 NTP   NDP + Pi 
 NDP   NMP + Pi 
 NMP   nucleoside + Pi 
 PPi   2 Pi 
 
Ecto-5’-nucleotidase 
 
This enzyme is responsible for the formation of extracellular adenosine from 
released adenine nucleotides. 
 
 NMP   nucleoside + Pi 
 
The situation is more complicated since many of the enzymes have shown tissue 
colocalisation. Finally, there are many other surface-located converting enzymes, 
e.g. ecto-nucleoside diphosphokinase that may interconvert ATP and UDP to ADP 
and UTP, the presence of which can result in an underestimation of ligand 
potency. These misinterpretations have led to an intensive search for compounds 
that inhibit ecto-nucleotidases and preferably have no or only a small effect on P2 
receptors.  
The only selective ecto-nucleotidase inhibitor that has just a small antagonistic 
effect on P2X receptors is the ATP analogue 6-N,N-diethyl-D-,-
dibromomethylene ATP (ARL 67156, formerly FPL 67156) (Kennedy et al., 1996). 
When purified ecto-enzymes were used, the analysis of structure-activity 
requirements of the enzyme suggested that substitutions at the purine ring had 
virtually no effect on removal of the terminal phosphate from the ATP analogues, 
and compounds, such as 2-MeSATP and 2-ClATP, are good substrates of ecto-
nucleotidases. However, methylene isoesters of ATP, e.g. ,-meATP and ,-
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meATP, or compounds with substitutions on the terminal phosphate of the 
nucleotide, ADPS and ADPS, proved to be resistant to degradation (for review 
see Zimmermann, 1996). 
Furthermore, the ability of P2 receptor antagonists to inhibit some ecto-
nucleotidases and thereby protect ATP and other nucleotidases from degradation 
may complicate their use (Chen et al., 1996; Lambrecht et al., 1999). 
 
 
1.2.7. Signal transduction mechanisms 
 
P2X receptors can modulate cell function by gating Na
+
, K
+
 and Ca
2+
 permeability 
resulting in an increase in intracellular Ca
2+
 ([Ca
2+
]i) and depolarisation (see 
Surprenant, 1996). The direct flux of extracellular Ca
2+
 through the channel 
constitutes a significant source of the increased [Ca
2+
]i. On the other hand, 
membrane depolarisation leads to the secondary activation of voltage-dependent 
Ca
2+
 channels, which probably make the primary contribution to Ca
2+
 influx and 
to the increase of [Ca
2+
]i. Because this transduction mechanism does not depend 
on the production and diffusion of second messengers within the cytosol or cell 
membrane, the response time is very rapid, and appropriately plays an important 
role in fast neuronal signalling and regulation of muscle contractility (Ralevic and 
Burnstock, 1998).  
 
P2Y receptors belong to the seven transmembrane domain superfamily of 
receptors, which may couple, via heterotrimeric G proteins, to ion channels as well 
as to enzymes. In the following the substantial second messenger pathways for 
P2Y receptors are described briefly. 
 
Phospholipase C (PLC) 
  The main signal transduction pathway of all cloned and functionally defined 
P2Y receptors is activation of PLC via PTX-sensitive Gi/o and -insensitive Gq/11 
proteins, resulting in increased levels of inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). The consequence of IP3 formation and entailed Ca
2+
 
mobilisation is the stimulation of a variety of signalling pathways, e.g. activation of 
phosphokinase C (PKC), phospholipase A2 (PLA2), Ca
2+
-dependent K
+
 channels, 
nitric oxide synthase (NOS) and subsequent endothelium-derived relaxing factor 
(EDRF) formation. DAG leads to activation of PKC, which in turn may stimulate 
PLC, phospholipase D (PLD), mitogen-activated protein kinase (MAPK) pathway 
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and voltage-dependent Ca
2+
 channels (reviewed by Barnard et al., 1997; Ralevic 
and Burnstock, 1998). 
 
Adenylate cyclase (AC) 
  The regulation of cAMP levels by P2Y receptors is a result of direct 
inhibition of the AC via PTX-sensitive Gi proteins. This pathway has been 
observed for P2Y11 (Communi et al., 1997) and P2Y12 (Hollopeter et al., 2001) 
receptor subtypes. 
 
Ion channels 
  P2Y receptors can regulate plasmalemma ion channels indirectly, as a 
result of second messenger production, or directly via either  or  subunits. The 
receptor stimulation results in a rise of intracellular Ca
2+
 by mobilisation of 
intracellular stores, leading to the sequential opening of two types of Ca
2+
-
sensitive channels: transient depolarising Cl
-
 (for example described for P2Y 
receptors in airway epithelia) and hyperpolarizing K
+
 channels (Boarder and 
Hourani, 1998).  
 
Phospholipase A2 (PLA2) 
  In endothelial cells, activation of Ca
2+
-sensitive PLA2 results in an 
increased production of prostacyclin (reviewed by Ralevic and Burnstock, 1998). 
 
Tyrosine kinase - MAPK cascades 
  MAPK are key elements of signal transduction pathways involved in cell 
growth. These cytoplasmatic enzymes transduce signals from both receptor 
tyrosine kinases and G protein-coupled receptors to the nucleus, resulting in the 
activation and/or induction of transcription factors, thereby leading to gene 
expression and cell growth. The tyrosine kinase and p42-p44 MAPK cascades are 
now recognised as a part of response to activation of P2Y receptors. Three routes 
for the regulation of MAPK by P2Y receptors are conceivable: activation of the 
tyrosine kinase - MAPK cascades directly by  subunits, activation following PLC 
stimulation, and by an autocrine mechanism involving production of a growth 
factor, which then acts on a tyrosine kinase receptor (Neary, 1996; Boarder and 
Hourani, 1998). As with the P2Y1 receptor, protein tyrosine phosphorylation and 
MAPK activation seem to be the major route for P2Y2 receptor-mediated 
prostacyclin production in endothelial cells.  
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1.2.8. Localisation and physiological roles 
 
In view of the ubiquitously occurrence of purines and pyrimidines and the 
widespread distribution of P2 receptors (for review see Ralevic and Burnstock, 
1998), only a few examples have been selected and will be focused in the 
following. 
 
Nervous system 
  Since Burnstock’s first proposal of purinergic nerves, a large body of 
evidence has been accumulated and unambiguously demonstrated that ATP, 
released upon stimulation and action on P2 receptors, is a neurotransmitter in the 
efferent autonomic nervous system and peripheral sensory nerves (Chen et al., 
1995b). 
 
In 1976, Burnstock introduced the concept of co-transmission. It appears that ATP 
is a principal transmitter and that it has been retained as a co-transmitter with 
other neurotransmitters, such as noradrenaline and ACh, in many different nerve 
types, albeit in proportions that vary between locations and species. So it was 
found, that in sympathetic nerves ATP co-exists and is co-released with 
noradrenaline and neuropeptide Y, in some parasympathetic nerves with ACh, in 
some sensory-motor nerves with calcitonin gene-related peptide (CGRP) and 
substance P, and in NANC inhibitory nerves together with NO and vasoactive 
intestinal peptide (VIP; for review see Burnstock, 1996). 
 
Additionally, ATP co-released with noradrenaline or ACh, also plays a feedback 
role in modulation of transmitter release via presynaptic P2 receptors in the 
autonomic nervous system. The facilitation on noradrenergic and/or cholinergic 
transmission has been reported in the rabbit ear artery, GPI, saphenous artery 
and rat sympathetic neurons (for review see Chen et al., 1995b).  
 
Glia cells, as a constitutional and functional part of the nervous system, play an 
important role in the modulation of synaptic efficacy. Astrocytes, oligodendrocytes 
and microglial cells are all direct targets for extracellular nucleotides via various P2 
receptor subtypes, which mediate a variety of biological processes (Chen et al., 
1995b; Abbracchio and Burnstock, 1998; Inoue, 1998). 
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Cardiovascular system 
  The importance of ATP as an extracellular signalling molecule was first 
appreciated in the cardiovascular tissue. ATP, acting at distinct P2 receptor 
subtypes located on endothelial and smooth muscle cells, affects vascular tone 
and blood flow by causing either contraction or dilatation.  
Vasoconstriction is mediated through the stimulation of P2X receptors present on 
vascular smooth muscle cells. Synaptic release of ATP from sympathetic 
perivascular neurons activates excitatory P2X receptors to produce the NANC 
component of vasoconstriction that remains after blockade of adrenergic and 
cholinergic receptors. The purinergic nature of this response was demonstrated by 
its attenuation following application of ,-meATP, which desensitises these 
receptors (reviewed by Brake and Julius, 1996). In the rat vascular system 
mRNAs for P2X1, P2X2 and P2X4 receptor subtypes were found by in situ 
hybridisation and reverse transcriptase PCR (Nori et al., 1997). 
P2Y receptors are also involved in the regulation of vascular tone. ATP, released 
from endothelial cells during hypoxia, activates endothelial P2Y1, P2Y2 and 
probably P2Y4 receptors resulting in activation of endothelial NOS and release of 
EDRF, thereby in potent vasodilatation. Adenosine, produced following breakdown 
of ATP, contributes to the later component of vasodilatation by direct action of P1 
receptors on vascular smooth muscle (reviewed by Abbracchio and Burnstock, 
1998). 
 
Within the cardiovascular system, ATP and ADP also function as paracrine 
regulators of platelet aggregation. Platelets aggregating at sites of damage in 
arterial walls release high concentrations of ATP and ADP as constituents of their 
dense granules. ADP recruits additional platelets through activation of P2Y12 
(Hollopeter et al., 2001) receptors on their surface. It has been shown that ADP 
stimulates platelets acting on three distinct P2 receptors, P2X1 (Sun et al., 1998), 
P2Y1 and P2Y12, leading to increase of intracellular Ca
2+
, rapid Ca
2+
 influx, 
activation of PLC and inhibition of AC, shape change of the platelets, exposure of 
glycoprotein IIb/IIIa complex as binding sites for cross-linking of platelets by 
fibrinogen, amplification of the response by release of a range of proaggregatory 
mediators including thromboxane A2, 5-hydroxytryptamine and ADP, and 
sustained aggregation (Kunapuli, 1998; Ingall et al., 1999; Brass, 2001). 
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Immune system 
  Extracellular ATP is known to act on a variety of cells within the immune 
system. The P2X7 receptor is thought to be involved in this action of ATP, since it 
was found in functional studies that P2X7 receptor distribution is generally limited 
to cells of hematopoietic origin including mast cells, macrophages and 
lymphocytes (reviewed by Abbracchio and Burnstock, 1998; Ralevic and 
Burnstock, 1998).  
ATP acting via P2X7 receptors has been implicated as an initiator of programmed 
cell death, i.e. apoptosis. For example, exposure of mouse macrophages to 
extracellular ATP leads to nuclear DNA fragmentation and release of processed 
interleukin-1, two responses that are associated with apoptotic death in some cell 
types (reviewed by Brake and Julius, 1996). 
 
 
1.2.9. Therapeutic targets 
 
Cardiovascular system 
  In the cardiovascular system the most immediate target for therapeutic 
intervention is in the control of platelet function. The central role of ADP as an 
aggregating agent, not only in the physiological processes of haemostasis but also 
in the development and extension of arterial thrombosis, has been long 
established and makes ADP receptors of potential clinical importance. Platelet 
activation by ADP leads to rapid calcium entry and mobilisation of intracellular 
calcium stores, inhibition of AC, shape change from discoid to spherical form, and 
aggregation. 
The antithrombotic drugs ticlopidine and clopidogrel are thought to act by reducing 
the number of P2Y12 receptors on platelets, thereby reducing the responsiveness 
of platelets to ADP. Both compounds are inactive in vitro and must be metabolised 
in the liver to thiol derivatives in order to acquire their anti-aggregatory properties 
in this way that they modify a cysteine residue on the receptor (Hollopeter et al., 
2001). 
A more direct mechanism to prevent platelet aggregation is the ATP analogue 
APL66096, a platelet ADP receptor antagonist, which has shown promising results 
in experimental models of thrombosis (for review see Boarder and Hourani, 1998; 
Hechler et al., 1998). Recently, Ingall and co-workers reported on two ATP 
analogues, which structurally differ from ATP in modifications of the 
polyphosphate side chain to prevent breakdown and substitution of the adenine 
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moiety to enhance affinity and selectivity for P2YADP (P2Y12) receptors. The 
compounds, termed AR-C67085MX and AR-C69931MX, exhibited IC50 values of 
2.5 nM and 0.4 nM, respectively, against ADP-induced aggregation of human 
platelets (Ingall et al., 1999). Antagonists of the P2Y12 receptor represent a major 
step forward in the treatment of thrombotic disease (reviewed by Cusack and 
Hourani, 2000). 
 
Respiratory tract 
  Cystic fibrosis (CF), a hereditary disease, is recognised as a result of 
mutations in a gene encoding for the cystic fibrosis transmembrane conductance 
regulator (CFTR) that results in a defect in cAMP-stimulated chloride transport. 
Subsequently, mucus may become altered in its rheological properties and 
bacterial adhesivity, leading to inflammation and then mucus hypersecretion. ATP 
and UTP have been proposed as therapeutic agents acting on P2 receptors 
resulting in intracellular calcium mobilisation through PLC. This increase in 
calcium leads to an activation of a chloride channel distinct from CFTR, which is 
localised on respiratory epithelia and which is not defective in cystic fibrosis 
(Boarder et al., 1995; Merten et al., 1998). UTP is currently in phase II clinical 
trials as a treatment for CF (Bennett et al., 1996; Olivier et al., 1996). 
Disadvantages of ATP are the bronchoconstrictor and cardiac depressant effects 
of adenosine formed from the hydrolysis of ATP (Bhagwat and Williams, 1997). 
 
Sensory neurons 
  ATP has long been known to induce nociceptive responses following 
peripheral administration. These effects are due to direct activation of peripheral 
nerve terminals or indirectly through actions on inflammatory cells. ATP, 
originating from platelets, mast cells, postganglionic sympathetic nerve terminals 
or from sensory afferents, may be released into extracellular spaces as a 
consequence of tissue injury. Which P2 receptor subtype could mediate the 
nociceptive effect of ATP is still unknown, but there is strong evidence that 
homomeric P2X3 or heteromeric P2X2+3 receptors are involved (Cook et al., 
1997; Ding et al., 2000; Burnstock and Williams, 2000; Hamilton and McMahon, 
2000).  
 
Endocrinal system 
  ATP also has important endocrine functions acting on P2Y receptors, 
probably P2Y1 receptors, of pancreatic ß cells. Insulin secretion induced by 
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physiological agents such as ACh and glucose was potentiated by ATP and ADP. 
The stable analogue ADPßS was approximately 100-fold more potent than ATP 
itself in increasing insulin secretion in isolated perfused rat pancreas. In vivo 
experiments in rats and dogs showed that after oral administration of ADPßS the 
insulin secretion was stimulated and glucose tolerance was improved (Hillaire-
Buys et al., 1993). Studies with ADPßS in streptozotocin-diabetic rats further 
supported the hypothesis that P2Y receptors of the pancreatic ß cells may be 
suitable target for the development of new orally-active antidiabetic drugs (for 
review see Abbracchio and Burnstock, 1998). Recently, Petit and colleagues 
provided evidence that on pancreatic ß cells, additionally to the P2Y, P2X 
receptors are localised, which transiently stimulate insulin release at low non-
stimulating glucose concentration and slightly affect the potassium conductance of 
the membrane (Petit et al., 1998). 
 
Tumor growth 
  P2 receptor agonists such as ATP, ADP, AMP, ,-meATP,  ,-meATP 
and ATPS were claimed as antineoplastic agents (for review see Fischer, 1999). 
These compounds may be useful for the treating of any hormone independent 
cancer, including prostate, ovarian, breast and endometrial cancer. The claim is 
based on the expression of P2 receptors on these cancer cells, and stimulation of 
these receptors inhibits the growth of the cells. This new approach for the 
treatment of neoplasm is of special interest since the metastatic disease cannot 
be controlled by a hormonal therapy. 
 
In conclusion, P2 receptors may be promising clinical targets and P2 agonists or 
antagonists helpful for the treatment of various diseases. Nonetheless, the use of 
knockout mice will be a beneficial way to clarify the participation of P2 receptor 
subtypes in physiological as well as in pathophysiological processes (Burnstock 
and Williams, 2000). 
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2.  AIM OF THE THESIS 
 
 
2.1.  Investigations of the isomers of glycopyrronium bromide and their 
tertiary analogues at muscarinic receptors 
 
As mentioned above, muscarinic receptors are composed of a family of four 
functionally characterised subtypes, which can be distinguished pharmacologically 
and structurally. The physiological role of each subtype in the central and 
peripheral nervous system remains to be clarified due, in part, to a lack of agonists 
and antagonists with adequate subtype selectivity. In this regard, the development 
of subtype selective muscarinic ligands could provide both improved tools for 
receptor classification and novel therapeutics with reduced cholinergic side 
effects. Indeed, several selective muscarinic receptor ligands are now in advanced 
clinical evaluation (Eglen and Watson, 1996). 
 
Selective blockade of muscarinic M3 receptor may be therapeutically useful in the 
treatment of respiratory disorders, such as COPD. Vagal stimulation induces 
brochoconstriction and mucus secrection, by activation of muscarinic M3 receptors 
located on smooth muscle, vascular endothelium, submucosal cells and neural 
elements (Barnes, 1993). The evidence that quaternary atropine derivatives such 
as ipratropium bromide (Fig. 2.1.) produce significant bronchodilation has recently 
been stimulated interest in antimuscarinics as bronchodilators. These highly polar 
ammonium compounds are poorly absorbed across mucosal surfaces, and thus 
systemic effects are unlikely with drug inhalation. 
 
Instead of subtype-selective M3 receptor antagonists, some new therapeutic 
approaches exploit differences in receptor kinetics. Tiotropium bromide (BA 679 
BR; Fig. 2.1.) is a novel antagonist, developed as a long-acting antimuscarinic 
bronchodilator for the treatment of patients with COPD. It inhibits exogenous ACh-
induced bronchospasm three times more potently than ipratropium bromide. 
Tiotropium bromide binds non-selectively to cloned human M1 - M3 receptors but 
dissociates more rapidly from M2 and M1 than from M3 receptors, thus achieving 
M3 subtype selectivity through a kinetic mechanism (Disse et al., 1993; Maesen et 
al., 1993; Haddad et al., 1994). 
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Glycopyrronium bromide (glycopyrrolate; Fig. 2.1.) is a quaternary compound with 
antimuscarinic properties similar to those of atropine, but with minimal 
cardiovascular, ocular and CNS effects. It has two chiral carbon atoms resulting in 
four stereoisomers. Glycopyrrolate (Robinul
) is one of the two diastereomeric 
forms of glycopyrronium bromide and represented by the (R/S)-(S/R) pair (Demian 
and Gripshover, 1990). The safety of glycopyrrolate has been established by 
nearly 20 years of clinical use, orally to control gastric acidity and parenterally as 
an antisialogogue, and in the reversal of neuromuscular blockade as a substitute 
of atropine (Mirakhur and Dundee, 1981; Johnson et al., 1984; Ali-Melkkilä et al., 
1993). 
 
The impetus for the present study came from the interesting findings by Fuder and 
Meincke (1993), who analysed the antimuscarinic properties of glycopyrronium 
bromide in vitro at rabbit vas deferens (RVD; M1), paced rat left atria (M2), and 
guinea-pig ileum (GPI; M3). Glycopyrronium bromide blocked with very high 
affinity (>11, apparent -log pKB) the muscarinic M1 receptor, and it showed 
intermediate affinity (10.31) at M3 and lower affinity (9.09) at M2 receptors. With 
exception of M1 receptors, the antagonism appeared to be of simple competitive 
type. At RVD the slope of the Schild regression line was lower than unity at higher 
concentrations (1 nM) and steepened when the lowest concentration (0.1 nM) was 
taken into account. Thus, a virtual apparent -log KB value of 11.41 ± 0.14 was 
estimated from dose ratios of all antagonist concentrations assuming a slope of 
unity. Testing low antagonist concentrations comparatively close to the apparent 
KB resulted, probably, in incomplete drug equilibrium between organ bath and 
tissue even after an equilibration time of 3 to 5 h. 
 
In light of these results, the selectivity profile of the individual stereoisomers of 
glycopyrronium bromide at the muscarinic receptor subtypes would be interesting 
to investigate. Hence, the aim of the present investigation was to determine the 
affinities of the quaternary isomers of glycopyrronium bromide as well as of the 
corresponding tertiary analogues and to evaluate the stereochemical demands for 
the binding to the muscarinic receptor subtypes. 
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Fig. 2.1. Chemical structure of the muscarinic antagonists used or in development 
for the treatment of COPD. The asterisks denote the centres of chirality. 
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2.2.  Evaluation of the guinea-pig ileal longitudinal smooth muscle with 
respect to the distribution of P2 receptors 
 
ATP plays a widespread role in cell signalling, acting at surface receptors called 
P2 receptors and promoting a diverse array of physiological functions. 
Classification based on rank order of agonist potency generated an initial 
subdivision into P2X and P2Y receptors, which are now known to be ion channels 
and seven transmembrane G protein-coupled receptors, respectively. Recently, 
successful cloning strategies have had a major impact on this area of 
pharmacology, with the cloning of seven P2X and six P2Y subtypes (see chapter 
1.2.3.). The integration of this molecular information into an understanding of the 
cellular and tissue functions of these receptors is very important, especially since 
a heterogenous population of P2 receptors is very often found in native tissues.  
 
The guinea-pig ileal longitudinal smooth muscle (GPI) preparation is established 
as a robust in vitro test system for different receptor classes, e.g. muscarinic, 5-
hydroxytryptamine and histamine receptors. Recently, in several studies P2 
receptors were found to be located in this tissue. Using ,-meATP as agonist 
contraction of the ileal longitudinal muscle segments could be shown which may 
be due to its action at P2X receptors. Since the evoked contractile response was 
inhibited by tetrodotoxin and atropine, ,-meATP seems to act, probably, on 
P2X-like receptors situated on cholinergic nerves and, subsequently, to release 
acetylcholine causing an atropine-sensitive contraction of the GPI. Moreover, it is 
proposed the involvement of an endogenous P2 ligand, possibly ATP, acting as a 
positive modulator of ACh release or stimulating a further P2 receptor located at 
the postsynaptic site, since its contractile effect was atropine- and TTX-insensitive 
(Kennedy and Humphrey, 1994; Barthó et al., 1997; Matsuo et al., 1997; Sawyer 
et al., 2000). 
 
Accordingly, the present study was addressed to elucidate the pre- and 
postsynaptically located receptor subtypes mediating the responses to ,-meATP 
and other P2 receptor agonists in guinea-pig ileal longitudinal smooth muscle as 
well as their sensitivity to various commonly used P2 antagonists (Fig. 2.2.). 
 
 
 
48 
2. AIM OF THE THESIS 
 
     
 
 
Fig. 2.2. Funtional heterogeneity of P2 receptors mediating contraction in guinea-
pig ileal longitudinal smooth muscle. 
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2.3.  Characterisation of functional P2 receptor subtypes mediating 
contraction in the rat ileal longitudinal smooth muscle 
 
The identification and characterization of rat P2 receptors in native tissues are of 
special interest because one of the main current challenges is to relate the cloned 
rat P2X and P2Y receptor subtypes (see chapter 1.2.3.) to the diverse 
physiological responses caused by nucleotides.  
 
Previous studies examined the effect of ATP on myenteric plexus preparation of 
rat ileum. Using myocytes isolated from the longitudinal muscle layer of rat ileum, 
Pacaud et al. (1996) postulated a PPADS-sensitive P2 receptor with properties 
similar to the P2Y1 subtype stimulation of which led to a rise in intracellular Ca
2+
, 
resulting from coupling to PLC. Moreover, Blottière et al. (1996) suggested that 
these myocytes do not possess functional P2X receptors, because ,-meATP 
had no effect, but that 2-MeSATP and UTP gave hints for the existence of P2Y or 
P2U receptor subtypes. Both agonists induced a rise in [Ca
2+
]i, probably via an 
all-or-nothing mobilisation of Ca
2+
 from intracellular stores. 
Furthermore, the coexistence of ATP and NO was reported in myenteric neurons 
of the rat ileum (Belai and Burnstock, 1994). In experimens with electrical field 
stimulation, Smits and Lefebvre (1996) have found that ATP, NO and putative 
other neurotransmitters caused relaxation in the precontracted rat ileal longitudinal 
smooth muscle (RI). Because of the complex pattern resulting from EFS which in 
non-adrenergic, non-cholinergic conditions in precontracted RI consists of a 
primary (nitrergic) contraction, a primary relaxation, an off-relaxation (also nitrergic 
in nature) and a rebound contraction, it has been very difficult to determine the P2 
receptors that were involved. 
 
Thus, the present study was undertaken to characterise the P2 receptor subtypes 
subserving contraction of RI in order to define similarities and differences to native 
P2 receptors found functionally in GPI. 
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3.  MATERIALS AND METHODS 
 
 
3.1. Drugs 
 
3.1.1. Commercially available drugs 
 
  Adenosine 3’,5’-diphosphate (A3P5P; Sigma, Deisenhofen, Germany) 
 Adenosine  5’-O-(2-thiodiphosphate) dilithium salt (ADPßS; Sigma, 
 Deisenhofen,  Germany) 
 Adenosine  5’-O-(3-thiotriphosphate) dilithium salt (ATP  S; Sigma, 
 Deisenhofen,  Germany) 
  Atropine sulfate (Merck, Darmstadt, Germany) 
 2-Chloro-N
6
-cyclopentyladenosine (CCPA; RBI, Natick, USA) 
  8-Cyclopentyl-1,3-dipropylxanthine (DPCPX; RBI, Natick, USA) 
  Dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany) 
  Glycopyrronium bromide (Brenner Efeka - Wyeth, Münster, Germany) 
  Hexamethonium chloride (Sigma, Deisenhofen, Germany) 
  Histamine dihydrochloride (Sigma, Deisenhofen, Germany) 
  ,ß-Methyleneadenosine 5’-diphosphate dilithium salt (,ß-meADP; 
  Sigma, Deisenhofen, Germany) 
  ,ß-Methyleneadenosine 5’-triphosphate dilithium salt (,ß-meATP; Sigma, 
 Deisenhofen,  Germany) 
  2-Methylthioadenosine 5’-triphosphate tetrasodium salt (2-MeSATP; RBI, 
 Natick,  USA) 
  Naloxone (Sigma, Deisenhofen, Germany) 
 N
G
-Nitro-L-arginine (L-NOARG; Sigma, Deisenhofen, Germany) 
  Pentobarbital sodium (Nembutal
; Sanofi, Hannover, Germany) 
  Physostigmine (Merck, Darmstadt, Germany) 
  Procaine hydrochloride (Sigma, Deisenhofen, Germany) 
  Suramin (Bayer, Leverkusen, Germany) 
  Tetrodotoxin (TTX; Sigma, Deisenhofen, Germany) 
  Yohimbine hydrochloride (Sigma, Deisenhofen, Germany) 
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3.1.2. Gifts 
 
  MRS2179 (K. A. Jacobson; National Institutes of Health, Bethesda, 
 USA) 
  p-F-HHSiD (Prof. Dr. R. Tacke, University of Würzburg, Germany) 
  Himbacine hydrochloride (Dr. W. C. Taylor, University of Sidney, Australia) 
  NF023, NF031, NF279 (Prof. Dr. P. Nickel, Bonn, Germany) 
  PPADS (Dr. H. G. Bäumert, University of Frankfurt, Germany) 
  Pirenzepine hydrochloride (Dr. Karl Thomae GmbH, Biberach, Germany) 
 
 
3.1.3. Syntheses 
 
Arecaidine propargyl ester (APE) and 4-(4-fluorophenylcarbamoyloxy)-2-butynyl-
N-methyl-pyrrolidinium tosylate (4-F-PyMcN
+
) were synthesised in our laboratories 
by Dr. U. Moser and Mrs. U. Hermanni. 
The four isomers of glycopyrronium bromide and their four tertiary analogues were 
synthesised by M. Elgert, University of Frankfurt, Germany. 
 
 
3.2.  Preparation of buffer and stock solutions 
 
Bath fluids and buffers were freshly prepared for each experiment from 
commercially available chemicals of analytical grade purity. Their compositions 
are listed in the table below (Tab. 3.1.). 
 
Drugs were dissolved and diluted in 0.9 % (w/v) aqueous NaCl solution prior to 
use in the experiments. Stock solutions of CCPA and DPCPX were made up in 
dimethyl sulfoxide. Control experiments assured that the final concentration of 
dimethyl sulfoxide present after dilution in the bath fluid had no pharmacological 
effect itself. 
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Tab. 3.1. Compositions (in mM) of the bath fluids used in the pharmacological 
experiments 
 
 
 
 
Tyrode solution 
 
Krebs solution 
 
 
NaCl 
 
137.0 
 
118.0 
 
KCl      2.7  4.7   
CaCl2      1.8  1.0   
MgCl2       1.05  -   
MgSO4     -  0.6   
NaHCO3    11.9  25.0   
NaH2PO4        0.42  -   
KH2PO4     -  1.2   
(+)-Glucose      5.6  11.1   
 
 
3.3. Animals 
 
All laboratory animals were housed in an air-conditioned room at a temperature of 
23°C and a relative atmospheric humidity of 50 % in a light-dark cycle of 12 hours 
each. 
Male New Zealand white rabbits (2.5 - 3.0 kg body weight) were purchased from 
Koch, Edingen-Neckarhausen, Germany. 
Male guinea-pigs (250 - 350 g body weight) and male Sprague Dawley rats (200 - 
300 g body weight) were generously provided by Hoechst AG, Frankfurt/Main, 
Germany. 
All animals were fed a standard diet (rabbits/guinea-pigs: Altromin
 3022, rats: 
Altromin
 1324, Altromin GmbH, Lage, Germany) with free access to food and tap 
water. 
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3.4. Methods 
 
3.4.1. Rabbit vas deferens (RVD) 
 
Experiments on RVD were carried out according to the method described by Eltze 
(1988), Eltze et al. (1988) and Dörje et al. (1991b). Briefly, new Zealand white 
rabbits were killed by i.v. injection of 120 mg/kg of pentobarbital sodium 
(Nembutal
) into the ear vein, locally anaesthetised by a procaine solution (10 %, 
w/v). The abdomen was opened and the vasa deferentia were excised. After 
clearing of connective tissue the vasa deferentia were divided into six segments of 
approximately 1.0 cm length. Each segment was fixed vertically by means of 
platinum ring electrodes (Fleck, Mainz, Germany) and a cotton thread, which was 
connected to a force displacement transducer, in 6 ml water-jacketed organ baths 
containing Krebs buffer (for its composition see Tab. 3.1.). Additionally, 1 µM 
yohimbine was added to the buffer to block 2-adrenoceptors. 
The bath fluid was maintained at 31°C and was continuously bubbled with 
carbogen (95 % O2, 5 % CO2). The tension of the preparation was set at 375 mg 
and they were left to equilibrate for 30 min before the continuous field stimulation 
(0.05 Hz, 0.5 ms, 40 V; HSE Stimulator, II/215, Hugo Sachs Elektronik, March-
Huchstetten, Germany) was started. The contractions were measured 
isometrically via a force displacement transducer (TF6V5) connected to a DMS 
DC amplifier (both from Fleck, Mainz, Germany), and were registered on a pen 
recorder (Knauer, Berlin, Germany). 
 
Antagonist studies: The neurogenic contractions were concentration-dependently 
inhibited by the M1 receptor agonist p-F-PyMcN
+
 (Lambrecht et al., 1993; Moser 
et al. 1993; Grimm et al., 1994a). Antagonist affinities were determined by 
constructing cumulative concentration-response curves of the agonist in the 
absence and presence of the antagonist. The equilibration time was dependent on 
the used concentration of the antagonist, but it was at least 1 hour. EC50 values of 
p-F-PyMcN
+
 for the control (absence of antagonist) and the shifted concentration-
response curve (presence of antagonist) were determined graphically for 
calculation of the dose ratio from which the pA2 value was assessed. 
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3.4.2. Guinea-pig atria (GPA) 
 
Male guinea-pigs were killed by cervical dislocation. After exsanguination of the 
animals the left atria were isolated and transferred into Tyrode solution (pH = 7.4; 
T = 32°C, for its composition see Tab. 3.1.) gassed with carbogen. The organs 
were divided into two segments and fixed vertically by a cotton thread and 
platinum electrodes connected to a force displacement transducer (TF6V5) in 6 ml 
water-jacketed organ baths containing Tyrode solution. Atria were paced 
electrically with supramaximal rectangular impulses (2 Hz, 3 ms, 5 V). The force of 
the resulting contractions was measured using a Hellige amplifier and recorder 
(Hellige, Freiburg, Germany). After 10 min equilibration time with half-maximum 
tension, the resting tension was raised to 250 mg and kept throughout. After 
another 20 min equilibration period, the negative inotropic responses to the 
cumulative addition of the muscarinic agonist APE were registered as changes in 
isometric tension. 
 
Antagonist studies: Antagonist affinities were determined by constructing 
concentration-response curves to APE as described for RVD. 
 
 
3.4.3. Guinea-pig ileum (GPI) 
 
3.4.3.1.  Preparation for experiments with exogenously applied 
muscarinic agonist 
 
Male guinea-pigs were killed by cervical dislocation and exsanguinated. The distal 
part of the ileum was dissected at about 5 cm from the ileocaecum. Strips of ileal 
longitudinal smooth muscle (1 - 1.5 cm) were prepared according to the technique 
described by Paton and Zar (1968), mounted in 6 ml water-jacketed organ baths 
and loaded with a tension of 500 mg. Tyrode solution (pH = 7.4; T = 32°C, for its 
composition see Tab. 3.1.) aerated with carbogen served as bath fluid. 
Mechanical responses of ileal longitudinal muscle strips to APE were measured as 
isotonic contractions via an isotonic force displacement transducer (TF6V5 iso) 
and registered with a DMS DC amplifier and a Knauer recorder. 
 
Antagonist studies: Antagonist affinities were determined in essentially the same 
manner as described for RVD. 
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3.4.3.2.  Preparation for experiments with endogenous acetylcholine as 
agonist 
 
The prepared ileal longitudinal smooth muscle strips were fixed by means of two 
platinum electrodes, transferred in 6 ml water-jacketed tissue baths containing 
Krebs solution (pH = 7.4; T = 37°C, for its composition see Tab. 3.1.) gassed with 
carbogen and connected to a force displacement transducer (TF6V5). The tissue 
was excited with supramaximal single rectangular impulses (0.1 Hz, 0.5 ms, 60 V). 
Neurogenic twitch contractions were measured isometrically using a DMS DC 
amplifier, and were registered on a Knauer pen recorder. 
 
Antagonist studies: After a stabilisation period (1 - 2 h) the inhibition of neurogenic 
twitch contractions was measured by cumulative application of increasing 
concentrations of muscarinic antagonists to obtain pIC50 values. The inhibition of 
the contractile responses was calculated as percentage of control contractions. 
 
 
3.4.3.3. Preparation  for  experiments with exogenously applied P2 
agonists 
 
The GPI was prepared and fixed as described in 3.4.3.1. and incubated, under a 
resting tension of 1 g, in 6 ml tissue baths containing modified Krebs solution (1.3 
mM Ca
2+
; Tab. 3.1.) aerated with carbogen (pH = 7.4; T = 37°C). Mechanical 
responses of the muscle strips to the P2 agonists were measured isometrically via 
a force displacement transducer (TF6V5) and registered with a DMS DC amplifier 
and a Knauer recorder. 
 
Antagonist studies: First, the muscle strips were contracted by administration of 
100 µM ,-meATP or ADPS, respectively, to increase the sensitivity of the 
tissue. After a rest of 1 hour, contractions were obtained to single doses (every 15 
min) of exogenous ,-meATP (Krebs solution supplemented with 70 nM 
physostigmine) or ADPßS (Krebs solution containing 300 nM atropine). Two 
concentration-response curves were constructed on each preparation, the first in 
the absence and the second in the presence of the antagonist (60-min exposure). 
One ileal strip from each animal was used as a control to monitor time-dependent 
variation in responses to the respective agonist. Generally, all contractile 
responses from a single tissue were normalised and expressed as percentage of 
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those evoked by the highest agonist concentration used in the control curve. 
Concentration-effect curves were fitted to the data in the form log10 concentration 
of the agonist vs. normalised effects by logistic, non-linear regression analysis 
(Fig. P Software Corporation, Durham, NC, USA). 
 
 
3.4.4. Rat ileum (RI) 
 
Male Sprague Dawley rats (body weight 250 - 350 g) were killed by asphyxiation, 
exsanguinated, and the ileum (distal 10 cm discarded) was removed. Strips of ileal 
longitudinal smooth muscle (1 - 1.5 cm) were prepared and mounted as described 
for GPI (see 3.4.3.1.). The plexus-containing smooth muscle strips of the rats 
were equilibrated in modified Krebs solution (1.3 mM Ca
2+
; Tab. 3.1.) in 6 ml 
organ baths under a resting tension of 1 g. Mechanical muscular activity to the P2 
agonists was recorded isometrically by a force displacement transducer (TF6V5) 
and registered with a DMS DC amplifier and a Knauer recorder. 
 
Antagonist studies: As described above, muscle strips were contracted by 
administration of 100 µM of the respective P2 receptor agonist. After a 
stabilisation period (1 - 2 h), the contractions were obtained to single doses (every 
15 min) of the exogenously applied agonist. Two concentration-response curves 
were constructed on each preparation, the first in the absence and the second in 
the presence of the antagonist (60-min exposure).  
To obtain pIC50 values, the inhibition of contractions to one concentration of the 
P2 agonist was measured by application of increasing concentrations of the 
antagonist. The inhibition of the contractile responses was calculated as 
percentage of control contractions. 
 
 
3.5.  Evaluation of data 
 
Antagonist affinities were obtained by constructing concentration-response curves 
for agonists in the absence and presence of increasing antagonist concentrations 
(log intervals 0.5 or 1.0). The corresponding EC50 values were determined 
graphically from semilogarithmic plots (effects vs. log concentration). Control 
experiments were carried out to assure that equilibrium conditions were achieved 
within the incubation period. If possible, four concentrations of the antagonist were 
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tested and tissues of at least two animals were used. Each concentration of 
antagonist was investigated in at least two independent experiments. Apparent 
affinities of antagonists (pA2 values) were obtained from Arunlakshana-Schild 
plots (Arunlakshana and Schild, 1959). Slopes were determined by linear 
regression of the experimental data to the following equation using the method of 
least squares: 
 
        log (DR - 1) = m pAx - log KD    
 
DR  =  dose ratio of EC50 values of the agonist in the presence and 
  absence of the antagonist 
m  =  slope of regression line 
pAx  =  -log [antagonist] (M) 
KD  =  antagonist dissociation constant 
 
If the slope of the regression line was found not significantly different from -1.00 (P 
> 0.05), the antagonism was regarded as purely competitive. In this case, the pA2 
value was calculated as the x-intercept of a regression line by fitting to the data 
the best straight line with a slope of unity (m = -1), the latter called ‘constrained 
plot’ (McKay, 1978; Tallarida et al., 1979; Tallarida and Murray, 1986). 
 
When it was impossible to investigate more than two concentrations (or even only 
one concentration) of an antagonist, the pA2 value was calculated from the 
individual dose ratios according to the following equation (Tallarida et al., 1979): 
 
    p A 2 = log (DR - 1) + pAx 
 
 
3.6. Statistics 
 
Data are presented as means ± SEM (n) with n indicating the number of individual 
experiments. Differences between mean values were tested for statistical 
significance by Student’s t-test; P < 0.05 was accepted as being significant. Linear 
regression analysis was carried out using least-squares fit. Calculations are based 
on the personal computer program ”Pharm/PCS-Version 4.0” (Pharmacological 
Calculation System, Tallarida and Murray, 1986). 
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4. RESULTS 
 
 
4.1. Functional  in vitro experiments with the isomers of glycopyrronium 
bromide and their corresponding tertiary analogues at muscarinic 
receptors 
 
4.1.1. General considerations 
 
Neurogenic twitches elicited by electrical field stimulation of the rabbit vas 
deferens were concentration-dependently inhibited by the muscarinic agonist 4-F-
PyMcN
+
 yielding a pD2 value of 6.62 (± 0.05; n = 66). At guinea-pig atria and 
ileum, arecaidine propargyl ester caused negative inotropic effects in atria with a 
pD2 value of 7.99 (± 0.02; n = 86), and contractions of the ileal longitudinal 
smooth muscle with a pD2 of 7.63 (± 0.11; n = 15), respectively. All effects served 
as standards to assess antagonist potencies of the compound to be examined. 
 
 
4.1.2. Affinity profile of the parent compound glycopyrronium bromide 
 
Glycopyrronium bromide, 1,1-dimethyl-3-(2-cyclopentyl-2-hydroxy-phenylacetyl-
oxy)-pyrrolidinium bromide (Fig. 2.1.), is a quaternary ammonium compound with 
two chiral carbon atoms in its molecular structure. The parent compound is 
commercially available as a mixture of (R/S)-(S/R) stereoisomers (Demian and 
Gripshover, 1990). Fuder and Meincke (1993) described this compound as an 
ultrapotent M1-selective muscarinic receptor antagonist in vitro. Therefore, at first 
the antimuscarinic potency of the glycopyrrolate was determined functionally at 
muscarinic M1 (RVD), M2 (GPA) and M3 (GPI) receptors. 
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Fig. 4.1. Concentration-response curves of p-F-PyMcN
+ in the absence and in the 
presence of glycopyrronium bromide in RVD (left panel; n = 13), and the 
corresponding Schild plot (right panel) with slope of 1.29 ± 0.06. Error bars falling 
within the area covered by a symbol are not shown. 
 
 
 
 
 
 
 
Fig. 4.2. (legend, see page 61)  
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Fig. 4.2. Concentration-response curves of APE in the absence and in the 
presence of glycopyrronium bromide in GPA (left panel; n = 12), and the 
corresponding Schild plot (right panel) with slope of 1.30 ± 0.06. Error bars falling 
within the area covered by a symbol are not shown. 
 
 
 
At M1 (Fig. 4.1.) and M2 (Fig. 4.2.) receptors glycopyrronium bromide produced 
parallel shifts of the agonist concentration-response curve to higher 
concentrations with pA2 values of 10.24 ± 0.06 (n = 13) for the M1 and a pA2 
value of 9.11 ± 0.06 (n = 12) for the M2 receptor subtype. In contrast to the above 
mentioned results the compound exhibited only a slight M1 receptor selectivity 
(13-fold) over the M2 subtype. 
 
At the M3 receptor subtype a very slow dissociation of the antagonist was 
observed in the functional experiments and the agonist could not reach the 
maximum of the control curve in presence of the antagonist. Thus, a pIC50 value 
was determined at electrically stimulated GPI to give a value of the antimuscarinic 
potency. The pIC50 value resulting from inhibition of neurogenic twitch 
contractions was 8.89 ± 0.06 (Fig. 4.3.).  
 
 
 
 
 
 
 
 
 
Fig. 4.3. Inhibition curve of glycopyrronium 
bromide to contractions elicited by 
electrical field stimulation in GPI. Data are 
presented as mean values ± S.E.M. 
(n  =  8). Error bars falling within the area 
covered by a symbol are not shown. 
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The potency estimates of glycopyrronium bromide at M1, M2 and M3 receptors are 
summarised in Fig. 4.4. 
 
    
Fig. 4.4. Antagonist potency of glycopyrronium bromide (pA2: M1 and M2; pIC50: 
M3) determined in functional studies at muscarinic receptor subtypes. Data are 
shown as mean values ± S.E.M. from 8 - 13 experiments. 
 
 
4.1.3. Affinity profile of the quaternary stereoisomers of glycopyrronium 
bromide 
 
The two centres of chirality of the parent compound, glycopyrronium bromide, 
result in the existence of four stereoisomers whose absolute configurations are 
shown in Fig. 4.5. (R = CH3). To get detailed information about the influence of 
the steric arrangement it was of special interest to examine the antagonistic 
properties of these stereoisomers. Consequently, in the following experiments the 
four isomers of glycopyrronium bromide, designated 1 (3S/2’S), 2 (3S/2’R), 3 
(3R/2’S) and 4 (3R/2’R), were tested in three functional muscarinic M1, M2 and M3 
receptor models. 
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Fig. 4.5. Chemical structure of the tertiary (R = H) and quaternary (R = CH3) 
stereoisomers of glycopyrronium bromide. The asterisks denote the centres of 
chirality. 
 
 
In RVD and GPA the quaternary stereoisomers shifted the dose-response curves 
of 4-F-PyMcN
+
 and APE, respectively, to the right. The Schild plots have shown 
that the rightward shifts were only parallel for the (3S/2’S)-configured isomer with 
slopes not significantly different from unity in both models.  
The antagonistic properties (pA2 values for M1 and M2; pIC50 values for M3) are 
listed in Tab. 4.1. 
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Tab. 4.1. Antimuscarinic potencies (pA2/pIC50) and slopes of Schild plots (in 
parenthesis) of the quaternary compounds 1, 2, 3 and 4 at muscarinic receptor 
subtypes examined in functional studies in RVD (M1), GPA (M2) and GPI (M3). 
Data are presented as means ± S.E.M. (n = 3 - 13). 
 
 
compound 
 
configuration
M1 
pA2 
 
M2 
pA2 
M3 
pIC50 
1 
 
3S / 2’S  8.22 ± 0.04 
(1.01 ± 0.06) 
7.92 ± 0.03 
(1.02 ± 0.05) 
6.82 ± 0.06 
2 
 
3S / 2’R  10.27 ± 0.14  9.39 ± 0.10 
(1.52 ± 0.10) 
9.39 ± 0.09 
3 
 
3R / 2’S  9.53 ± 0.10  8.69 ± 0.03 
(1.34 ± 0.08) 
8.57 ± 0.08 
4 
 
3R / 2’R  10.30 ± 0.07  9.43 ± 0.11 
(1.59 ± 0.14) 
8.76 ± 0.06 
 
 
In case of compounds 2 and 4 only one concentration (0.1 nM; n = 3; for 
compound 2 see Fig. 4.6.) and of compound 3 two concentrations (1 and 3 nM; 
n  =  8) were included in the calculation at the M1 receptor, since at higher 
concentrations pseudoirreversible antagonism was observed. However, the values 
for compounds 2 and 4 are probably underestimated because of the long time 
needed to reach equilibrium at M1 receptor. 
 
Figs. 4.7. and 4.8. show examples for the concentration-response curves that are 
observed in RVD and GPA, respectively. 
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Fig. 4.6. Concentration-response curves of p-F-PyMcN
+ in the absence and in the 
presence of 0.1 nM of the quaternary (3S/2’R)-configured stereoisomer of 
glycopyrronium bromide in RVD (n = 3).  
 
 
 
 
 
 
 
 
Fig. 4.7. Concentration-response curves of p-F-PyMcN
+ in the absence and in the 
presence of the quaternary (3S/2’S)-configured stereoisomer of glycopyrronium 
bromide in RVD (left panel; n = 13), and the corresponding Schild plot (right panel) 
with slope of 1.01 ± 0.06 not significantly different from unity (P > 0.05). Error bars 
falling within the area covered by a symbol are not shown. 
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Fig. 4.8. Concentration-response curves of APE in the absence and in the 
presence of the quaternary (3S/2’S)-configured stereoisomer of glycopyrronium 
bromide in GPA (left panel; n = 12), and the corresponding Schild plot (right panel) 
with slope of 1.02 ± 0.05 not significantly different from unity (P > 0.05). Error bars 
falling within the area covered by a symbol are not shown. 
 
 
In the concentration range tested, the quaternary amines (1 - 4) proved to be 
surmountable antagonists in the functional studies at muscarinic receptors in 
rabbit vas deferens (M1) and guinea-pig atria (M2). 
However, because all isomers behaved as pseudoirreversible antagonists in the 
M3 assay, the inhibition of neurogenic twitch contractions in GPI was measured by 
increasing concentrations of the antagonist, to obtain pIC50 values. The pIC50 
values, resulting from the inhibition curves of the respective isomers to 
contractions elicited by electrical field stimulation (Fig. 4.9. A - D), are listed in 
table 4.1. 
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Fig. 4.9. Inhibition curves of the quaternary stereoisomers (3S/2’R) [A], (3S/2’R) 
[B], (3R/2’S) [C] and (3R/2’R) [D] of glycopyrronium bromide to contractions 
elicited by electrical field stimulation in GPI. Data are presented as mean values ± 
S.E.M. (n  =  4). Error bars falling within the area covered by a symbol are not 
shown. 
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The results show that the affinity/potency and muscarinic subtype selectivity of the 
tested compounds depend greatly on their absolute configuration. All isomers 
displayed in functional experiments a slight preference for M1 over M2 [2-fold for 1 
(3S/2S’) to 8-fold for 2 (3S/2R’)]. Finally, the diastereomers 2 and 4, with (R)-
configuration in the glycolic acid part, were the most potent and the isomer 1 with 
(3S/2’S)-configuration the least potent among the four quaternary stereoisomers 
at the three muscarinic receptor subtypes. 
 
 
4.1.4.  Affinity profile of the tertiary stereoisomeric analogues of 
glycopyrronium bromide 
 
Besides the quaternary compounds, also antimuscarinic potencies of the 
corresponding four tertiary analogues (Fig. 4.5., R = H), 1-methyl-3-(2-cyclopentyl-
2-hydroxy-phenylacetyloxy)-pyrrolidium hydrogentartrate, were tested functionally 
in the same models at muscarinic M1 - M3 receptors. The compounds were 
designated 5 (3S/2’S), 6 (3S/2’R), 7 (3R/2’S) and 8 (3R/2’R). With exception of 
compound 5 (pA2 = 7.61 ± 0.05 with a slope of the Schild plot of 1.19 ± 0.07; Fig. 
4.10 A), all isomers behaved as pseudoirreversible antagonists in GPI, and thus, 
pIC50 values were determined to examine their antimuscarinic potencies. As an 
example, the inhibition curve of the (3S/2’S)-configured tertiary compound to 
contractions elicited by electrical field stimulation in GPI is illustrated in Fig. 
4.10 B. 
 
In Tab. 4.2, affinity/potency estimates are presented. The pA2 values resulted 
from the rightward shift of the agonist curves in the presence of increasing 
concentrations of the antagonist in the RVD (M1) and GPA (M2), respectively. To 
determine the pIC50 values the following concentrations of the respective isomer 
were used: 5 (0.03 - 3 µM), 6 (0.3 - 10 nM), 7 (1 - 10 nM) and 8 (0.1 - 3 nM). The 
pIC50 values resulted from inhibition curves of the stereoisomers to contractions 
elicited by electrical field stimulation in GPI. 
 
 
 
 
 
 
 
68 
4. RESULTS 
 
 
 
69
 
 
 
Fig. 4.10. [A] Concentration-response curves of APE in the absence and in the 
presence of the tertiary (3S/2’S)-configured stereoisomer of glycopyrronium 
bromide in GPI (n = 16), and [B] inhibition curve of this compound to contractions 
elicited by electrical field stimulation in GPI. Data are presented as mean values ± 
S.E.M. (n  =  3). Error bars falling within the area covered by a symbol are not 
shown. 
 
Tab. 4.2. Antimuscarinic potencies (pA2/pIC50) and slopes of Schild plots (in 
parenthesis) of the tertiary amines 5, 6, 7 and 8 at muscarinic receptor subtypes 
examined in functional studies in RVD (M1), GPA (M2) and GPI (M3). Data are 
presented as means ± S.E.M. (n = 9 - 13). 
 
 
compound 
 
configuration 
M1 
pA2 
 
M2 
pA2 
M3 
pIC50 
5 
 
3S / 2’S  7.70 ± 0.07 
(0.80 ± 0.09) 
7.52 ± 0.03 
(1.02 ± 0.05) 
6.35 ± 0.08 
6 
 
3S / 2’R  9.98 ± 0.04 
(0.92 ± 0.09) 
9.03 ± 0.04 
(1.18 ± 0.06) 
8.80 ± 0.02 
7 
 
3R / 2’S  8.97 ± 0.07 
(0.98 ± 0.15) 
8.71 ± 0.04 
(1.12 ± 0.06) 
8.47 ± 0.02 
8 
 
3R / 2’R  10.00 ± 0.12 
(0.70 ± 0.23) 
9.45 ± 0.02 
(1.02 ±0.03) 
9.05 ± 0.03  
4. RESULTS 
 
As with the quaternary analogues 1 - 4 (Tab. 4.1.), the highest antimuscarinic 
potency was observed for the tertiary diastereomers 6 and 8 possessing the (R)-
configuration in the acid part of the molecules (Tab. 4.2.). As far as M1 and M2 
receptors are concerned, compound 6 (3S/2’R) displayed the greatest subtype-
selectivity (9-fold, based on affinity data). 
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4.2.  P2 receptor heterogeneity in the guinea-pig ileal longitudinal smooth 
muscle preparation 
 
4.2.1. Experiments at neuronal P2 receptors 
 
4.2.1.1.  Preliminary experiments with ,-meATP 
 
Based on observations by Kennedy and Humphrey (1994) the metabolically stable 
and P2X1- and P2X3-selective agonist ,-meATP was used in the following 
experiments to elucidate the exact nature of the P2X-like receptors expressed in 
myenteric neurons of GPI. 
 
Single doses of ,-meATP (10 µM) elicited biphasic contractile responses 
consisting of a rapid (phasic) response followed by a more sustained (tonic) 
response. In the present study, only the phasic contractions, which desensitised 
rapidly (Fig. 4.11.), were examined. 
 
   
 
 
Fig. 4.11. Desensitisation of ,-meATP (10 µM)-induced contractions of the GPI. 
Responses are expressed as % of response to initial dose of ,-meATP 
administered. Control responses to ,-meATP amounted to 1201 ± 122 mg 
tension (n = 3).  
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Since the contractile effects of ,-meATP in GPI are mediated by acetylcholine, 
released from cholinergic neurons (Kennedy and Humphrey, 1994), and since 
these cholinergic neurons are endowed with prejunctional adenosine (Moody and 
Burnstock, 1982) and opiate receptors (Vizi et al., 1981), control experiments were 
carried out to characterise the action of ,-meATP in our experimental design. 
Therefore, in a first run of experiments the influence of 2-chloro-N
6
-
cyclopentyladenosine (CCPA), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 
naloxone and physostigmine on the contractions elicited by 10 or 30 µM ,-
meATP, respectively, was investigated. 
 
CCPA: The A1-selective agonist CCPA (Lohse et al., 1988) concentration-
dependently reduced contractions (1000 nM CCPA: reduction to 4 % of control 
without CCPA) elicited by 10 µM ,-meATP (Fig. 4.12.), consistent with the 
existence of a prejunctional adenosine A1 receptor. 
 
 
   
 
Fig. 4.12. Effect of increasing concentrations of CCPA on the contractile response 
of the GPI produced by ,-meATP (10 µM). Responses are expressed as 
percentage of control responses (1114 ± 103 mg tension generated) without 
CCPA (n = 3 - 5). 
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DPCPX: Additionally, three concentrations of the A1 receptor antagonist DPCPX 
(Lohse et al., 1987) (30, 100 and 300 nM) were tested against 30 µM ,-meATP 
(n = 1 - 2). However, contractions elicited by ,-meATP remained unaffected in 
the presence of DPCPX. 
 
Naloxone: To exclude the influence of prejunctional opiate receptors, naloxone 
(30 - 1000 nM) was tested against 30 µM ,-meATP (n = 2). Again, there was no 
difference between ,-meATP potency in the absence and in the presence of 
naloxone. 
 
Physostigmine: As an inhibitor of the enzyme acetylcholinesterase physostigmine 
(30 and 100 nM) increased the contractile effect to ,-meATP (30 µM). At higher 
concentrations (300 and 1000 nM) it also acted as an antimuscarinic agent (Fig. 
4.13.). Consequently, all subsequent experiments were carried out in the 
continuous presence of 70 nM physostigmine. 
 
 
    
 
Fig. 4.13. Effect of increasing concentrations of physostigmine on the contractile 
response of the GPI produced by ,-meATP (30 µM). Responses are expressed 
as percentage of control responses (848 ± 79 mg tension generated) without 
physostigmine (n = 3 - 4). 
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In order to confirm the neuronal localisation of the P2X-like receptor and the 
release of ACh via this receptor, the Na
+
 channel blocking agent tetrodotoxin 
(TTX) as well as the non-selective muscarinic antagonist atropine were tested. As 
illustrated in Fig. 4.14., the responses to 10 µM ,-meATP were totally abolished 
by TTX (1 µM) and greatly reduced by atropine (300 nM), respectively. 
 
 
    
 
Fig. 4.14. Influence of TTX (1 µM) and atropine (0.3 µM) on contractions elicited 
by ,-meATP (10 µM) in GPI. Responses are expressed as percentage of control 
responses (1728 ± 222 mg tension generated) without TTX or atropine (n = 4). 
 
 
4.2.1.2.  Antagonism by suramin, PPADS and NF023 
 
,-meATP (0.1 - 30 µM; EC50 = 0.79 ± 0.09 µM; 1401 ± 87 mg tension 
generated in control experiments) produced concentration-dependent contractions 
in GPI. To avoid desensitisation, the agonist was added at regular intervals of 15 
min. Time controls revealed that the dose-response curves remained stable during 
the course of the experiments. Unless stated otherwise, the Krebs buffer (1.3 
Ca
2+
) was supplemented with 70 nM physostigmine to prevent breakdown of 
endogenously released ACh.  
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Suramin (10 - 100 µM) antagonised contractile responses to ,-meATP in a 
roughly parallel manner, with a pA2 value of 5.10 ± 0.07. Fig. 4.15. demonstrates 
the dose-response curves of suramin to ,-meATP (left panel) as well as the 
resulted Schild plot, the slope of which (0.94 ± 0.09) was not significant different 
from unity (right panel). 
 
 
 
 
 
 
 
 
 
 
Fig. 4.15. Concentration-response curves of ,-meATP in the absence and in the 
presence of suramin in the GPI, and the corresponding Schild plot with slope not 
significantly different from unity (P > 0.05). The graphs show mean data ± S.E.M 
(n = 4). Error bars falling within the area covered by a symbol are not shown. 
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PPADS (0.3 - 100 µM) antagonised contractile responses to ,-meATP in a 
pseudoirreversible fashion. The calculated apparent pKB of PPADS, derived from 
a double reciprocal regression (Kenakin, 1993), was 6.17 ± 0.09 (Fig. 4.16.). 
 
 
 
 
 
 
 
 
Fig. 4.16. Effect of PPADS on the mechanical response of the GPI produced by 
,-meATP. The graphs show mean data ± S.E.M. (n = 3 - 4). Error bars falling 
within the area covered by a symbol are not shown. The right panel shows the 
double reciprocal plot: antagonism by PPADS of ,-meATP-induced contractions 
of the GPI. [A] and [A’] denote the equieffective agonist concentrations in the 
absence and in the presence of PPADS (10 µM). 
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Increasing concentrations of NF023 (30 - 300 µM) produced rightward shifts of the 
concentration-effect curve for ,-meATP, and Schild transformation of these data 
revealed that NF023 is a competitive P2X receptor antagonist with a pA2 value of 
4.56 ± 0.07 and a slope of the Schild regression line of 0.94 ± 0.01, which is not 
significantly different from unity (Fig. 4.17.). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.17. Concentration-response curves of ,-meATP in the absence and in the 
presence of NF023 in the GPI (left panel), and the corresponding Schild plot (right 
panel) with slope not significantly different from unity (P > 0.05). The graphs show 
mean data ± S.E.M. (n = 4). Error bars falling within the area covered by a symbol 
are not shown. 
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4.2.1.3.  Antagonism by NF279 
 
The antagonist properties of NF279 were very interesting due to its specific P2X1 
receptor selectivity (Lambrecht, 2000). The concentration-response curves for 
NF279 against ,-meATP are shown in Fig. 4.18. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.18. Concentration-response curves of ,-meATP in the absence and in the 
presence of NF279 in the GPI (left panel), and the corresponding Schild plot (right 
panel) with slope not significantly different from unity (P > 0.05). The graphs show 
mean data ± S.E.M. (n = 4). Error bars falling within the area covered by a symbol 
are not shown. 
 
 
NF279 (3 - 30 µM; Fig. 4.18.) produced concentration-related rightward 
displacements of the concentration-response curve to ,-meATP in a parallel 
fashion. A pA2 value of 5.95 ± 0.08 could be determined. The corresponding 
Schild plot was linear, and the slope of the regression line (1.01 ± 0.10) was not 
significantly different from unity (P > 0.05), indicating a competitive nature for this 
antagonistic effect.  
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4.2.1.4.  Investigations on the postjunctional muscarinic receptor 
subtype responsible for contraction of GPI 
 
Previous studies have shown, that the neuronal P2X-like receptor, which has been 
investigated, acts after its stimulation through facilitation of ACh release causing a 
contraction of the GPI. In the following set of experiments the postjunctional 
muscarinic receptor subtype responsible for ACh-mediated contractions to ,-
meATP or contractions elicited by electrical field stimulation of GPI was 
characterised by means of atropine and the subtype-preferring muscarinic 
antagonists pirenzepine, himbacine and p-F-HHSiD. It is worth mentioning that 
PPADS (100 µM), suramin (100 µM), NF023 (100 µM) and NF279 (100 µM) failed 
to affect contractions eliciting by single doses (100 nM) of the muscarinic agonist 
arecaidine propargyl ester (APE) at GPI. Hence, a direct interaction of the P2 
antagonists employed with postjunctionally located muscarinic receptors can be 
excluded (Lambrecht, 2000 and unpublished results). 
 
As previously shown, contractions elicited by single doses of ,-meATP were 
greatly reduced by atropine (300 nM; cf. 4.2.1.1.), indicating that these responses 
are indirect-muscarinic, ACh-mediated and caused by stimulation of soma-
dendritic P2X-like receptors on cholinergic neurones. To examine the exact nature 
of the postjunctionally localised muscarinic receptor, the antagonistic effect of 
atropine (0.003 - 0.1 µM), p-F-HHSiD (0.01 - 3 µM), himbacine (0.3 - 30 µM) and 
pirenzepine (0.1 - 30 µM) was determined to ,-meATP (3 µM)-induced 
contractions. All these muscarinic antagonists concentration-dependently 
decreased contractile responses of the GPI to almost 100 % (Fig. 4.19.). 
 
Electrical field stimulation (EFS; 0.1 Hz) of the GPI elicited neurogenic (TTX-
sensitive, 1 µM) and monophasic rapid twitch contractions. These responses were 
muscarinic (ACh-mediated) in nature, since they were (nearly) abolished by 
muscarinic antagonists atropine (0.3 - 30 nM), p-F-HHSiD (1 - 1000 nM), 
himbacine (10 - 1000 nM) and pirenzepine (30 - 3000 nM; Fig. 4.19.). 
 
Although the antagonists used (Fig. 1.2.) were less potent against ,-meATP 
than against EFS, the same antagonist profile could be noticed for both methods: 
atropine > p-F-HHSiD (7- to 10-fold) > himbacine (5- to 8-fold) > pirenzepine (1- to 
2-fold) (Tab. 4.3.). 
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Fig. 4.19. Concentration-inhibition curves of atropine (A), p-F-HHSiD (B), 
himbacine (C) and pirenzepine (D) in GPI on contractions elicited by EFS (0.1 Hz; 
) or ,-meATP (3 µM; ▲). The graphs show mean data ± S.E.M. (n = 4). Error 
bars falling within the area covered by a symbol are not shown. 
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Tab. 4.3. Potencies (pA2 and pIC50 values) of muscarinic antagonists to inhibit 
cholinergically mediated responses in the GPI. The pIC50 values are given as 
mean values ± S.E.M. from 4 - 6 experiments. 
 
 
Muscarinic 
antagonist 
pA2 
M3 
pIC50 
,-meATP 
pIC50 
EFS 
 
Atropine 
 
8.99
2)
 
 
7.76 ± 0.05 
 
8.44 ± 0.04 
 
p-F-HHSiD 
 
7.84
1)
 
 
6.93 ± 0.04 
 
7.42 ± 0.04 
 
Himbacine 
 
7.10
2)
 
 
6.01 ± 0.02 
 
6.69 ± 0.02 
 
Pirenzepine 
 
6.88
1)
 
 
5.88 ± 0.04 
 
6.39 ± 0.02 
 
1)
 Lambrecht et al., 1988; 
2)
 Eltze et al., 1993. 
 
 
Table 4.3. summarises the pA2 values derived from Schild plots at M3 receptors in 
GPI and the pIC50 values obtained either with ,-meATP (3 µM) or EFS (0.1 Hz) 
in GPI for the four muscarinic key antagonists. The excellent correlations, r = 
0.993 for pIC50 (EFS) vs. pIC50 (,-meATP) and r = 0.992 for pA2 (M3) vs. pIC50 
(,-meATP), are shown graphically in Fig. 4.20. A and B. 
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Fig. 4.20. Correlation plots for the pIC50 values (using ,-meATP as agonist) 
obtained with muscarinic receptor antagonists in GPI and (A) pIC50 values for 
these compounds towards neurogenic (EFS-induced) contractions or (B), 
respectively, affinity estimates (pA2) towards M3 receptors identified by classical 
Schild analysis. The correlation coefficients of 0.993 (A) and 0.992 (B) regard the 
best fitting line through the data points. 
 
 
 
 
4.2.2. Experiments at postjunctionally localised P2 receptors 
 
4.2.2.1.  Potency profile of P2 agonists 
 
The three nucleotide agonists ADPßS (0.3 - 100 µM), ,-meADP (0.3 - 100 µM) 
and 2-MeSATP (0.3 - 100 µM) were investigated for their contractile activity in the 
GPI in order to establish a rank order of potency (Fig. 4.21.). 
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Fig. 4.21. Concentration-response curves of nucleotides ( ADPßS;  2-
MeSATP;    ,-meADP) eliciting contractions in the GPI. Contractions were 
measured as increase in tension. Mean values (± S.E.M.) consist of 3 - 8 
individual determinations. Error bars falling within the area covered by a symbol 
are not shown. 
 
 
The nucleotides produced biphasic contractile responses consisting of a phasic 
contraction, followed by a tonic response. In the present study, only the phasic 
contractions were examined (Fig. 4.21.). The following rank order of potency 
based on the generation of 750 mg tension (pEC750 value) was obtained (Tab. 
4.4.): ADPßS > 2-MeSATP  ,-meADP. 
 
 
Tab. 4.4. Potency of the P2 agonists ADPßS, 2-MeSATP and ,-meADP based 
on generation of 750 mg tension (pEC750 values ± S.E.M.) in GPI. 
 
 
    ADPßS      2-MeSATP           ,-meADP 
 
         5.18 ± 0.04      4.67 ± 0.03           4.46 ± 0.07 
    ( n  =  8 )             ( n  =  4 )       ( n  =  3 )   
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Although a maximum response was not reached by any of the agonists, ADPßS 
clearly was the most efficacious compound and therefore used for the following 
experiments. 
 
 
4.2.2.2.  Effects of atropine, TTX and CCPA 
 
Exogenously administered ADPßS (10 µM) produced contractions of GPI, which 
were partially reduced by TTX (1 µM; 32 ± 3 %), atropine (0.3 µM; 45 ± 1 %) or 
CCPA (1 µM; 24 ± 3 %; Fig. 4.22.). 
 
 
   
 
Fig. 4.22. Influence of TTX (1 µM), atropine (0.3 µM) and CCPA (1 µM) on 
contractions of the GPI elicited by ADPßS (10 µM). Responses are expressed as 
percentage of control responses (1066 ± 112 mg tension generated) without TTX, 
atropine or CCPA (n = 3 - 4). 
 
Higher concentrations of atropine (1 and 3 µM; n = 4) did not enhance the 
inhibition to contractions produced by ADPßS. 
Contractions produced by 2-MeSATP (10 µM) in GPI were also decreased either 
by TTX (1 µM; 49 ± 6 %; n = 3) or atropine (0.3 µM; 50 ± 3 %; n = 5). Similar  
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observations were made with 100 µM ,-meADP, where contractions were 
depressed by 1 µM TTX (80 ± 8 %; n = 4) and 0.3 µM atropine (62 ± 7 %; n = 4). 
These results imply that ADPßS (as well as 2-MeSATP and ,-meADP) acts at 
different P2 receptors located at two sites in GPI: (1) the neuronal ,-meATP-
sensitive receptor (,-meATP >> ADPßS), and (2) a postjunctional ,-meATP-
insensitive receptor (ADPßS >>> ,-meATP). Thus, to isolate the stimulatory 
action of ADPßS at the postjunctional P2 receptors pharmacologically, atropine 
(0.3 µM) was present throughout the experiments with P2 antagonists. 
 
 
4.2.2.3.  Effects of N
G
-nitro-L-arginine and hexamethonium on 
contractions elicited by ADPßS 
 
In the following experiments the influence of N
G
-nitro-L-arginine (L-NOARG) and 
hexamethonium on contractions elicited by ADPßS was investigated. 
The nicotine receptor antagonist hexamethonium (30 and 100 µM) and the NO-
synthase inhibitor L-NOARG (30 and 300 µM) failed to modify the effects of 
ADPßS, suggesting that nicotine receptors as well as NO may not be involved in 
the action of ADPßS. 
 
 
4.2.2.4.  Antagonism by suramin, PPADS and NF023 
 
Single doses of ADPßS (0.3 - 300 µM; EC50 = 0.70 ± 0.04 µM; 1232 ± 59 mg 
tension generated in control experiments; n = 33) produced concentration-
dependent contractions in GPI (Krebs 1.3 mM Ca
2+
; containing 0.3 µM atropine) 
(Figs. 4.23. - 4.25.). No desensitisation to these responses could be observed by 
addition of single doses of 10 µM ADPßS given every minute without wash-out 
phase. 
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Suramin (10 - 100 µM; Fig. 4.23.) shifted the concentration-response curves of 
ADPßS in a dose-dependent manner to the right. The regression line of the 
corresponding Schild plot had a slope of 0.94 ± 0.05 (not significantly different 
from unity), and a pA2 value of 5.68 ± 0.24 could be estimated. 
 
 
 
 
 
 
 
 
 
Fig. 4.23. Concentration-response curves of ADPßS in the absence and in the 
presence of suramin in the GPI (left panel), and the corresponding Schild plot 
(right panel) with slope not significantly different from unity (P > 0.05). The graphs 
show mean data ± S.E.M. (n = 4). Error bars falling within the area covered by a 
symbol are not shown. 
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PPADS (1 - 10 µM; Fig. 4.24.) antagonised contractile responses to ADPßS in a 
pseudoirreversible manner. Analysis of these data by a double reciprocal plot 
yielded a pKB estimate of 6.20 ± 0.05. 
The effects of PPADS were reversed to the maximum of the control curve after a 
wash-out period of 15 - 30 min. 
 
 
 
Fig. 4.24. Effect of PPADS on the mechanical response of the GPI produced by 
ADPßS (left panel). The graphs show mean data ± S.E.M. (n = 4). Error bars 
falling within the area covered by a symbol are not shown. The right panel shows 
the double reciprocal plot: antagonism by PPADS of ADPßS-induced contractions 
of the GPI. [A] and [A’] denote the equieffective agonist concentrations in the 
absence and in the presence of PPADS (3 µM). 
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NF023 (100 - 1000 µM; Fig. 4.25.) caused reversible and concentration-related 
antagonism of responses to ADPßS. The corresponding Schild plot was linear 
with a slope not significantly different from unity (1.01 ± 0.06), and a pA2 value of 
4.74 ± 0.03 could be determined. 
 
 
 
 
 
 
 
 
 
Fig. 4.25. Concentration-response curves of ADPßS in the absence and in the 
presence of NF023 in the GPI (n = 3; left panel), and the corresponding Schild plot 
(right panel) with slope not significantly different from unity (P > 0.05). Error bars 
falling within the area covered by a symbol are not shown. 
 
 
4.2.2.5.  Antagonism by NF279 
 
The antagonism of NF279 (30 µM) to ADPS was determined only for one 
concentration. 
NF279 shifted the concentration-response curve of ADPS to the right in a parallel 
fashion with a resulting pA2 value of 5.11 ± 0.04 (n = 6; Fig. 4.26). 
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Fig. 4.26. Concentration-response curves for the contractile responses to ADPßS 
in the absence () and in the presence of 30 µM NF279 () in GPI. Data are shown 
as means ± S.E.M. (n = 6). Error bars falling within the area covered by a symbol 
are not shown. 
 
 
4.2.2.6.  Antagonism by A3P5P and MRS2179 
 
Progress in the P2 receptor field has been slowed by the lack of availability of 
receptor subtype-selective antagonists. Thus, the observation by Boyer et al. 
(1996) that adenosine 3’,5’-bisphosphate (A3P5P; Fig. 4.27.) acted as competitive 
antagonist with slight partial agonist activity at P2Y1 receptors in turkey 
erythrocyte membranes was of considerable interest. The effect of this 
bisphosphate ATP analogue was selective for the PLC-coupled P2Y1 receptor, 
since neither agonist nor antagonist activities were observed on recombinant 
P2Y2, P2Y4, and P2Y6 receptors. 
In the present study, A3P5P (100 µM; Fig. 4.27.) shifted the concentration-
response curve to ADPßS to the right in a roughly parallel manner with depression 
of the maximum of the control response curve. The resulting pA2 value was 
4.45 ± 0.16 (n = 6). No agonist activity of A3P5P itself could be observed. 
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  A3P5P 
 
 
 
Fig. 4.27. Concentration-response curves for the contractile responses to ADPßS 
in the absence () and in the presence of 100 µM A3P5P () in GPI. Data are 
shown as means ± S.E.M. (n = 6). Error bars falling within the area covered by a 
symbol are not shown. 
 
 
Another P2Y1-selective antagonist, 2’-deoxy-N
6
-methyladenosine 3’,5’-
bisphosphate (MRS2179; Fig. 4.28.), was described by Camaioni et al. (1998). 
The potency of this antagonist was measured in turkey erythrocyte membranes 
with a Ki value of approximately 100 nM. 
In this study, the antagonistic property of MRS2179 (0.1 - 30 µM; Fig. 4.28.) 
against 10 µM ADPS was determined. In this way, a pIC50 value of 5.37 ± 0.04 
(n = 4) could be estimated. 
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Fig. 4.28. Inhibition curve of MRS2179 to 10 µM ADPßS in GPI. Data are means ± 
S.E.M. from 4 experiments. Error bars falling within the area covered by a symbol 
are not shown. 
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4.3.  Experiments with the longitudinal smooth muscle of the rat ileum 
 
4.3.1. Experiments with P2 agonists 
 
In a first set of experiments the four nucleotide agonists ADPßS, ,-meADP, ,-
meATP and ATPS were investigated for their contractile activity in the rat ileal 
longitudinal smooth muscle (RI) in a concentration range from 0.3 to 300 µM in 
order to establish a rank order of potency. 
All agonists elicited concentration-dependent contractions of the RI. The highest 
efficacy was observed with the P2X-selective agonist ,-meATP, which showed a 
relatively steep concentration-response curve. The curves for the other three 
nucleotides appeared to be parallel with ADPßS being more potent than ,-
meADP, which in turn was more potent than ATPS (Fig. 4.29.). 
 
 
       
 
Fig. 4.29. Concentration-response curves of nucleotides ( ADPßS;   ,-
meATP;    ,-meADP;   ATPS) eliciting contractions in the RI. Contractions 
were measured as increase in tension. Mean values (± S.E.M.) consist of 4 - 14 
individual determinations. Error bars falling within the area covered by a symbol 
are not shown. 
 
 
,-meATP: After cumulative addition (3 times) of 30 µM ,-meATP every minute 
without washing-out period no desensitisation of the receptor could be noticed. 
 
 
92 
4. RESULTS 
 
ADPßS: The contractile effect of ADPßS could not be increased neither through a 
priming with 100 µM ADPßS before starting the dose-response curve nor through 
extension of the time between the next addition of the agonist. 
After cumulative addition (3 times) of 10 µM ADPßS every minute without 
washing-out period no desensitisation of the receptor could be noticed. 
 
 
4.3.2. Effects of TTX and atropine on responses to ,-meATP 
 
TTX: Contractions elicited by 30 µM ,-meATP were reduced by 1 µM TTX to 
34 ± 2 % (n = 5; 961 ± 46 mg tension generated) (Fig. 4.30.). 
 
Atropine: The contractile response to 100 µM ,-meATP after addition of 0.3 µM 
atropine amounted to 44 ± 8 % (n = 4; 585 ± 133 mg tension generated) of control 
response without atropine (Fig. 4.30.). 
 
    
Fig. 4.30. Influence of TTX (1 µM) and atropine (0.3 µM) on contractions elicited 
by  ,-meATP (30 µM in case of TTX or 100 µM in case of atropine) in RI. 
Responses are expressed as percentage of control responses without TTX or 
atropine (n = 4 - 5). 
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4.3.3. Effects of TTX and atropine on responses to ADPßS 
 
No influence of either 1 µM TTX (n = 6) or 0.3 µM atropine (n = 4) on contractions 
elicited by 10 µM ADPßS was observed, indicating that the agonist acts at P2 
receptors, probably P2Y receptors, located on the postsynaptic site. 
 
 
4.3.4. Effects of NF023, suramin and PPADS on responses to ADPßS 
 
In the following experiments, ADPßS (0.3 - 300 µM) was used as agonist and the 
influence of NF023, suramin and PPADS was investigated. 
 
ADPS (EC50 = 5.10 ± 0.03 µM; 1550 ± 81 mg tension generated in control 
experiments; n = 36) produced concentration-dependent contractions in RI. The 
agonist was added in single doses every 15 min. Time controls revealed that the 
dose-response curves remained stable during the course of experiments. The 
three antagonists shifted the concentration-response curve of the agonist to the 
right in a roughly parallel fashion. However, they exhibited only a weak 
antagonism with pA2 values of 4.34 ± 0.25 for NF023 (n = 3; Fig. 4.31.), 4.60 ± 
0.10 for suramin (n = 3 - 4; Fig. 4.32.) and 4.79 ± 0.16 for PPADS (n = 3; Fig. 
4.33.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.31. Concentration-response curves of 
ADPßS in the absence and in the presence of 
NF023 (10 - 300 µM) in RI. Data are shown as 
mean values of 3 experiments. 
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Fig. 4.32. Concentration-response curves of 
ADPßS in the absence and in the presence of 
suramin (30 - 300 µM) in RI. Data are shown as 
mean values of 3-4 experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.33. Concentration-response curves of 
ADPßS in the absence and in the presence of 
PPADS (10 - 300 µM) in RI. Data are shown as 
mean values of 3 experiments. 
 
 
Remarkably, the antagonist curves shown in Figs. 4.31. - 4.33. were always 
steeper than the corresponding control curve and in some cases the maximum of 
the antagonist curves was higher than that of the agonist control curve. The pA2 
values were calculated from the shift that was observed at 50 % of the respective 
control curve. 
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4.3.5. Effects of NF279 and A3P5P on responses to ADPßS 
 
For these two selective antagonists, pIC50 values to 10 µM ADPßS were 
determined. 
 
NF279, a wholly P2X1-selective antagonist, showed only a weak antagonism 
against ADPS in RI (Fig. 4.34.; pIC50 = 3.92 ± 0.04, n = 4). 
 
 
    
 
 
Fig. 4.34. Inhibition curve of NF279 to 10 µM ADPßS in RI. Data are means ± 
S.E.M. from 3 - 4 experiments. 
 
 
A3P5P, described as a P2Y1-selective antagonist, had no influence on 
contractions elicited by ADPßS (n = 4) up to a concentration of 100 µM. 
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5. DISCUSSION 
 
 
5.1. Functional  in vitro experiments with glycopyrronium bromide, its four 
stereoisomers and their corresponding tertiary analogues at 
muscarinic receptors 
 
5.1.1. Affinity profile of glycopyrronium bromide 
 
As mentioned before, glycopyrronium bromide is a synthetic quaternary 
ammonium compound with two asymmetrical carbon atoms. One of the 
racemates (R/S-S/R) was shown to exhibit antimuscarinic properties in functional 
as well as in radioligand binding experiments (Lau and Szilagyi, 1992; Gomez et 
al., 1995). Basic findings about the affinity and subtype selectivity of 
glycopyrronium bromide at muscarinic M1 - M3 receptors were demonstrated by 
Fuder and Meincke (1993). They described that this compound blocks effects 
elicited by muscarinic agonists at rabbit vas deferens (M1), paced rat left atria (M2) 
and guinea-pig ileum (M3) with very high potency (chapter 2.1.). Glycopyrrolate 
was about 10- or 100-fold more potent at the M1 receptor than in blocking M3 or 
M2 receptors, respectively. 
 
In the present study, the affinity profile of glycopyrronium bromide was determined 
at RVD (M1), GPA (M2) and GPI (M3) as reference for subsequent experiments. 
The affinity of the parent compound at M1 and M2 receptors pointed to a slight 
preference for the M1 receptor subtype (13-fold over M2; Fig. 4.4.). At the M3 
receptor subtype a pIC50 value was determined because of the very slow 
dissociation of the antagonist from the receptor observed in the functional 
experiments (chapter 4.1.2.). So, a direct comparison with pA2 values was not 
possible. 
The results obtained in radioligand binding studies with recombinant human 
muscarinic receptor subtypes stably expressed in CHO-K1 cells showed the 
following antagonistic profile: M3 = M4 = M1   M 2 with Ki values in the lower 
nanomolar range (Kreutzmann, personal communication). The pKi value at the M1 
receptor was only 4-fold lower than the functionally determined pA2 value, and in 
case of the M3 affinity there was a difference by a factor of 6. Nevertheless, if one 
can speculate that the pIC50 at the M3 receptor of GPI is lower than the respective 
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pA2 value, the same rank order of antagonist potency could be assumed for 
functionally obtained data. 
 
 
5.1.2. Affinity profile of the four stereoisomers of glycopyrronium bromide 
 
Since glycopyrronium bromide contains two chiral centres in its molecule the 
compound consists of the following four stereoisomers: 1 (3S/2’S), 2 (3S/2’R), 3 
(3R/2’S), and 4 (3R/2’R) (Fig. 4.5.). 
First of all, the data obtained in functional experiments (Tab. 4.1.) were confirmed 
in radioligand binding studies at recombinant M1, M3 and M4 receptors stably 
expressed in CHO cells as well as at native M2 receptors present in rat heart (Fig. 
5.1.). [
3
H]N-methylscopolamine was used as radioligand and its binding to 
muscarinic receptors was competitively inhibited by compounds 1 - 4 (Czeche et 
al., 1997). 
 
 
 
Fig. 5.1. (legend, see page 100) 
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Fig. 5.1. Antagonist affinities of the quaternary stereoisomers of glycopyrronium 
bromide determined in radioligand binding studies at recombinant M1, M3 and M4 
receptors stably expressed in CHO cells and at native M2 receptors present in rat 
heart. 
 
 
The affinities of the quaternary compounds 1 - 4 determined in functional 
experiments at M1 and M2 receptor subtypes were in good agreement with data 
examined in radioligand binding studies (Fig. 5.2.; M1: slope = 0.94, r = 0.99; M2: 
slope = 1.19, r = 0.99). Although the regression lines at the M1 and M2 receptor 
subtypes have not been represented for reasons of clearness, the location of the 
data points around the solid line (y = x) proves the excellent correlation. Data at 
M3 receptor (pKi vs. pIC50) are best correlated by the dotted line (slope = 1.08, r = 
0.99). A comparison of pKi values obtained at M3 receptors with pIC50 values 
obtained in GPI showed that the pIC50 values are consistently lower (up to 32-
fold) than the pKi values due to the experimental design using endogenous 
acetylcholine as agonist in functional studies. 
 
    
 
Fig. 5.2. Comparison of pKi and pA2/pIC50 values for the quaternary isomers of 
glycopyrronium bromide obtained in binding and functional studies, respectively, 
at muscarinic receptor subtypes. The solid line represents the 1:1 relationship. 
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Taken together, it can be concluded that the quaternary compounds 1 - 4 behaved 
as surmountable competitive antagonists in functional studies at muscarinic 
receptors in RVD (M1 receptors) and GPA (M2 receptors) as well as in radioligand 
competition experiments at M1 - M4 receptors. Because of the very slow 
dissociation from the receptor, which could be observed, but unfortunately has still 
not been quantified, during the experimental study at M3 receptor subtype in GPI, 
it was impossible to determine pA2 values. However, because of the long time 
needed to get an equilibrium at the M3 receptor in the binding assay too, 
Waelbroeck has determined the dissociation half-lifes (t1/2) of the four 
stereoisomers at this receptor subtype (personal communication). The following 
t1/2 (min) could be observed: 1 [1 (3S/2’S)] << 70 [2 (3S/2’R)] < 90 [3 (3R/2’S)] < 
120 [4 (3R/2’R)]. Consequently, the determination of pIC50 values in the electrical 
stimulated GPI was used as an alternative method. The benefit arised from this 
design was the evaluation of the antagonistic properties of the compounds, but 
disadvantageous was that the release of endogenous ACh could not be 
quantified. If compared the rank order of t1/2 with the rank order of the 
antagonistic potency of the compounds, no direct correlation could be estimated. 
 
Taken the data from binding studies into account, the quaternary stereoisomers 
were almost non-selective at the four muscarinic receptor subtypes or had only a 
slight preference (up to 6-fold for compound 2) for M1, M3 and M4 over M2 
receptors.  
 
 
5.1.3.  Affinity profile of the tertiary stereoisomeric analogues of 
glycopyrronium bromide 
 
In analogy to the quaternary stereoisomers, the tertiary derivatives of 
glycopyrronium bromide exist in the corresponding steric forms: 5 (3S/2’S), 6 
(3S/2’R), 7 (3R/2’S), and 8 (3R/2’R). 
 
A comparison with data obtained in the binding assays has been undertaken as 
well. The data determined in radioligand competition studies (Czeche et al., 1997; 
Fig. 5.3.) at M1 - M4 receptor subtypes showed that all tertiary amines exhibit a 
slight selectivity (up to 13-fold for compound 6) for M1, M3 and M4 over M2 
receptors. 
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Fig. 5.3. Antagonist affinities of the tertiary stereoisomeric analogues of 
glycopyrronium bromide determined in radioligand binding studies at recombinant 
M1, M3 and M4 receptors stably expressed in CHO cells and at native M2 receptors 
present in rat heart. 
 
 
There is also an excellent correlation between functional and binding data at M1 
and M2 receptors (Fig. 5.4.: M1: slope = 0.90, r = 0.99; M2: slope = 0.99, r = 0.97), 
which is proved by the small straggling of data points around the solid line (y = x). 
Data at M3 receptor (pKi vs. pIC50) are best correlated by the dotted line (slope = 
0.88, r = 0.96). As already mentioned for the quaternary derivatives, the 
regression line of the pIC50 values was displaced to the left in a roughly parallel 
fashion. The factor of the shift was up to 27 due to the experimental design 
considering the use of endogenous acetylcholine of unknown concentration. 
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Fig. 5.4. Comparison of pKi and pA2/pIC50 values for the tertiary stereoisomeric 
analogues of glycopyrronium bromide obtained in binding and functional studies, 
respectively, at muscarinic receptor subtypes. The solid line represents the 1:1 
relationship. 
 
 
As their quaternary analogues, compounds 5 - 8 behaved as surmountable 
competitive antagonists in functional studies at muscarinic receptors in RVD (M1 
receptors) and GPA (M2 receptors), and in radioligand binding experiments at 
M1 - M4 receptors. The problems occurring with inclusion of pIC50 values in the 
comparison are already discussed in chapter 5.1.2. Again, dissociation half-lifes 
were determined only at the M3 receptor subtype in radioligand binding studies 
(Waelbroeck, personal communication), and were not quantified in the respective 
functional model at GPI. The following rank order of t1/2 (min) resulted: 
20 [5 (3S/2’S)] < 50 [6 (3S/2’R)] = 50 [7 (3R/2’S)] < 60 [8 (3R/2’R)], and compared 
with the rank order of t1/2 values of the quaternary isomers, the differences 
between the stereoisomers were less.  
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5.2. Stereoselectivity and eudismic analysis of the isomers of 
glycopyrronium bromide 
 
Differences between the biological activity of optical isomers have been of 
continuing interest. The study of chiral compounds can help to understand how 
chemical modifications could change the binding affinity for different receptor 
subtypes. In this context, stereoselectivity has been proven to be a useful tool for 
structure-activity relationship studies and in understanding how the structure of a 
given molecule contributes to the pharmacological receptor-mediated effects. The 
analysis of dependence of stereoselectivity on affinity was considerably simplified 
by developing a method called eudismic analysis (Lehmann et al., 1976; Testa, 
1990; Casy, 1993). To describe this model the following terminology was 
introduced: In a series of congeneric chiral pairs the more potent isomer in each is 
designated eutomer and the less potent distomer regardless of their absolute 
configuration (Lehmann, 1986; Testa, 1990). For any given pair the 
potency/affinity ratio is called eudismic ratio (= stereoselectivity), and its logarithm, 
eudismic index. 
 
Since glycopyrronium bromide possesses two centres of chirality the 
stereoisomers can be separated into enantiomers and epimers. Enantiomers are 
characterised by the fact that they have identical physical and chemical properties 
in achiral environments. Epimers are so-called diastereomers in which only one of 
the two (or more) chiral centres is inverted (Lehmann, 1990). Contrary to the 
enantiomers, there is no mirror-image relationship and therefore they differ in their 
physico-chemical properties. Thus, enantiomers of chiral drugs and chiral 
diastereomers are equal in that they are composed of the same number and kinds 
of atoms bonded in the same fashion, but differ in the way in which the atoms 
within the molecule are oriented in space (Lambrecht and Mutschler, 1986). In 
case of glycopyrronium bromide and its tertiary analogues diastereomers with the 
same configuration in the pyrrolidinyl part [(3R/2’R) vs. (3R/2’S) and (3S/2’R) vs. 
(3S/2’S)] as well as diastereomers with the same configuration in the acid part 
[(3S/2’R) vs. (3R/2’R) and (3R/2’S) vs. (3S/2’S)] exist besides the enantiomeric 
pairs. 
 
The influence of the configuration is portrayed as stereoselectivity ratio for the 
enantiomers (enantioselectivity) in Figs. 5.5. (quaternary compounds) and 5.7. 
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(tertiary compounds) and for the diastereomers (diastereoselectivity) in Figs. 5.6. 
(quaternary compounds) and 5.8. (tertiary compounds). 
 
It is noteworthy that meanwhile the quaternary and tertiary stereoisomers of 
glycopyrronium bromide have been synthesised in an alternative way (Walter, 
personal communication) and furthermore, binding data have been determined in 
our laboratory, with CHO cells stably expressing muscarinic M1 to M5 receptor 
subtypes, by Kreutzmann (personal communication). The data obtained with these 
‘new’ isomers are in good agreement with data using the ‘older’ isomers presented 
here (see chapter 4.1.3., Tab. 4.1. and chapter 4.1.4., Tab. 4.2. as well as chapter 
5.1.2., Fig. 5.1. and chapter 5.1.3., Fig. 5.3.). An exception has been found for the 
quaternary compound 3 (3R/2’S) and in analogy for the corresponding tertiary 
compound 7, with (R)-configuration in the pyrrolidinyl part and (S)-configuration in 
the acid part of the molecule, too. These differences are a result of impurity of 
these compounds with the respective (3R/2’R) isomer. And, as the (3R/2’R)-
configured substances exhibited a very high antagonistic potency at the 
muscarinic receptor subtypes the potency of the (3R/2’S)-configured substances 
was markedly increased. In consequence, for the interpretation of the eudismic 
ratios the binding data from Kreutzmann for compounds 3 (M1 = 8.10 ± 0.13; M2 = 
8.11 ± 0.05; M3 = 7.94 ± 0.06) and 7 (M1 = 8.22 ± 0.10; M2 = 7.97 ± 0.05; M3 = 
8.01 ± 0.12) were included. The stereochemical purity of both compounds has 
been checked by analytical methods (Lambrecht, personal communication). 
 
Quaternary compounds 
  For almost all quaternary compounds the stereoselectivity was least 
pronounced at M2, middle at M1 and highest at M3 receptors. The low ratios at M2 
receptors (24 to 72) go in keeping with the lower affinities found for the respective 
eutomers in binding studies (Kreutzmann, personal communication) as well as the 
higher M1 (70 to 74) and M3 (87 to 110) ratios in nearly the same range 
correspond well with the compounds’ preference for these subtypes. 
Exceptions are the extremely lower selectivity ratios of 1 and 2 at M1 to M3 
subtypes for the diastereomers with the same configuration, either (R) or (S), in 
the glycolic acid part of the molecule (Fig. 5.6., right panel). As these low ratios 
are a result of similar affinities of the respective eutomers vs. distomers, one can 
postulate, that the steric arrangement of the acid part is of paramount importance. 
On the one hand, when it is (R)-configured, high affinities were obtained, on the 
other hand, when it was (S)-configured the affinities were likewise lower at the 
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individual muscarinic receptor subtypes. Thus, the influence of the steric 
alignment in the pyrrolidinyl part was of minor importance. 
However, regarding the individual muscarinic receptor subtypes no stringent 
configurational demands could be concluded for one subtype, although 
quantitative differences exist. Therefore, in case of the quaternary isomers of 
glycopyrronium bromide and its tertiary analogues, which are discussed below, the 
stereoselectivity ratios failed to be helpful as an additional parameter to 
characterise muscarinic receptor subtypes (Waelbroeck et al., 1991, 1996). 
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Fig. 5.5. Eudismic ratios for the 
quaternary enantiomers: 4 (3R/2’R) 
vs.  1 (3S/2’S) and 3 (3R/2’S) vs. 2 
(3S/2’R) at the muscarinic receptor 
subtypes in RVD, GPA and GPI. 
 
 
 
 
 
 
 
Fig. 5.6. Eudismic ratios for the quaternary diastereomers with the same 
configuration in the pyrrolidinyl part, 4 (3R/2’R) vs. 3 (3R/2’S) and 2 (3S/2’R) vs. 1 
(3S/2’S) (left panel), and with the same configuration in the acid part, 2 (3S/2’R) 
vs. 4 (3R/2’R) and 3 (3R/2’S) vs. 1 (3S/2’S) (right panel), respectively, at native or 
recombinant muscarinic receptor subtypes M1 - M3. 
  
5. DISCUSSION 
 
 
108
 
 
 
 
 
 
 
 
 
Fig. 5.7. Eudismic ratios for the 
tertiary enantiomers: 8 (3R/2’R) vs. 5 
(3S/2’S) and 7 (3R/2’S) vs. 6 (3S/2’R) 
at the muscarinic receptor subtypes in 
RVD, GPA and GPI. 
 
 
 
 
 
 
Fig. 5.8. Eudismic ratios for the tertiary diastereomers with the same configuration 
in the pyrrolidinyl part, 8 (3R/2’R) vs. 7 (3R/2’S) and 6 (3S/2’R) vs. 5 (3S/2’S) (left 
panel), and with the same configuration in the acid part, 6 (3S/2’R) vs. 8 (3R/2’R) 
and 7 (3R/2’S) vs. 5 (3S/2’S) (right panel), respectively, at native or recombinant 
muscarinic receptor subtypes M1 - M3. 
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Tertiary compounds 
  The calculated stereoselectivity ratios of the tertiary stereoisomers show 
similarities to that of the quaternary compounds, with a wide range of differences 
in affinity for the individual isomers at the receptor subtypes. The lowest ratios 
were found for the M2 subtype (13 to 78) that is in a good agreement with the fact 
that almost all compounds were least potent at this receptor in the binding assay 
(Kreutzmann, personal communication). A selectivity or preference for either the 
M1 or M3 subtype could not been noted, so relatively wide ranges (20 to 151 for 
M1 and 54 to 83 for M3) resulted. 
In analogy to the quaternary isomers, clearly lower eudismic ratios (1 to 4) were 
observed at M1 - M3 receptors for the diastereoisomeric pairs with the same 
configuration in the acid part. Thus, also within the series of tertiary compounds 
the configuration of the acid part is of greatest relevance. 
 
As far as the absolute configuration of the quaternary stereoisomers of 
glycopyrronium bromide and their tertiary analogues are concerned, the rank order 
of affinity for M1 - M4 receptors is (calculated from binding and functional data): 
[RR’]  (1- to 2-fold) [SR’] > (13- to 87-fold) [RS’]  (1- to 4-fold) [SS’]. This implies, 
as previously mentioned, that the steric arrangement in the glycolic acid centre of 
the molecules, (R)-configuration, is of paramount importance for high affinity. In 
the case of compounds with (S)-configuration in the acid part, affinity for 
muscarinic receptors is also governed by the configuration in the pyrrolidinyl 
moiety with (R) > (S). Similar results were reported by Noronha-Blob et al. (1992) 
with the four optical isomers of 3-quinuclidinyl atrolactate (QNA). The rank order of 
potency of the QNA analogues was the same at M1, M2 and M3 receptors: (RR) > 
(RS) > (SR) > (SS) with (RR)-QNA being 182 to 308-fold more potent than (SS)-
QNA. These findings suggest that (R)-isomers conform more stringently to the 
stereochemical demands imposed by muscarinic receptor subtypes than do (S)-
isomers. However, comparing a series of structurally non-related chiral muscarinic 
antagonists the priority rules of the Cahn-Ingold-Prelog nomenclature has to be 
taken into account (Waelbroeck et al., 1996). 
 
Related to the structure of the quaternary stereoisomers of glycopyrronium 
bromide and their tertiary analogues are the enantiomers of 3-benziloyloxy-N-
methylpyrrolidine and their methiodides that have been investigated by Wehrle 
(1997). The exchange glycolic acid/ benzilic acid resulted in a loss of the chiral 
carbon atom in the acid part of the molecule with the consequence that only 
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enantiomers exist with either (R)- or (S)-configuration in the pyrrolidinyl part. As 
determined by Wehrle, the quaternary enantiomers of the benzilate analogues of 
glycopyrronium bromide displayed higher affinities at the muscarinic receptors 
than the corresponding derivatives. And also contrary to the results of the present 
study was that these compounds showed no stereoselectivity. And although the 
affinities for muscarinic receptors were very high, up to the subnanomolar range, 
for the quaternary (R)-configured benzilate, a really subtype-selectivity as well as 
kinetic-selectivity could not be observed. However, a slight preference for 
muscarinic M1 and M3 receptor subtypes (up to 4-fold) over M2 has been found. 
 
 
5.3.  Therapeutical implications of the isomers of glycopyrronium bromide 
 
Parasympathetic nerves provide the dominant neuronal bronchoconstrictor control 
of human airway smooth muscles. Cholinergic neuronal tone is the major 
reversible component in COPD and, through the circadian variation of vagal tone, 
also contributes to nocturnal asthma. The duration of action of the present 
available antimuscarinic drugs as well as the unwanted side effects are insufficient 
to provide convenient maintenance therapy for the patients. Furthermore it was 
shown that prejunctional muscarinic M2 receptors on postganglionic cholinergic 
nerves in airways inhibit ACh release. Non-selective antagonists, such as 
ipratropium bromide, therefore increase the release of ACh via blockade of M2 
receptors (Barnes, 2000). Consequently, there is a clinical need to develop more 
selective antimuscarinic agents that have a longer duration of action than present 
drugs. 
In radioligand binding studies with CHO-K1 cells, the (3R/2’R)-configured 
quaternary isomer of glycopyrronium bromide showed at the M3 receptor a 
dissociation half-live of 120 min (Waelbroeck, personal communication). The 
compound exhibits in functional experiments at muscarinic receptors pA2 values 
of 10.30 (M1; RVD), 9.43 (M2; GPA) and a pIC50 value of 8.76 (M3; GPI) and in 
the binding assay pKi values of 10.18 (M1), 9.63 (M2), 10.20 (M3) and 10.27 (M4). 
Thus, in comparison with the (SS’)-, (SR’)- and (RS’)-configured quaternary 
isomers this compound was potent at the M3 receptor and had a long duration of 
action. These results suggest a ‘kinetic receptor subtype selectivity’ for this 
stereoisomer, although the kinetic parameters at M1, M2 and M4 receptor have yet 
to be quantified. 
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Similar results were reported by Disse et al. (1993) with Ba 679 BR (Fig. 2.1.). It 
has been demonstrated that Ba 679 BR binds with high affinity but non-selectively 
to cloned human M1 - M3 receptors and dissociates more rapidly from M2 (t1/2 = 
3.6 h) than from M1 (t1/2 = 14.6 h) and M3 (t1/2 = 34.7 h) receptors, thus achieving 
subtype selectivity through a kinetic mechanism. Studies by Takahashi et al. 
(1994) at human bronchi confirmed the high potency (IC50 = 0.24 nM), slow onset 
(43.5 min) and long duration of action (> 300 min) of Ba 679 BR, suggesting that it 
may be a useful drug to provide convenient therapy for patients with COPD. 
 
Johnson et al. (1984) reported on the effect of glycopyrrolate, the mixture of (SR’)- 
and (RS’)-configured stereoisomers, in asthma precipitated by exercise and cold 
air inhalation. Glycopyrrolate was as effective as atropine in producing 
brochodilation in this in vivo study. However, its long duration of action and the 
few side effects with inhalation may enhance its clinical utility. Walker et al. (1987) 
supported these results by studying the effectiveness, optimal dose and duration 
of action of glycopyrrolate in patients with nonexercise-asthma. In view of these 
findings it can be expected that the quaternary (RR’)-configured isomer of 
glycopyrronium bromide may be a promising new drug for patients with COPD. 
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5.4.  P2 receptor heterogeneity in the guinea-pig ileal longitudinal smooth 
 muscle  preparation 
 
5.4.1. Experiments at neuronal P2 receptors 
 
5.4.1.1.  Preliminary experiments with ,-meATP 
 
In the present study, P2 receptors expressed in myenteric neurons of the GPI 
were stimulated with single doses of the stable ATP analogue ,-meATP, a 
putative P2X-selective agonist (Lambrecht, 2000). These contractions were 
biphasic, consisting of a rapid, i.e. phasic, response followed by a more sustained, 
i.e. tonic, contraction. To get comparable results in the following experiments with 
,-meATP only the phasic, rapidly desensitising contractions were evaluated. 
 
To examine, whether the response to ,-meATP is based exclusively on P2X-like 
receptors, mediating ACh release, CCPA, DPCPX, and naloxone were tested in 
this model. The A1-selective agonist CCPA (0.001 - 1 µM, Fig. 4.12.) 
concentration-dependently reduced the contractions elicited by ,-meATP (10 
µM), indicating the existence of prejunctional A1 receptors in the GPI. Addition of 
the A1-selective receptor antagonist DPCPX (0.03 - 0.3 µM) has no effect on the 
contractile responses evoked by ,-meATP, indicating that there was no 
endogenous tone at the prejunctional A1 receptors under the present experimental 
conditions. Thus, these results are consistent with earlier studies suggesting the 
existence of adenosine receptors on cholinergic nerve terminals in the GPI 
(Moody and Burnstock, 1982), which later were characterised as A1 receptor 
subtype (Nitahara et al., 1995). It seems likely that stimulation of prejunctional 
adenosine receptors causes modulation, i.e. inhibition, of ACh release (Somogyi 
and Vizi, 1988). Nitahara et al. (1995) confirmed these findings by investigating 
the presynaptic receptor-mediated modulation of evoked release of [
3
H]ACh and 
consequent contraction of GPI. On one hand, adenosine and N
6
-
cyclopentyladenosine (A1 receptor agonist) inhibited both the release of ACh in a 
concentration-dependent manner, on the other hand, 8-phenyltheophylline and 
DPCPX antagonised these inhibitory effects. In consequence, for the following 
experiments the metabolically stable P2X-selective agonist ,-meATP was used 
for P2X receptor subtype characterisation, because the influence of possible 
degradation products, such as adenosine, could be circumvented. 
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Furthermore, it has been found that cholinergic neurons in GPI are endowed with 
opiate receptors stimulation of which might influence contractile responses 
(Somogyi and Vizi, 1988; Katsoulis et al., 1992). In the present study, ,-meATP-
induced contractions remained unaffected by naloxone. Thus, there was no tone 
at prejunctional opiate receptors by endogenous opiates in the present 
experiments. 
 
The next step was to confirm that really ACh, as already mentioned, is also 
released when the presynaptic P2X-like receptor has been stimulated. The 
administration of physostigmine, an inhibitor of the acetylcholinesterase, led to an 
increase of the contractile responses to 30 µM ,-meATP at concentrations of 30 
and 100 nM (Fig. 4.13.). This expected observation was due to the prevented 
breakdown of ACh and a resulting increased quantity of this endogenous agonist 
in the synaptic cleft. The maximum effect of 30 µM ,-meATP was reached with 
100 nM physostigmine, whereas at higher concentrations (300 and 1000 nM 
physostigmine) no benefit was observed. It can be concluded that physostigmine 
at higher concentrations also shows antimuscarinic properties. Thus, for the 
characterisation of the P2X-like receptor, which can modulate the release of ACh, 
and to reinforce the contractile response to ACh by preventing its breakdown, all 
further experiments with P2 antagonists were done in the presence of 70 nM 
physostigmine. 
 
 
5.4.1.2.  Effects of TTX and atropine 
 
A helpful tool for the determination that the receptor’s location is at the neuronal 
site is the sodium channel blocker TTX. In the present study, 1 µM TTX 
completely abolished responses to 10 µM ,-meATP (Fig. 4.14.), confirming the 
neuronal nature of this P2X receptor. 
The blocking effect of the non-selective antagonist atropine (300 nM; Fig. 4.14.) 
following administration of 10 µM ,-meATP has confirmed the fact that ACh is 
released via stimulation of P2X receptors, and additionally, the observed 
contractions of the GPI are a result of binding of ACh to postjunctional muscarinic 
receptors. These interesting findings will be discussed in detail in chapter 5.4.1.5. 
 
To summarise these results (5.4.1.1. and 5.4.1.2.) it can be concluded that ,-
meATP acts on P2 receptors, presumably P2X-like receptors, which are 
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expressed on the cell bodies of myenteric neurones in GPI. The stimulation of 
these receptors resulted in the release of endogenous ACh and a subsequent 
contraction of the muscle via muscarinic receptors. 
 
 
5.4.1.3.  Antagonism by P2 antagonists 
 
The pharmacological characterisation of P2 receptor subtypes requires a battery 
of different antagonists, since there is still a lack of highly selective compounds for 
the individual P2 receptor subtypes. Suramin, PPADS, NF023 and NF279 belong 
to the most popularly and best examined antagonists at P2 receptors in native 
tissues as well as at recombinant receptor subtypes (Lewis et al., 1995; Ziyal et 
al., 1996, 1997; Soto et al., 1997, 1999; Lê et al., 1998; Ralevic and Burnstock, 
1998; Bianchi et al., 1999; Lambrecht et al., 1999; Lambrecht, 2000). Despite the 
non-selective behaviour of suramin and PPADS for a single receptor subtype, 
comparison with the affinity estimates determined in various earlier studies at 
native and recombinant receptors can give hints to the receptor subtype to be 
investigated. 
 
It has already been reported that the P2 agonists ,-meATP, 2-MeSATP and 
ATP led to contraction of GPI by acting at two different P2 receptors. Responses 
to  ,-meATP, but not to 2-MeSATP or ATP, were antagonised by TTX and 
atropine, suggesting that ,-meATP activates P2 receptors on cholinergic nerve 
terminals, whilst the other two compounds act on smooth muscle P2 receptors 
(Kennedy and Humphrey, 1994). Matsuo et al. (1997) confirmed these findings 
and described that ,-meATP produced contractions of ileal longitudinal smooth 
muscle segments. The contractile response was inhibited by suramin, TTX and 
atropine indicating that this effect results mainly from stimulation of, probably, P2X 
receptors on cholinergic nerves. Further evidence for the involvement of P2 
receptors in the cholinergic contraction of the GPI was given by Barthó et al. 
(1997). They found that PPADS and suramin strongly inhibited the ACh-mediated 
contractile effect of ,-meATP, but contractions evoked by exogenous ACh 
remained to be unaffected by both P2 antagonists. Additionally, cholinergic 
contractions due to electrical field stimulation (EFS) were inhibited by PPADS and 
suramin in a non-additive manner, suggesting that an endogenous ligand that 
stimulates prejunctional P2 receptors, possibly ATP, is involved in the contractile 
effect of EFS as a positive modulator of ACh release. 
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In the present study, ,-meATP (0.1 - 30 µM) elicited concentration-dependent 
contractile responses. Suramin (10 - 100 µM; Fig. 4.15.), NF023 (30 - 300 µM; Fig. 
4.17.) and NF279 (3 - 30 µM; Fig. 4.18.) shifted the concentration-response curve 
of ,-meATP to the right in a parallel manner. The corresponding Schild plots of 
these compounds were linear, and the slopes of their regression lines did not 
differ from unity. 
 
In the presence of PPADS (0.3 - 100 µM; Fig. 4.16.) concentration-response 
curves of ,-meATP were displaced to the right in a roughly parallel fashion with 
reduction of the maximum response. This might be due to a pseudoirreversible or 
non-competitive antagonism of PPADS (Windscheif, 1995). 
 
To summarise the antagonistic properties of the four compounds mentioned 
above, it could be concluded that they, with exception of PPADS, behaved as 
competitive antagonists at the neuronal P2X-like receptor. On the basis of the 
affinity estimates (pA2 values) the following antagonist profile was obtained: 
PPADS > NF279 > suramin > NF023. The pA2 values are presented in decreased 
order graphically in Fig. 5.9. 
 
 
 
 
Fig. 5.9. Affinity estimates (pKB value for PPADS; pA2 values for NF279, suramin 
and NF023) of P2 receptor antagonists in GPI using ,-meATP as agonist (n = 4 
for each antagonist). 
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As already pointed out, the comparison between functional affinity estimates and 
potencies reported at recombinant receptors could be a suitable method for 
subtype identification by means of a battery of antagonists. Especially suramin, 
PPADS, NF023 and NF279 have been widely used in functional studies at native 
and cloned P2 receptors of various species. Their antagonistic properties at 
recombinant rat and human P2 receptor subtypes are illustrated in Figs. 5.10. to 
5.12. 
 
 Comparison of pA2 values functionally determined at P2X-like receptors in GPI 
with pIC50 values determined at recombinant human and rat P2X receptors for 
PPADS and suramin: 
 
 
 
 
Fig. 5.10. Selectivity profiles of PPADS (, ) and suramin (, ) at recombinant 
rat (opened symbols) and human (filled symbols) P2X receptor subtypes. Potency 
estimates (pIC50 values) were determined as inhibition of ATP-induced inward 
currents. Data taken from Soto et al., 1997; Ralevic and Burnstock, 1998. 
 
 
The pA2 value of 6.17 determined in functional experiments for PPADS seems to 
correlate best with potencies (pIC50 values) found at recombinant rat P2X1 (6.0), 
rat P2X2 (5.7) and/or rat P2X3 (6.0; Fig. 5.10.). However, the P2X2 receptor 
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subtype can be excluded, because it belongs to the ,-meATP-insensitive 
receptors, which show slow desensitisation or sustained depolarising currents 
(reviewed by MacKenzie et al., 1999; Burnstock and Williams, 2000), whereas, as 
already mentioned (see 4.2.1.1.), in GPI ,-meATP produced rapidly 
desensitising contractile responses. 
The functionally determined pA2 value (5.1) of suramin is very similar to the pIC50 
value (4.9) obtained at recombinant human P2X3 receptors. However, taken the 
pIC50 value of 5.5 determined at recombinant rat P2X3 into account, there is a 
slight difference by a factor of 2.5. Besides, also the pIC50 values of the rat P2X1 
(5.6), rat P2X2 (5.5) and rat P2X5 (5.4) are nearby the pA2 value found in GPI, but 
the latter two subtypes can be excluded because of their ,-meATP-insensitivity. 
 
 
 Comparison of pA2 values functionally determined at P2X-like receptors in GPI 
with pA2 values determined at recombinant human P2Y receptors for PPADS and 
suramin: 
 
 
   
 
Fig. 5.11. Selectivity profiles of PPADS () and suramin () at recombinant 
human P2Y receptor subtypes. Affinity estimates (pA2 values) were determined as 
inhibition of inositol phosphate accumulation induced by nucleotides. Data taken 
from Soto et al., 1997; Ralevic and Burnstock, 1998; Communi et al., 1999. 
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Although the effect of ,-meATP strongly indicated the presence of a neuronal 
P2X-like receptor subtype, a comparison with affinities at P2Y is still necessary to 
argument against them. A good agreement to the functional pA2 value of PPADS 
has only shown the pA2 value (6.0) at recombinant human P2Y1 receptors. 
Neither the affinity estimates of PPADS at any further recombinant human P2Y 
receptor subtype nor the pA2 values for suramin at these receptors were nearly in 
the range of the pharmacologically determined affinity estimates for both 
antagonists in GPI. Apart from these facts, the ‘agonist-selectivity’ of ,-meATP 
for P2X receptors led to the conclusion that P2Y receptors can be excluded, 
although this ligand has also been described as a weak P2Y agonist and the 
relationship between its function and selectivity for both P2 classes deserves 
careful attention (Fredholm et al., 1994). 
 
 Comparison of pA2 values functionally determined at P2X-like receptors in GPI 
with pIC50 values determined at recombinant P2X and P2Y receptors for NF023 
and NF279: 
 
 
       
 
 
Fig. 5.12. (legend, see page 119) 
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Fig. 5.12. Selectivity profiles of NF023 (, ) and NF279 (, ) at recombinant rat 
(opened symbols) and human (filled symbols) P2X as well as at human (filled 
symbols) P2Y receptor subtypes. At P2X1 and P2X4 receptors opened symbols 
are covered by the filled symbols, i.e. the affinity properties were the same for 
these rat and human subtypes. Both compounds have also the same potency at 
the human P2Y1 and P2Y2,4,6 receptors (symbols are covered). Potency estimates 
for P2X receptors were determined as inhibition of ATP-induced inward currents, 
and for P2Y receptors as inhibition of inositol phosphate accumulation induced by 
nucleotides. Data are taken from Soto et al., 1999; Klapperstück et al., 2000; 
Rettinger et al., 2000; Boyer, J.L. and Harden, T.K., personal communication. 
 
 
 
Compared to the functionally found pA2 values of NF023 (4.56) and NF279 (5.95), 
the pIC50 values that have been found for both antagonists at the rat recombinant 
P2X3 receptor subtype correlated best (Fig. 5.12.). At the P2X1 receptor subtype, 
which was considered at first (cf. antagonistic profile of PPADS at recombinant rat 
P2X subtypes), the potency of NF023 is higher by a factor of 110 and this of 
NF279 by a factor of 56 compared with the pA2 values determined in GPI.  
 
In conclusion, PPADS, NF279, suramin and NF023 competitively antagonised 
,-meATP-induced contractions in GPI with potency decreasing in that order 
(Fig. 5.9.). The best correlation of pA2 values from functional experiments and 
potencies reported at recombinant P2X receptor subtypes for these four 
antagonists was found at the P2X3 receptor. 
 
Another aspect seems to be important: human and rat P2X receptor subtypes 
have shown different functional phenotypes with regard to agonist 
responsiveness, especially to ,-meATP, antagonist sensitivity, particularly to 
PPADS and suramin, and desensitisation (North and Barnard, 1997). P2X1 and 
P2X3 are the only two subtypes at which ,-meATP is an effective agonist with 
EC50 around 1 µM. Moreover, P2X1 and P2X3 desensitise within milliseconds, 
whereas the other P2X subtypes needs a few seconds for desensitisation. In view 
of the antagonists PPADS and suramin the situation is not so simple. Only rat 
P2X4 receptors are rather insensitive to both antagonists. For further potency 
estimates see Figs. 5.10. and 5.11. 
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Eventually, the question arises, which subtypes are responsible for contraction of 
GPI since P2X receptors have been functionally characterised by whole-cell patch 
clamp method in neurons isolated from guinea-pig myenteric plexus resulting in 
the identification of two types of cells: The major proportion of neurons (92 %) 
responded to ATP with slowly desensitising inward currents, which were 
antagonised by PPADS. ,-meATP was a rather poor agonist in these cells. In a 
minority of neurons (8 %), ATP and ,-meATP activated with similar potency 
rapidly desensitising inward currents. Thus, it could be speculated that a 
heterogeneous P2X receptor population may exist: It was proposed that the 
greater proportion may bear P2X2-like receptors, whereas the smaller proportion 
of myenteric neurons may be of P2X1 or P2X3 receptor subtype (Zhou and 
Galligan, 1996; Nörenberg and Illes, 2000). In view of these results it can be 
assumed that in the present study with ,-meATP the minority of neurons of 
guinea-pig myenteric plexus neurons has been activated, but further P2X receptor 
subtypes, homomeric or heteromeric, may be present, and it would be interesting 
to investigate this suggestion. 
 
 
5.4.1.4. Concluding  remarks 
 
Upon comparing the above characteristics of each subtype with the 
pharmacological profile obtained in the present study, the data suggest again that 
neuronal P2X receptors of the GPI that can be stimulated by ,-meATP are of 
P2X3 subtype. Hence, one should be cautious in extrapolating pharmacological 
data, based largely on findings in guinea-pig, to other species including human 
and rat. But unfortunately, with exception of the P2X2 receptor subtype, no other 
P2X receptor has been cloned from guinea-pig tissue so far (Housley et al., 1999). 
It can also not be excluded that this subtype is a heteromer. Thus, to answer 
these questions and to establish the GPI as a robust and unequivocal model for 
studying P2X3 receptors, the receptor has to be cloned from this tissue. 
 
 
5.4.1.5.  Investigations on the muscarinic receptor subtype responsible 
    for contraction of GPI 
 
In this set of experiments the effect of ,-meATP in GPI has been compared with 
that of electrical field stimulation based on the assumption that with both methods 
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endogenous ACh would be released, which in turn, leads to stimulation of 
postjunctional muscarinic receptors. Additionally, the muscarinic receptor subtype 
responsible for the resulted contraction of the ileal smooth muscle has been 
investigated by means of some muscarinic key antagonists. 
 
It is important to note, that the P2 antagonists, used so far in this study, at a 
concentration of 100 µM failed to affect contractions elicited by single doses of the 
muscarinic agonist arecaidine propargyl ester (APE; 100 nM). Accordingly, a direct 
interaction of PPADS, suramin, NF023 and NF279 with postjunctionally located 
muscarinic receptors can be excluded at their highest concentration used. 
 
Hints to the muscarinic nature of the postjunctionally localised cholinergic receptor 
were already given in chapter 4.2.1.1.: the non-selective muscarinic antagonist 
atropine in a concentration of 300 nM strongly suppressed contractile responses 
to 3 µM ,-meATP. For further investigations of the antagonistic properties a 
series of different muscarinic antagonists were employed, since there is still a 
shortage of highly-selective compounds. Atropine (0.003 - 0.1 µM), the ‘M3-
selective’ antagonist p-F-HHSiD (0.01 - 3 µM), the ‘M2-selective’ antagonist 
himbacine (0.3 - 30 µM), and the ‘M1-selective’ antagonist pirenzepine (0.1 - 30 
µM) antagonised contractions to 3 µM ,-meATP to almost 100 % (Fig. 4.19. A - 
D). The following antagonist profile in GPI was found: atropine > p-F-HHSiD > 
himbacine > pirenzepine (Tab. 4.3.). The low pIC50 value of pirenzepine (5.88) 
excludes the existence of M1 receptors. In addition, himbacine exhibited a low 
affinity with pIC50 value of 6.01 and therefore it can be excluded that M2 or M4 
receptors are involved. p-F-HHSiD displayed a pIC50 value of 6.93 and thus can 
exclude the participation of M2 receptors, but is in good agreement with the 
existence of M3 receptors. The highest pIC50 value was found for atropine (7.76), 
which was also in best accordance with the occurrence of M3 receptors. It is 
important to note that most potency estimates of antagonists are documented as 
pA2 values in literature. The pIC50 values obtained in the present study remained 
constantly by a factor of 10 lower than the respective pA2 values (Tab. 4.3.). 
 
As outlined before, activation of the soma-dendritic P2X receptor modulates 
release of endogenous ACh accompanied by contractile responses in GPI. 
Another standard method to liberate endogenous ACh is the electrical field 
stimulation of this tissue with 0.1 Hz. As before, the muscarinic antagonists were 
tested in the following concentrations: atropine (0.03 - 30 nM), p-F-HHSiD (1 - 
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1000 nM), himbacine (10 - 1000 nM), and pirenzepine (30 - 3000 nM). The 
antagonist profile (pIC50 values are given in parenthesis) was identical to that of 
GPI stimulated with ,-meATP: atropine (8.44) > p-F-HHSiD (7.42) > himbacine 
(6.69) > pirenzepine (6.39). However, the inhibition curves of the electrically 
stimulated GPI were shifted to the left in a parallel manner, indicating that more 
ACh was released. The excellent correlation with r = 0.993 between both methods 
is illustrated in Fig. 4.20. A. 
 
Previous reports (Eglen et al., 1996) have clearly identified the muscarinic 
receptor located at the postsynaptic site of GPI and responsible for contraction of 
the smooth muscle as M3 subtype. Meanwhile, the GPI is a standard model for 
characterisation of new muscarinic antagonists and their structure-activity 
relationships in a functional way. To evaluate, whether the way of indirect ACh 
release after stimulation of the neuronal P2X3-like receptor might be used for 
investigations in the muscarinic field, the exact nature, i.e. subtype, of this 
postsynaptically located muscarinic receptor has been determined. For that 
purpose, differences of pIC50 values of the above mentioned four muscarinic 
antagonists examined with ,-meATP were compared to the corresponding 
differences in pKi values obtained from radioligand binding studies at native M1 - 
M4 receptor subtypes. The graphical correlation is given in Fig. 5.13. Hence it 
becomes evident that only the regression line for the M3 receptor subtype with a 
slope of 1.03 ± 0.16 provides a convincing correlation: M1: r = 0.35; M2: r = 0.15; 
M3: r = 0.96; M4: r = 0.54. To confirm this finding, pIC50 values obtained with ,-
meATP in GPI were compared to pA2 values identified functionally at M3 
receptors in GPI (Fig. 4.20. B). The noticeable excellent correlation (r = 0.992) 
again led to the conclusion that activation of soma-dendritic P2X3-like receptors in 
GPI causes an indirect ACh-mediated contraction via postjunctional M3 receptors. 
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Fig. 5.13. Comparison of differences () of pIC50 values for atropine, p-F-HHSiD, 
himbacine and pirenzepine, respectively, inhibiting ,-meATP-induced 
contractions at postsynaptically located muscarinic receptors in GPI (present 
study) with differences () in binding affinities (pKi values) determined in 
radioligand binding assays (data from Waelbroeck et al., 1989, 1990, 1991, and 
personal communication) at native M1 to M4 receptors (Pfaff et al., 1995). The 
dotted lines represent the 1:1 relationship. 
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5.4.2. Experiments at postjunctionally localised P2 receptors 
 
5.4.2.1.  Potency profile of P2 agonists 
 
In the field of P2 receptors a first idea of the receptor subtype to be characterised 
may be given through rank order of different agonists. ADPS, ,-meADP and 2-
MeSATP in concentrations from 0.3 to 100 µM produced concentration-dependent 
contractions in GPI. As none of them reached a really maximum response 
comparable pEC750 values based on the development of 750 mg tension were 
uniformly determined, because for ADPS it represents the presumable 
halfmaximal effect in the concentration range used. In consequence, the following 
affinity profile could be established: ADPS > 2-MeSATP > ,-meADP, with 
ADPS as the most potent agonist indicating the presence of postjunctional P2Y 
receptors. 
 
 
5.4.2.2.  Effects of atropine, TTX and CCPA 
 
The contractile responses of the aforementioned agonists were partially reduced 
by either TTX (1 µM), atropine (0.3 µM) or CCPA (1 µM). These observations (see 
Fig. 4.22.) imply that these three P2 agonists stimulated not only the P2 receptors 
on smooth muscle but also P2 receptors, probably P2X3, located in myenteric 
neurons and characterised in chapter 4.2.1. The inhibitory effect of the A1-
selective agonist CCPA could be explained by its modulatory effect on ACh 
release following stimulation of soma-dendritic P2X receptors with P2 agonists 
(Somogyi and Vizi, 1988). Upon these findings it can be concluded that there are 
two different P2 receptors in GPI: a neuronal ,-meATP-sensitive receptor with 
,-meATP >> ADPS; and a postjunctional ,-meATP-insensitive with ADPS 
>>> ,-meATP. Again, these results are in good agreement with previous studies 
(Kennedy and Humphrey, 1994; Matsuo et al., 1997). For the characterisation of 
the postjunctional P2 receptor ADPS was used as agonist, since it was the most 
effective one, and atropine was present throughout the experiments with the P2 
antagonists to prevent the influence of the neuronal P2X3 receptor, which 
mediates ACh release and, subsequently, a contractile response via 
postjunctional muscarinic M3 receptors. 
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5.4.2.3.  Antagonism by P2 antagonists 
 
Single doses of ADPS (0.3 - 300 µM; 1232 ± 59 mg tension generated in control 
experiments) produced concentration-dependent contractions in GPI. 
 
The commonly used antagonists PPADS, suramin, NF279 and NF023 
antagonised contractions elicited by ADPS with potency decreasing in that order 
(Fig. 5.14.). 
 
 
 
 
 
Fig. 5.14. Affinity estimates (pA2 values for NF279, suramin and NF023; pKB value 
for PPADS) of P2 receptor antagonists in GPI using ADPS as agonist (n = 3 - 6). 
 
 
First, strong evidence for the involvement of P2Y receptors was given since the 
GPI under the present experimental design, e.g. with atropine in the bath solution 
to exclude the described effect of P2X3-like receptors located postjunctionally, 
was sensitive to the P2Y receptor agonist ADPS. Second, if compared the 
functional affinity estimates with those obtained at recombinant rat and human 
P2Y receptors (Fig. 5.11.) the following can be summed up: the high potencies of 
PPADS and suramin correlate best with affinities found for both compounds at 
human P2Y1 receptor subtype. At P2Y11, suramin has also shown high affinity, 
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but there is a great discrepancy to the pA2 value of PPADS that is less than 4.0. 
At all other P2Y subtypes the pA2 values were clearly lower than observed in the 
present study from functional experiments in GPI. The pA2 values of NF023 and 
NF279 at recombinant P2Y1 receptors also correlate best with pA2 values 
functionally determined in GPI. 
 
Nevertheless, the pIC50 values obtained for the standard antagonists in this study 
at P2X receptors one should into account. In case of PPADS, only the pIC50 
values at recombinant rat P2X1 (6.0) and P2X3 (6.0) and for suramin at P2X1 
(5.6), P2X2 (5.5) and P2X3 (5.5) receptors could be taken into consideration (cf. 
Fig. 5.10.). However, because of their rapid desensitisation the P2X1 and P2X3 
receptors can be excluded. Regarding the pIC50 values for NF023 (4.2) and 
NF279 (6.4) at P2X2 receptors it seems rather doubtful whether this subtype is 
involved. 
 
 
5.4.2.4.  Antagonism by A3P5P and MRS2179 
 
Although progress has been made in identifying adenine nucleotide analogues 
that exhibit selectivities among P2 receptors, the availability of antagonists with 
subtype-selectivity is still limited. In consequence, a step forward were structure-
activity relationships (SAR) from adenine nucleotides with phosphate substitution 
in 2’- and/or 3’-positions. From this series, A3P5P was the most promising one. In 
the adenine nucleotide-promoted inositol lipid hydrolysis response of turkey 
erythrocyte membranes A3P5P caused a parallel rightward shift of the 2-MeSATP 
concentration-effect curve, and a calculated pKB of 5.66 ± 0.21 was determined 
from Schild regression with slope not significantly different from unity. Similar 
antagonistic activities were observed in 1321N1 human astrocytoma cells stably 
expressing the cloned P2Y1 receptor. The calculated pKB value of 6.05 ± 0.01 
was essentially the same as that obtained in the turkey erythrocyte membrane 
preparation, but in contrast, no partial agonist activity could be noticed. 
Additionally, A3P5P was neither agonist nor antagonist at P2Y receptor of C6 rat 
glioma cells, human P2Y2 and P2Y4, or rat P2Y6 receptors stably expressed in 
1321N1 astrocytoma cells (Boyer et al., 1996). Recent reports from Hollopeter et 
al. (2001) have shown, that A3P5P failed to exhibit inhibitory effects on signals 
evoked by ADP on recombinant rat or human P2Y12 receptors in concentrations 
up to 300 µM. 
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In the study presented here, the functionally determined pA2 value resulting from 
only one concentration (100 µM) of A3P5P was 4.45 ± 0.16. The difference to the 
above mentioned antagonist potencies amounted to a factor of 16 (P2Y1 in turkey 
erythrocytes) to 40 (P2Y1 stably expressed in astrocytoma cells). However, the 
selectivity of A3P5P observed exclusive for P2Y1 receptors gives strong evidence 
for this subtype in the smooth muscle of guinea-pig.  
The chemical structure of A3P5P could raise the question to a potential 
degradation by enzymes described in chapter 1.2.6. Possibly from these enzymes 
the ecto-5’-nucleotidase may split of the terminal phosphate group resulting in 
adenosine 3’-phosphate. However, Park et al. (1998) have examined the 
degradation of adenosine 3’-phosphate 5’-phosphosulfate in rat vas deferens. It 
was rapidly broken down to A3P5P, but no further degradation of A3P5P was 
observed. In view of these results one could assume that A3P5P is also a stable 
compound under the experimental conditions of the present study in GPI. 
 
Extension of SAR culminated in a new series of deoxyadenosine bisphosphates 
with substitutions in the adenine base, ribose moiety and phosphate groups. 
Among them, the most interesting compound was MRS2179 (Camaioni et al., 
1998; Nandanan et al., 1999). MRS2179 behaved as competitive antagonist at the 
turkey P2Y1 receptor with a pKB value of 102 nM, and was inactive at P2Y2, P2Y4 
and P2Y6 subtypes as well as at the adenylate cyclase-linked P2Y receptor in C6 
glioma cells and canine P2Y11 receptor (Nandanan et al., 1999, 2000). The pKB 
value of 6.99 ± 0.13 found by Boyer et al. (1998) for MRS2179 at human P2Y1 
receptors expressed in 1321N1 human astrocytoma cells provides further 
evidence for its P2Y1 selectivity since no antagonistic effect of this compound has 
been observed at human P2Y2, human P2Y4 or rat P2Y6 receptors. The presence 
of an N
6
-methyl group and the absence of a 2’-hydroxyl group both enhanced 
affinity and decreased agonist efficacy, thus resulting in a pure antagonist at both 
turkey and human P2Y1 receptors. In the present study, MRS2179 yielded a 
pIC50 value of 5.37 ± 0.04, and in view of its selectivity, this result is in a good 
agreement with the previous findings indicating that the P2 receptor located on the 
postsynapic site of the GPI is a P2Y1 subtype. Although this bisphosphate 
derivative was helpful to characterise the P2Y receptor subtype on smooth 
muscle, it should be noted that MRS2179 also inhibited P2X1 receptor-mediated 
responses and that its affinity at the human P2Y11 is not known (Von Kügelgen 
and Wetter, 2000), whereas its affinity to the newly cloned P2Y12 receptor to date 
can be excluded (Savi et al., 2001). 
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5.4.3. Conclusion 
 
Upon comparing the functionally determined antagonist properties of the 
aforementioned antagonists with data from recombinant P2 receptors, the 
postjunctional P2Y receptor in GPI mediating contractile responses is certainly of 
P2Y1 subtype. The cloning of P2 receptors from the GPI might be helpful for 
further investigations. 
 
 
In summary, the guinea-pig ileal longitudinal smooth muscle preparation is an 
excellent model in which P2X3 and P2Y1 receptor selectivity of antagonists can be 
determined concomitantly with different agonists. Thus, it is a unique system in 
which P2X3-like receptors seem to be located on the soma-dendritic region and 
P2Y1 receptors on the postsynaptic site (Fig. 5.15.). 
 
 
     
 
Fig. 5.15. Functional heterogeneity of P2 receptors mediating contraction in GPI. 
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5.5.  Experiments at the longitudinal smooth muscle of rat ileum 
 
The present study was undertaken to characterise the P2 receptors in RI to 
establish a further possible model for studying P2 receptor subtypes, and to 
compare the situation of P2 receptors in RI with that of GPI. 
 
 
5.5.1. Experiments with P2 agonists 
 
First of all, the potency of commonly used P2 agonists were examined. ,-
meATP, ADPS,  ,-meADP and ATPS elicited concentration-dependent 
contractile responses in RI with efficacy/potency decreasing in that order.  
 
Since ,-meATP and ADPS were the most efficacy/potent agonists they were 
used for further investigations.  
,-meATP has shown no desensitisation after cumulative addition. This 
observation led to the conclusion that the ,-meATP-sensitive, but rapidly 
desensitising P2X receptor subtypes, i.e. P2X1 and P2X3 receptors, can be 
excluded. On the other hand, P2X2, P2X4, P2X5 and P2X6 receptors show slow 
desensitisation, but are rather insensitive to ,-meATP. Therefore, one can 
speculate, that the P2 receptor subtype could be a hetero-oligomeric channel, e.g. 
P2X2+3 or P2X1+5 (Lewis et al., 1995; Lê et al., 1999). Another explanation could 
be that in RI ,-meATP mainly stimulates P2Y receptors. 
Administration of 1 µM TTX reduced contractions elicited by 30 µM ,-meATP to 
nearly 40 % of control (Fig. 4.29.) indicating that the agonist acts at the neuronal 
as well as at the postsynaptic site. Addition of 0.3 µM atropine led to a decrease of 
contraction evoked by 100 µM ,-meATP to about 45 % of control (Fig. 4.29.). 
Thus, it can be assumed that, as it was observed at GPI, contractions of RI are 
partly indirectly ACh-mediated. 
 
In case of ADPS, cumulative addition also failed to result in desensitisation. But 
contrary to ,-meATP, contractions elicited by ADPS remained unaffected by 
administration of either 1 µM TTX or 0.3 µM atropine indicating that this agonist 
acts only directly at the smooth muscle of the rat ileum. ADPS was therefore 
used to determine the potency of antagonists in RI. 
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5.5.2. Effects of P2 antagonists on responses to ADPS 
 
The commonly used P2 antagonists PPADS (10 - 300 µM; Fig. 4.32.), suramin 
(30  - 300 µM; Fig. 4.31.) and NF023 (10 - 300 µM; Fig. 4.30.) produced rightward 
displacements of the concentration-effect curve of ADPS in a roughly parallel 
manner with potency decreasing in that order. It was characteristic for all these 
antagonists that the control curve was somewhat flatter and the antagonist curves 
showed a higher maximum than the control curve. A reason for this fact could be 
that by the antagonist a relaxation-mediating P2 receptor was blocked. 
 
 
5.5.3. Conclusion 
 
Little information is given in the literature concerning the localisation of P2 
receptor subtypes in the smooth muscle of the rat ileum (cf. chapter 2.3), and in 
the study presented here, the presence of P2 receptors could be proved 
unequivocally, but it was impossible with the functional methods to characterise 
the involved subtypes exactly. Besides the lack of really subtype-selective 
agonists and antagonist for P2 receptors, there are many further caveats within 
the field of P2 receptors that might complicate the receptor characterisation: first, 
the existence of hitherto unknown P2 receptor subunits can not be excluded or a 
single subunit may predominate the phenotype of a heteromeric complex. A 
further complication may arise from alternative splicing. Second, the coexistence 
of ionotropic P2X together with metabotropic P2Y receptors could also influence 
the neuronal response. 
In summary, the situation concerning the localisation and response of P2 
receptors in RI is quite different from that observed in GPI. 
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The interest in receptors for acetylcholine hands back into the passed century as 
nicotinic and muscarinic receptors as well as their subtypes could to be discovered 
and characterised. Due to the abundance of muscarinic receptors within the 
central and peripheral nervous system as well as in innervated organs they are 
still of large interest as targets for certain clinical indications. 
Particularly within the area of the chronical obstructive pulmonary disease (COPD) 
bronchodilators are the first line approach to treatment. Although the use of 
muscarinic receptor antagonists as ipratropium bromide, either alone or in 
combination with a short-acting 2 receptor agonist, is recommended, their use is 
hampered by unwanted side effects. Besides M3 receptors human airways contain 
also M2 and its blockade results in an increased ACh release and is therefore 
undesirable. Thus, the development of antagonists with M3-selectivity and/or 
extended duration of action would be a large progress for the treatment of patients 
with COPD or even asthma. 
 
Investigations on the stereoisomers of glycopyrronium bromide and their 
four corresponding tertiary analogues 
 
In the present study both the four pure stereoisomers of glycopyrronium bromide 
and the corresponding tertiary analogues were investigated. To date, the 
diastereoisomeric pair (RS/SR) of this compound (launched as Robinul
) is 
predominantly used therapeutically as antisialagogue for premedication under 
anaesthesia or as antispasmodic. 
 
The molecular structure of glycopyrronium bromide indicates two centres of 
chirality, which result in four stereoisomers. The pharmacological investigation of 
both the quaternary and corresponding tertiary isomers in functional standard 
models, rabbit vas deferens for M1 receptors, guinea-pig left atria for M2 receptors 
and the guinea-pig ileal longitudinal smooth muscle for M3 receptors, has shown 
that all compounds behaved as potent antagonists at the respective muscarinic 
receptor subtypes. However, their receptor selectivity was relatively small, 
whereby generally the lowest affinity was observed at the M2 receptors. Among 
the stereoisomers, the (R/R')- and (S/R')-configured compounds exhibited the 
highest, the (S/S')-configured isomers the lowest antagonistic properties. These 
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results could be confirmed in radioligand binding studies. Remarkably, at M3 
receptors an extremely slow dissociation of the substances has been determined. 
With a dissociation half-life of 120 min, determined in the binding assay and an 
affinity in the subnanomolar range, the quaternary (R/R’)-configured stereoisomer 
of glycopyrronium bromide might be a suitable alternative to the present treatment 
of COPD: the long dissociation half-life would permit a once-daily administration 
which may enhance patients’ compliance, the high affinity enables a small dosage 
and the so-called 'kinetic selectivity’ as well as the quaternary structure may result 
in a minimisation of unwanted side effects. Due to these advantages the 
substance was patented and put to the pharmaceutical industry for resuming 
investigations at the disposal. 
 
Evaluation of the guinea-pig ileal longitudinal smooth muscle preparation 
with respect to P2 receptor heterogeneity 
 
Due to the pioneering work, which was carried out at the end of the 70's by 
Burnstock and co-workers, the picture of ATP as an energy source of the cell has 
been changed to ATP as a neurotransmitter of ubiquitous occurrence with 
appropriate target structures, the P2 receptors. In the meantime it is generally 
recognised that one can differentiate between metabotropic P2Y and ionotropic 
P2X receptors. Cloning techniques have validated the original receptor 
classification and have gone on to unveil an exciting range of different receptor 
subtypes. Until today, seven subtypes of P2X (P2X1-7) receptors and six P2Y 
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11  and P2Y12) receptor subtypes have been 
cloned, pharmacologically characterised and accepted as true representatives of 
the P2 receptor family. 
 
In this rapidly expanding field, one of the main current challenges is to relate the 
cloned P2 receptors to the diverse physiological responses mediated by native 
receptors. Since the guinea-pig ileal longitudinal smooth muscle is a well-known 
preparation, for instance for studying muscarinic receptors, the goal of the present 
study was to evaluate this model with respect to P2 receptor subtype distribution.  
Besides agonists, which indicate a preference for ionotropic (,-meATP) or 
metabotropic (ADPS) P2 receptors, a number of well-examined antagonists with 
partially high affinity for a receptor subtype were used for the functional 
investigations. 
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The neuronal localisation of P2X receptors could be demonstrated. The almost 
complete inhibition of the contraction to ,-meATP after application of atropine or 
TTX, indicating an indirect, ACh-mediated effect. Due to these observations in all 
further experiments with P2 antagonists 70 µM physostigmine were added to the 
bath solution. 
 
The antagonists suramin, NF023 and NF279 behaved as competitive antagonists 
against  ,-meATP, while PPADS was found to be a pseudoirreversible 
antagonist. A comparison of functionally determined pA2 values with potencies 
obtained at recombinant rat and human P2 receptors let to the conclusion that the 
P2X3 receptor subtype causes a contraction of the ileal smooth muscle via an 
indirect mechanism of ACh release. Since P2X subunits can assemble to form 
heteromeric besides homomeric functionally active channels the present soma-
dendritic P2X receptor can also be a heteromer, at which the P2X3 predominates 
the native phenotype. As long as no unequivocal identification of this receptor has 
been reported on molecular level, one should use the designation P2X3-like 
receptor. 
 
The criteria of antagonist affinities were used to verify that the muscarinic receptor 
present in GPI which could be indirectly stimulated via neuronal localised P2X3-
like receptors causing ACh release were the same as previously characterised in 
GPI in a direct way with APE or electrical field stimulation of the tissue. 
These correlations demonstrated unequivocally that the postjunctional muscarinic 
receptors of GPI, stimulated through ACh, which was released after activation of 
soma-dendritical P2X3-like receptors, are equivalent to native or recombinant M3 
receptors. 
 
Moreover, addition of ADPS elicited contractions in GPI, which could not be 
abolished by either TTX or atropine. These observations led to the idea that there 
are postsynaptically localised P2Y receptors. In order to prevent the influence of 
the neuronal P2X3 receptors, all experiments were done in the presence of 0.3 µM 
atropine. 
Again, suramin, NF023 and NF279 behaved as competitive antagonists against 
ADPS , while PPADS caused a rightward shift of the control curve with maximum 
depression. A comparison of the antagonist potencies with described potency 
values obtained at recombinant P2 receptors permitted the conclusion that the 
P2Y receptor located postsynaptically in the GPI showed characteristics of the 
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P2Y1 receptor subtype. The P2Y1-selective bisphosphates A3P5P and MRS2179, 
although in the present study possessing lower pIC50 values than described in the 
literature, confirmed this conclusion. 
 
With the identification of the neuronal P2X3 receptor and the postsynaptic P2Y1 
receptor, the GPI is a unique functional pharmacological model to date, in which 
both P2 receptor subtypes can be pharmacologically isolated by the use of the 
respective agonist, ,-meATP or ADPS. 
 
Characterisation of P2 receptors in the rat ileal longitudinal smooth muscle 
 
One, in comparison to the GPI, completely different situation was found to be in 
the RI. The tested P2 agonists ADPS,  ,-meATP,  ,-meADP and ATPS 
produced contractions of the tissue, whereby ,-meATP proved to be the most 
efficacious agonist. However, in contrast to the GPI, a repeated addition of ,-
meATP led not to a desensitisation of the receptor. The inhibition of the 
contraction after addition of TTX and atropine suggested the presence of both pre- 
and postsynaptically located P2X receptors. 
Contractile responses to ADPS failed to be affected by the addition of TTX or 
atropine. Also suramin, NF023 and PPADS proved to be very weak antagonists at 
this preparation. Remarkably, in each case the antagonist curves were steeper 
and had a higher maximum effect than the agonist control curves. Thus, one can 
only speculate that the antagonists have blocked a relaxation-mediating receptor 
and in consequence only the effect of the contraction-mediating receptor 
remained. 
 
Although tissues of the rat are frequently used as functional models in 
experimental pharmacology, in face of the lack of subtye selective agonists and 
antagonists in the present study it was not possible to characterise the P2 
receptor subtypes responsible for contraction of RI. Moreover, a comparison with 
GPI shows that differences might exist when using the same tissue of two different 
species. 
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Die Beschäftigung mit Muskarinrezeptoren reicht bis in das vergangene 
Jahrhundert zurück als, in Folge der verschiedenen Wirkungen des 
Neurotransmitters Acetylcholin, einerseits Nikotin- und andererseits 
Muskarinrezeptoren sowie deren Subtypen entdeckt und charakterisiert werden 
konnten. Aufgrund der weiten Verbreitung von Muskarinrezeptoren innerhalb des 
zentralen und peripheren Nervensystems sowie in entsprechend innervierten 
Organen sind diese nach wie vor als Target für bestimmte klinische Indikationen 
von großem Interesse. 
Besonders im Bereich der chronisch obstruktiven Atemwegserkrankungen 
(COPD) sind Bronchodilatoren Mittel der Wahl. Obwohl die derzeitige 
Behandlungsstrategie im wesentlichen auf dem Einsatz des unselektiven 
muskarinischen Antagonisten Ipratropiumbromid, allein oder in Kombination mit 
einem kurzwirksamen 2-Sympathomimetikum, beruht, ist ihr Einsatz aufgrund 
der dabei auftretenden unerwünschten Nebenwirkungen limitiert. Neben M3-
Rezeptoren findet man in der menschlichen Lunge auch präsynaptische M2-
Rezeptoren, deren Blockade zu einem Anstieg der Acetylcholinfreisetzung führt. 
Demzufolge würde die Entwicklung eines hochselektiven und/oder langwirksamen 
muskarinischen M3-Rezeptorantagonisten einen großen Fortschritt für die 
Behandlung von Patienten mit COPD und auch Asthma bedeuten. 
 
 
Untersuchung der Stereoisomere des Glycopyrroniumbromids und der 
entsprechenden tertiären Analoga 
 
Im Rahmen der vorliegenden Arbeit wurden sowohl die vier reinen Stereoisomere 
des Glycopyrroniumbromids als auch die entsprechenden vier tertiären Analoga 
untersucht. Bislang wird das Diastereomerengemisch (RS/SR), das als Robinul
 
im Handel ist, vorwiegend als Antisialagogum in der Prämedikation der Narkose 
oder als Spasmolytikum therapeutisch eingesetzt. 
 
Die molekulare Struktur des Glycopyrroniumbromids weist zwei Chiralitätszentren 
auf, woraus sich vier stereoisomere Verbindungen ergeben. Die 
pharmakologische Untersuchung sowohl der quartären als auch der 
korrespondierenden tertiären Isomere in den funktionellen Standardmodellen, 
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Kaninchen-Vas-deferens für M1-Rezeptoren, linker Vorhof des 
Meerschweinchenherzens für M2-Rezeptoren und die Längsmuskulatur des 
Meerschweinchenileum für M3-Rezeptoren, ergab, dass sich alle Verbindungen 
an den untersuchten Muskarinrezeptorsubtypen als potente Antagonisten 
verhielten. Ihre Rezeptorselektivität war jedoch relativ gering, wobei im 
Allgemeinen die niedrigste Affinität zum M2-Rezeptor beobachtet wurde. Innerhalb 
der Stereoisomeren zeigten die (R/R’)- und (S/R’)-konfigurierten Verbindungen 
den stärksten, die (S/S’)-konfigurierten Isomere hingegen den geringsten 
antagonistischen Effekt. Diese Ergebnisse konnten durch Radioligand-
Bindungsstudien bestätigt werden. Bemerkenswert war jedoch, dass 
insbesondere am M3-Rezeptor eine extrem langsame Dissoziation der 
Substanzen vom Rezeptor festgestellt wurde. Verbunden mit der hohen Affinität 
und der in Bindungsstudien ermittelten Dissoziationshalbwertszeit von 120 min 
könnte das quartäre (R/R’)-konfigurierte Stereoisomer des 
Glycopyrroniumbromids eine geeignete Alternative zur Behandlung der COPD 
darstellen: Die lange Halbwertszeit sollte eine Einmalgabe pro Tag erlauben und 
somit die Patientencompliance erhöhen, die hohe Affinität eine geringe Dosierung 
ermöglichen und die ‘kinetische Selektivität’ sowie die quartäre Struktur könnten 
zur Minimierung unerwünschter Nebenwirkungen führen. Aufgrund dieser Vorteile 
wurde die Substanz patentiert und der pharmazeutischen Industrie für 
weiterführende Untersuchungen zur Verfügung gestellt. 
 
 
Untersuchungen an der Längsmuskulatur des Meerschweinchenileum in 
Hinblick auf die Verteilung von P2-Rezeptoren 
 
Aufgrund der Pionierarbeit, die Ende der 70er Jahre von Burnstock und seinen 
Mitarbeitern geleistet wurde, wandelte sich das Bild von ATP als einer 
Energiequelle der Zelle zu einem Neurotransmitter ubiquitären Vorkommens mit 
entsprechenden Zielstrukturen, den P2-Rezeptoren. Inzwischen ist allgemein 
anerkannt, dass zwischen metabotropen P2Y-Rezeptoren und ionotropen P2X-
Rezeptoren unterschieden werden kann. Mit Hilfe von Klonierungstechniken 
konnte diese Klassifizierung validiert und außerdem eine Vielzahl 
unterschiedlicher Subtypen identifiziert werden. Bis heute wurden sieben P2X- 
(P2X1-7) und sechs P2Y- Rezeptorsubtypen (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, 
P2Y12) kloniert und pharmakologisch charakterisiert. Sie gelten unumstritten als 
Vertreter der P2-Rezeptorfamilie. 
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Heute besteht eine der größten Herausforderungen auf diesem sich 
explosionsartig expandierendem Gebiet darin, die geklonten P2-Rezeptoren mit 
den verschiedenen physiologischen Antworten, die durch native P2-Rezeptoren 
vermittelt werden, in Einklang zu bringen. Da die Längsmuskulatur des 
Meerschweinchenileum ein bekanntes Modell, z.B. für Untersuchungen an 
Muskarinrezeptoren, darstellt, war das Ziel der vorliegenden Arbeit, dieses Modell 
in Bezug auf die Verteilung von P2-Rezeptoren hin zu untersuchen. 
Neben Agonisten, die eine Präferenz für entweder ionotrope (,-meATP) oder 
metabotrope (ADPS) P2-Rezeptoren aufweisen, wurden im wesentlichen eine 
Reihe gut untersuchter Antagonisten mit zum Teil hoher Affinität für einen 
Rezeptorsubtyp für die funktionellen Untersuchungen verwendet.  
 
Die neuronale Lokalisation des P2X-Rezeptors konnte durch die komplette 
Aufhebung der durch ,-meATP-vermittelten Kontraktionen nach Zugabe von 
TTX charakterisiert werden. Die ebenfalls fast vollständige Hemmung der 
Kontraktion nach Einsatz von Atropin wies auf einen indirekten, durch Acetylcholin 
vermittelten Effekt hin. Aufgrund dieser Beobachtungen wurden sämtliche 
Versuche mit P2-Antagonisten unter Zusatz von 70 µM Physostigmin in der 
Nährlösung durchgeführt.  
Die eingesetzten Antagonisten Suramin, NF023 und NF279 erwiesen sich als 
kompetitive Antagonisten, während PPADS neben der Rechtsverschiebung einen 
Maximumabfall der Agonistenkurven bewirkte. Ein Vergleich der funktionell 
ermittelten pA2-Werte mit den Wirkstärken an rekombinanten P2-Rezeptoren von 
Ratte und Mensch lässt vermuten, dass es sich hierbei um einen P2X3-
Rezeptorsubtyp handelt, der über die Freisetzung von Acetylcholin eine 
Kontraktion der glatten Muskulatur über einen indirekten Mechanismus auslöst. 
Da sich P2X-Rezeptoruntereinheiten neben homomeren auch zu heteromeren, 
funktionell aktiven Kanälen vereinen können, könnte es sich bei dem vorliegenden 
soma-dendritischen P2X-Rezeptor aber auch um ein Heteromer handeln, bei dem 
der P2X3-Rezeptor den Phänotyp bestimmt. Solange noch keine eindeutige 
Identifizierung dieses Rezeptors speziesspezifisch auf molekularer Ebene erfolgt 
ist, sollte man deshalb die Bezeichnung P2X3(-ähnlicher)-Rezeptor verwenden. 
 
Es konnte gezeigt werden, dass eine Stimulation des präsynaptischen P2X3(-
ähnlichen)-Rezeptors zur Ausschüttung von Acetylcholin führt, das wiederum 
postsynaptisch einen kontraktionsvermittelnden Muskarinrezeptor aktiviert. Um zu 
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beweisen, dass es sich dabei um denselben Muskarinrezeptorsubtyp handelt, der 
bereits auf direktem Weg durch APE oder mittels EFS als M3-Rezeptor 
charakterisiert werden konnte, wurden die Affinitäten muskarinischer Antagonisten 
als Kriterien herangezogen. Die erhaltenen Korrelationen wiesen eindeutig darauf 
hin, dass dieser postsynaptisch im GPI lokalisierte Muskarinrezeptor dem nativen 
und rekombinanten, kontraktionsvermittelnden M3-Rezeptorsubtyp entspricht. 
 
Durch Zugabe von ADPS konnten im GPI Kontraktionen ausgelöst werden, die 
allerdings mit TTX und Atropin nur zum Teil gehemmt wurden. Diese 
Beobachtungen führten zu der Erkenntnis, dass postsynaptisch P2Y-Rezeptoren 
lokalisiert sind. Ihre Subtypcharakterisierung erfolgte unter Zusatz von 0.3 µM 
Atropin in der Nährlösung, um den Einfluss der neuronalen P2X3-Rezeptoren zu 
unterbinden. Suramin, NF023 und NF279 zeigten wiederum einen kompetitiven 
Antagonismus gegen ADPS, während PPADS auch hier eine 
Rechtsverschiebung mit Maximumdepression der Agonistenkurve hervorrief. Ein 
erneuter Vergleich mit beschriebenen Affinitätswerten von rekombinanten P2-
Rezeptoren ließ den Schluss zu, dass der im GPI postsynaptisch gefundene P2Y-
Rezeptor Eigenschaften des P2Y1-Rezeptorsubtyps aufweist. Eine Bestätigung 
dafür gaben außerdem die P2Y1-selektiven Bisphosphate A3P5P und MRS2179, 
obgleich sie geringere pIC50-Werte aufzeigten als in der Literatur beschrieben. 
 
Mit der Charakterisierung des neuronalen P2X3-Rezeptors und des 
postsynaptischen P2Y1-Rezeptors ist das GPI ein bisher einzigartiges 
funktionelles pharmakologisches Modell, in dem beide P2-Rezeptorsubtypen 
durch Einsatz des jeweiligen Agonisten, ,-meATP oder ADPS, 
pharmakologisch isoliert werden können. 
 
 
Charakterisierung von P2-Rezeptoren in der Längsmuskulatur des 
Rattenileum 
 
Eine im Vergleich zum GPI gänzlich andere Situation zeigte sich im RI. Die 
getesteten P2-Agonisten ADPS, ,-meATP, ,-meADP und ATPS erzeugten 
Kontraktionen im untersuchten Gewebe, wobei sich ,-meATP als effektivster 
Agonist erwies. Im Unterschied zum GPI führte eine wiederholte Gabe von ,-
meATP allerdings nicht zu einer Desensibilisierung des Rezeptors. Die durch 
Zugabe von TTX und Atropin erreichte Kontraktionshemmung lässt auf das 
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Vorhandensein von sowohl prä- als auch postsynaptischen P2X-Rezeptoren 
schließen. Eine Trennung der durch diese Rezeptoren hervorgerufenen Effekte 
war im funktionellen Experiment jedoch nicht durchführbar. 
Keinerlei Effekt zeigte allerdings der Zusatz von TTX und Atropin auf die durch 
ADPS ausgelösten Kontraktionen. Suramin, NF023 und PPADS erwiesen sich 
als sehr schwache Antagonisten an diesem Präparat. Auffällig war hingegen, dass 
die durch den Antagonisten verschobenen Kurven jeweils steiler und im Maximum 
höher waren als die Kontroll-Agonistenkurve. Man kann also hier nur spekulieren, 
dass durch die Antagonisten zunächst ein relaxationsvermittelnder Rezeptor 
geblockt wurde und in Folge nur noch der Effekt des kontraktionsvermittelnden 
Rezeptors sichtbar war. 
 
Obwohl Gewebe der Ratte häufig als funktionelle Modelle in der experimentellen 
Pharmakologie eingesetzt werden, konnten auf Grund fehlender subtypselektiver 
Agonisten und Antagonisten die kontraktionsvermittelnden P2-Rezeptorsubtypen 
im RI nicht identifiziert werden. Des weiteren zeigt ein Vergleich mit dem GPI, 
dass bedeutende Unterschiede bei der Verwendung gleichen Gewebes zweier 
verschiedener Spezies existieren können, die bei der vergleichenden Betrachtung 
von Affinitätswerten von Agonisten und Antagonisten zur Charakterisierung von 
Rezeptorsubtypen beachtet werden müssen. 
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A  AC    Adenylate  cyclase 
 ACh    Acetylcholine 
 AChE    Acetylcholinesterase 
 AD    Alzheimer’s  disease 
 ADP    Adenosine  5’-diphosphate 
 ADPßS  Adenosine  5’-O-(2-thiodiphosphate) 
 AF-DX  116   11-[[2-[(Diethylamino)methyl]-1-piperidinyl]acetyl]-5,11- 
    dihydro-6H-pyrido(2,3-b)(1,4)-benzodiazepine-6-one 
 AF-DX  384   5,11-Dihydro-11-[[[2-[2-(dipropylamino)methyl)-1-  
    piperidinyl]ethyl]amino]-carbonyl]-6H-pyrido-(2,3-b)(1,4)- 
    benzodiazepine-6-one 
 AMP    Adenosine  5’-monophosphate 
 APE    Arecaidine  propargyl  ester;  1,2,5,6-tetrahydro-1-methyl-3- 
    [(2-propynyloxy)carbonyl]pyridinium  hydrobromide 
 APP    Amyloid  precursor  protein 
 A3P5P    Adenosine  3’,5’-diphosphate 
 APPs    Soluble  form  of  APP 
 ApxA    Adenine  dinucleotide  polyphosphates 
 AQ-RA  741   11-(4-[4-(Diethylamino)butyl]-1-piperidinylacetyl)-5,11- 
    dihydro-6H-pyrido(2,3b)(1,4)benzodiazepine-6-one 
 AR-C67085MX  2-Propylthio-,-dichloromethylene-D-ATP 
 AR-C69931MX  N
6-(2-Methylthioethyl)-2-(3,3,3-trifluoropropylthio)-,- 
    dichloromethylene-D-ATP 
 ARL66096   2-Propylthio-,-difluoromethylene-D-ATP 
 ARL  67156   6,N,N-Diethyl-D-,-dibromomethylene ATP (formerly FPL 
    67156) 
 ATP    Adenosine  5’-triphosphate 
 ATPS    Adenosine  5’-O-(3-thiotriphosphate) 
 
B BIBN  99    5,11-Dihydro-8-chloro-11-([4-3-[(2,2-dimethyl-1-  
    oxopentyl)ethylamino]propyl-1-piperidinyl]-acetyl)-6H- 
    pyrido(2,3-b)(1,4)-benzodiazepine-6-one 
 BzATP    2’-and  3’-O-(4-Benzoyl-benzoyl)adenosine  5’-triphosphate 
 
C  cAMP    Cyclic  adenosine  3’,5’-monophosphate 
 cDNA    Complementary  desoxyribonucleic  acid 
 CCPA    2-Chloro-N
6-cyclopentyladenosine 
 CF    Cystic  fibrosis 
 CGRP    Calcitonin  gene-related  peptide 
 CHO    Chinese  hamster  ovary 
 CNS    Central  nervous  system 
 COPD    Chronic  obstructive  pulmonary  disease 
 CTP    Cytosine  5’-triphosphate 
  CTRF      Cystic fibrosis transmembrane conductance regulator 
 
D  DAG    Diacylglycerol 
 4-DAMP   4-Diphenylacetoxy-N-methylpiperidine  methiodide 
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 DMSO    Dimethyl  sulfoxide 
 DNA    Desoxyribonucleic  acid 
 DPCPX   8-Cyclopentyl-1,3-dipropylxanthine 
 DR    Dose  ratio 
 
E EC50      Concentration of agonist producing 50 % of the maximum 
    e f f e c t  
 EDRF    Endothelium-derived  relaxing  factor 
 EFS    Electrical  field  stimulation 
 
F 4-F-PyMcN
+   4-(4-Fluorophenylcarbamoyloxy)-2-butynyl-N-methyl- 
    pyrrolidinium  tosylate 
 
G G i    Inhibitory  G  protein 
 G o      G protein of yet unknown function 
 G q      Phospholipase C stimulating G protein 
 GABA    -Aminobutyric acid 
 GDP    Guanosine  5’-diphosphate 
 GPA    Guinea-pig  atria 
  GPI      Guinea-pig ileal longitudinal smooth muscle 
  G protein    Guanine nucleotide binding regulatory protein 
 
 GTP    Guanosine  5’-triphosphate 
 
H  h    Hour(s) 
 HEK    Human  embryonic  kindey 
 HHSiD    Hexahydro-sila-difenidol 
 Hz    Hertz 
 
I  IC50    Concentration  of  agonist/antagonist  producing  halfmaximal 
    e f f e c t  
 IP3    Inositol  1,4,5-trisphosphate 
 ITP    Inositol  5’-triphosphate 
 
K K D    Dissociation  constant 
 kD    Kilodalton 
 
L L-NOARG    N
G-Nitro-L-arginine 
 Lu  25-109   5-(2-Ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-   
    tetrahydropyridine  maleate 
 
M  m      Slope of regression line 
 M    Molar 
 MAPK    Mitogen-activated  protein  kinase 
 McN-A-343   4-(3-Chlorophenylcarbamoyloxy)-2-     
    butynyltrimethylammonium  chloride 
  ,ß-meADP   ,ß-Methyleneadenosine 5’-diphosphate 
  ,ß-meATP   ,ß-Methyleneadenosine 5’-triphosphate 
  ,-meATP   ,-Mehthyleneadenosine 5’-triphosphate 
 2-MeSADP   2-Methylthioadenosine  5’-diphosphate 
 2-MeSATP   2-Methylthioadenosine  5’-triphosphate 
 min    Minutes 
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 mRNA    Messenger  ribonucleic  acid 
 MRS2179   N
6-Methyl 2’-deoxyadenosine 3’,5’-bisphosphate 
N  n      Number of individual experiments 
 NANC    Non-adrenergic  non-cholinergic 
  NB-OK 1    Human neuroblastoma cell line 
  NC-IUPHAR    International Union of Pharmacology Committee on  
    Receptor  Nomenclature  and  Drug  Classification 
 NDP    Nucleoside  5’-diphosphate 
 NF023    Symmetrical  3’-urea  of  8-(benzamido)naphthalene-1,3,5- 
    trisulfonic  acid 
 NF279    8,  8’-(Carbonylbis(imino-4,1-phenylenecarbonylimino-4,1- 
    phenylenecarbonylimino))bis(1,3,5-naphthalenetrisulfonic   
    a c i d )  
  NG 108-15    Neuroblastoma x glioma hybrid cell line 
 NMP    Nucleoside  5’-monophosphate 
 NO    Nitric  oxide 
 NOS    Nitric  oxide  synthase 
 NTP    Nucleoside  5’-triphosphate 
 
P P     Probability  level 
 pA2      Negative logarithm of the antagonist concentration shifting 
        the agonist concentration-response curve twofold to the  
    r i g h t  
 pAx      Negative logarithm of the antagonist concentration used 
 PC12    Pheochromocytoma  cells 
 PCR    Polymerase  chain  reaction 
 pD2      Negative logarithm of the agonist concentration producing 
        50 % of the maximum effect 
 p-F-HHSiD   (±)-para-Fluoro-hexahydro-sila-difenidol 
 Pi    Inorganic  phosphate 
  pH      Negative logarithm of the concentration of hydrogen ions 
 pIC50      Negative logarithm of the agonist/antagonist concentration 
    producing  halfmaximal  inhibition 
 PKA    Protein  kinase  A 
 PKC    Protein  kinase  C 
 pKi      Negative logarithm of the equilibrium dissociation konstant 
    of  inhibitor   
 PLA2    Phospholipase  A2 
 PLD    Phospholipase  D 
 PLC    Phospholipase  C 
 PPADS  Pyridoxal-5-phosphate-6-azophenyl-2’,4’-disulfonic  acid 
 PPi    Inorganic  pyrophosphate 
 PPNDS   Pyridoxal-5’-phosphate-6-(2’-naphthylazo-6’-nitro-4’,8’- 
    disulfonate) 
 PTAC    6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo-[3.2.1]- 
    octane 
 PTX    Pertussis  toxin 
 
Q  QNA    3-(1-Azabicyclo[2.2.2]octyl)2-hydroxy-2-phenylpropionate 
 
R  r    Correlation  coefficient 
 RB-2    Reactive  blue  2 
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  RI      Rat ileal longitudinal smooth muscle 
 RNA    Ribonucleic  acid 
 RVD    Rabbit  vas  deferens 
 
S  s    Second(s) 
 SAR    Structure-activity  relationship 
 SB9    6-[(4,6,8-Trisulfo-1-naphthyl)iminocarbonyl-1,3-(4-   
    methylphenylene)iminocarbonyl-1,3-phenylene-azo]- 
    pyridoxal-5’-phosphate 
  S.E.M.     Standard error of the mean 
 
T  TM    Transmembrane  domain 
 TTX    Tetrodotoxin 
 t 1/2    Dissociation  half-life 
 
U  UDP    Uridine  5’-diphosphate 
 UTP    Uridine  5’-triphosphate 
 
V V     Volt 
 VIP    Vasoactive  intestinal  polypeptide 
 v s .     V e r s u s  
 
W  w/v    Weight  per  volume 
 
X  XTP    Xanthine  5’-triphosphate 
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